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Abstract 
Large coregulator complexes are recruited to specific gene loci to modulate 
chromatin structure by altering epigenetic marks on DNA and histones to control gene 
expression. Mesoderm induction early response 1 (MIER1) is a nuclear protein known to 
function in transcriptional repression through its ability to recruit histone deacetylase 1 
(HDAC1) and 2. The MIER family consists of three related genes encoding proteins 
containing ELM2-SANT functional domains. MIER1 is the prototypical member, well 
characterized in our lab but little is known about MIER2 or MIER3 function and there is 
no data characterizing these two proteins. In my thesis, I have begun to characterize 
MIER2 and MIER3 proteins and to compare them to MIER1. I investigate their 
subcellular localization, their potential association with each other, their interaction with 
HDAC1 and 2 and chromodomain Y-like (CDYL), the activity of associated deacetylases 
and key residues for HDAC and CDYL recruitment.  
Immunostaining followed by confocal microscopy analysis revealed that, while 
MIER2 and MIER3 are mainly nuclear proteins, a substantial proportion (32%) of 
MIER2 is localized in the cytoplasm. Co-immunoprecipitation (co-IP) experiments 
demonstrated that the MIER proteins do not form dimers, neither homodimers nor 
heterodimers with either of the other two family members. Our data also showed that 
MIER2, but not MIER3, can recruit HDAC1 and 2. Co-IP experiments showed that 
MIER1 and MIER2, but not MIER3, interact with CDYL through the ELM2-SANT 
domains. Both MIER1 and MIER2 augment interaction between CDYL and HDACs.  
Finally, ChIP-Seq analysis revealed that each MIER member has unique targets 
and that they share target genes. In addition, consensus DNA sequences for MIER protein 
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occupancy are nearly identical to binding motif for the transcriptional repressor RE-1 
Silencing Transcription Factor (REST). REST is known to regulate expression of neural 
genes by recruiting corepressor complexes. Co-IP experiments demonstrated that MIER1 
and MIER2, but not MIER3, interact with REST. Suppression of MIER1 or MIER2 
expression in P19 embryonal carcinoma cells results in neuronal differentiation. 
Observations made in this report suggest that MIER1 and MIER2 play an important role 
in the repression of neuronal genes by the REST complex.  
Overall, I am the first to characterize MIER2 and MIER3. The results presented in 
this thesis show that MIER2 is similar to MIER1 in that it recruits some of the same 
epigenetic regulators and both proteins are enriched on REST target genes. In contrast, I 
showed MIER3 to be distinct: despite a high degree of amino acid similarity between 
MIER3 and MIER1/2, it did not interact with any of the MIER1/2 recruited regulators 
and is enriched on FOXA1 target genes.  
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Chapter 1: Introduction 
1.1 Cellular identity is determined by gene expression 
Cells are the basic units of tissues, organs and organisms. There are estimated 37 
trillions cells that make up the human body1. Almost all cells in any one organism, 
regardless of their form and function contain the same deoxyribonucleic acid (DNA) but 
differ dramatically in both structure and function2,3. The identity and function of a cell 
largely depends on changes in gene expression rather than on any changes in 
the nucleotide sequence of the cell's genome3,4.  
Gene expression is a highly regulated process by which genetic instructions from 
a DNA are used to synthesize protein. Gene expression can be controlled at the stage of 
transcription, RNA processing (post-transcriptional modifications), translation and 
protein degradation5. Jacob and Monod established the key concepts of transcriptional 
control half a century ago in bacterial systems6.  Those and many subsequent studies 
established that DNA binding transcription factors occupy specific DNA sequences at 
control elements and recruit and regulate the transcription apparatus. In eukaryotic 
systems, transcription factors, cofactors, the general transcription apparatus, chromatin 
regulators, DNA methylation and noncoding RNAs are all important players exerting 
control5. Consequently, deregulations in any of the regulatory mechanisms can alter 
protein expression and may result in many different disease states including cancer5.  
1.1.1 Gene transcription is a critical site of control  
Transcription is a process whereby messenger RNA (mRNA) is synthesized from 
DNA by the multi subunit enzyme called RNA polymerase II (Pol II). Transcription is 
 
 
2 
the key site for the regulation of gene expression5; thus mRNA synthesis is regulated both 
at the level of initiation and/or elongation stages by numerous transcriptional regulators7.  
Transcription factors (TF) are regulatory proteins that typically control gene 
transcription by binding regulatory elements upstream of the promoters and recruiting co-
modifiers and Pol II to target genes8. These factors contain DNA-binding domains, which 
specifically recognize and bind to short sequences (8-30bp in length) and exert their 
regulation. There are a core set of evolutionarily conserved transcription factors (TFIIB, 
TFIID, TFIIE, TFIIF, and TFIIH) that function directly with Pol II to control its 
recruitment to target genes promoters and its activity in transcription initiation and 
elongation7,9. The transcription elongation factors, TFIIS, Eleven-Nineteen Lysine-rich 
Leukemia, 5,6-Dichloro-1-b-D-ribofuranosylbenzimidazole Sensitivity Inducing Factor, 
Suppressor of Tyrosine 4/5, Elongin, and Positive Transcription Elongation Factor b 
assist Pol II to elongate its transcripts through different mechanisms10. In brief, regulation 
of transcription is the most common form of gene control4, which is achieved by the 
actions of transcription factors, Pol II, the transcriptional apparatus as well as two classes 
of cofactors namely corepressors and coactivators.  
1.2 Corepressors 
Corepressors are transcriptional regulators that are recruited by DNA-bound TFs 
to silence target gene expression11,12. They form multi-protein complexes containing 
structural, chromatin-binding, and DNA- and histone-modifying enzymes, which 
cooperate to establish and maintain transcriptional repression (Fig 1)11. Corepressors play 
essential roles in many biological pathways including differentiation, proliferation, 
programmed cell death, and cell cycle. Nuclear receptor corepressor (NCoR) and 
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silencing mediator for retinoid and thyroid hormone receptors (SMRT) are the first two 
corepressor complexes identified12,13. Since then, several corepressor complexes have 
been identified and most complexes contain at least the histone deacetylases (HDACs) 
among other histone modifying enzymes to aid in transcription repression11,12. These 
corepressor complexes include the switch independent 3a (SIN3A)14, corepressor for the 
RE1-silencing transcription factor (CoREST) 15, nucleosome remodeling deacetylase 
(NuRD) 16and polycomb repressive complex 2 (PRC2)17. 
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Figure 1. Structure and composition of co-repressor complexes 
A. Corepressor complexes (CoR) are composed of structural proteins bound to epigenetic 
modifier effector proteins, and recruited to chromatin by DNA- or histone-binding 
proteins (ChBP). B. Factors associated with the NCOR, NuRD, SIN3A, and CoREST co-
repressor complexes, including both core components and accessory co-factors. Figure 
adapted by permission from Elsevier: Neuropharmacology, 201411. 
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1.2.1 SIN3Acorepressor complex 
SIN3A is a multiprotein corepressor complex that mediates transcriptional 
silencing via interaction and recruitment of diverse transcription factors and chromatin 
remodellers18,19. SIN3A is a large scaffold protein containing four paired amphipathic 
helix (PAH) domains, an internal HDAC interaction domain (HID) and a highly 
conserved region19. The PAH domains recognize and bind to sequence-specific 
transcriptional factors, and the HID domain is responsible for bringing HDAC1 and 
HDAC2 to SIN3A to mediate transcriptional repression of SIN3A target genes19. SIN3 
protein is highly conserved from yeast to mammals and has varied numbers of isoforms. 
In mammals there are two paralogs of SIN3, SIN3A and SIN3B18,19. They share high 
sequence identity and similar expression patterns. Both proteins are widely expressed and 
bind common as well as distinct transcriptional repressors and complexes19.  
Biochemical analysis of the SIN3 complex to characterize the components of 
complex revealed that, in addition to SIN3, HDAC1, and HDAC2, five other proteins 
comprise the core of the complex— retinoblastoma binding protein 4, retinoblastoma 
binding protein 7, SIN3A associated protein 30, SIN3A associated protein 18, and 
Suppressor of defective silencing 14,18. A number of other associated proteins were also 
discovered in the complex, including SIN3A associated protein 180, Retinol binding 
protein 1, Transcriptional Repressor And Anoikis Regulator 1, SIN3A associated protein 
130, SIN3A associated protein 25, and inhibitor of growth protein 1/218–21. The roles of 
these proteins remain unclear: it is hypothesized that some may function in specialized 
subsets of SIN3/HDAC complexes18. 
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SIN3 corepressor complex is shown to play an important role in diverse cellular 
functions such as chromosome segregation, DNA silencing, DNA damage repair, cell 
cycle, senescence, organ development, oncogenesis and many more18,19. Although, SIN3 
is shown to interact with numerous proteins, the molecular mechanism of SIN3 action in 
such diverse cellular activities is still work in progress. 
1.2.2 CoREST complex 
CoREST was first identified as a corepressor of REST but later demonstrated to 
be an integral component of HDAC1/2-containing complexes11. The CoREST protein is 
also known as REST corepressor 1 (RCOR1). It contains one ELM2 (EGL-27 and MTA1 
homology 2) and two SANT (SWI3/ ADA2/NCoR/TFIIIB) domains, which are also seen 
in other repressor proteins such metastasis-associated proteins 1-3 (MTA1-3), NCoR and 
MIER1-311,22.  
The CoREST complex contains two key histone-modifying enzymes, lysine-
specific histone demethylase 1 (LSD1) and HDAC1 and HDAC222,23. The core complex 
also contains plant homeodomain (PHD) Finger Protein 21A, zinc finger protein 217 and 
the DNA-binding co-factor BRCA2-associated factor 35 (BRAF35)15,22. Co-
immunoprecipitation assays also showed association of CoREST complex with C-
terminal binding protein (CtBP) and histone methyltransferases [euchromatic histone-
lysine N-methyltransferase 2 (G9a) and G9a-like protein (GLP)]15,22. The CoREST 
complex is recruited to target genes by transcriptional factor REST but direct binding to 
the RE1 element on target genes via BRAF35 is also reported15,22. CoREST has been 
shown to play an important role in repression of neuronal gene expression and influence 
neuronal differentiation24. 
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1.2.3 The NuRD Complex 
The nucleosome remodeling and deacetylase (NuRD) is also a multiprotein 
complex first purified by many groups independently in 199825. The NuRD complex is a 
unique chromatin remodeler that possesses two distinct enzymatic activities, ATP-
dependent nucleosome remodeling and histone deacetylase activity16,26. It is highly 
conserved in plants and animals, and widely expressed in all cell types27. The core 
complex consists of HDAC1/2, ATP dependent remodeling enzymes chromodomain-
helicase-DNA-binding protein 3/4, histone-binding proteins retinoblastoma associated 
protein 46/48, CpG-binding proteins methyl-CpG-binding domain protein 2/3, nuclear 
zinc-finger protein GATAD2a and/or GATAD2b and specific DNA-binding proteins 
MTA1/2/327,28. Multiple subunits in the NuRD complex can interact directly with DNA, 
and with histones to alter genome structure and regulate gene expression. MTA is an 
essential component of the NuRD complex, functioning as a scaffold to facilitate binding 
of the complex to the target DNA and to HDAC 1 and 2, and also to other transcription 
factors and co-regulators29. 
The three members of the MTA family are highly similar and possess four highly 
conserved domains, which include a bromo adjacent homology domain, ELM2 domain, a 
SANT domain and a GATA domain30. MTA1 share 63% and 72 % identity with its 
homologues MTA2 and MTA3, respectively. The proteins are nearly identical in the 
internal four domains but differ significantly in the C-termini regions and proposed to be 
the reason as to why MTA1, MTA2 and MTA3 are present in mutually exclusive 
complexes31.   
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1.2.4 The NCoR/SMRT complex  
Nuclear receptor corepressor (NCoR) and silencing mediator for retinoid and 
thyroid receptor (SMRT) are corepressor complexes that bind to nuclear hormone 
receptors and act as scaffolds, recruiting numerous proteins including class I and II 
HDACs and SIN3A complex to form large multiprotein complexes23,32,33.  
SMRT and NCoR are homologous proteins, which share a similar domain 
organization. The C-terminal region of NCoR and SMRT contains three (NCoR) or two 
(SMRT) nuclear receptor interaction domains, important for interactions with the ligand-
binding domain of nuclear receptors11,12,32.  The N-terminus of NCoR and SMRT have 
been characterized to contain two SANT domains. The first SANT domain is also known 
as the deacetylase activation domain, which has been shown to both recruit and activate 
HDAC3. The second SANT domain has been reported to interact directly with histone 
tails and is also known as the HID.  
The SMRT and NCoR core complexes are made up of NCoR/SMRT, HDAC3, 
transducin β-like 1, TBL related 1, and G-protein pathway suppressor 232. SMRT and 
NCoR exert transcriptional repression on target genes by binding to nuclear receptors as 
well as large number of transcription factors and chromatin modifiers34.  
1.3 Coactivators  
Coactivators are the opposite in function to corepressors enhancing the 
transcription of target genes. Coactivators are very large proteins that harbour multiple 
activation domains and receptor-interacting domains35. Some of these coactivators 
include, the steroid receptor coactivator-1, transcription intermediary factor 2, receptor-
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associated coactivator 3, CREB binding protein (CBP) and p30036. Like corepressors, 
coactivators do not bind DNA directly; instead they act as a scaffold, bridging the DNA-
bound receptor to proteins in the preinitiation complex and chromatin modifying 
enzymes, and thereby augmenting transcription35. Numerous cofactors are characterized 
that facilitate the initial recruitment of Pol II to the promoter and to the subsequent 
transcript elongation, however, the mediator complex is found to the most crucial 
coactivator37,38.   
Mediator is a multiprotein complex that functions to relay regulatory signals from 
TFs directly to the Pol II37. The complex core is made up of 26 subunits and the diverse 
modules in the complex aid in protein–protein interactions between mediator, Pol II and 
other TFs37,38. Also, mediator is crucial for the organization of chromatin architecture, 
including gene loops, which are important structures in regulation of cellular 
transcription37,39.   
1.4 Chromatin  
The transcriptional state of each gene is jointly regulated by chromatin structure. 
In eukaryotes, genomic DNA is packaged into nucleosomes, which is comprised of DNA 
and two pairs of core histones H2A, H2B, H3, and H4 forming a protein octomer40. 
Nucleosomes are the initial mode of compaction of genomic DNA and provide a critical 
mechanism to regulate transcription by altering the binding of trans-acting factors to 
cognate DNA sequences22. Chromatin is a dynamic structure that alternates between a 
condensed, transcriptionally silent state and a less condensed structure, transcriptionally 
active state in a process called chromatin remodeling41. Structural reorganization is 
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triggered by two mechanisms; one initiated by nucleosome remodeling ATPases42 and 
other by various types of histone modifications43. 
1.4.1 Nucleosome remodeling complexes 
 Nucleosome remodelers play important roles in regulating the initiation and 
elongation of transcription26. In general, chromatin remodelers make DNA regulatory 
sequences more or less accessible to the transcriptional apparatus, thereby allowing 
transcription factors to activate or repress transcription26,44. There are four families of 
nucleosome remodelers, which include Switch/Sucrose Non-Fermentable (SWI/SNF), 
imitation switch (ISWI), Chromodomain helicase DNA-binding (CHD) and Inositol 
auxotrophy 80 (INO80)45. All four remodelers utilize ATP hydrolysis to alter histone-
DNA interactions and share a similar ATPase domain. However, all four remodelers 
function in unique biological contexts, imparted by specific domains residing in their 
catalytic ATPases and also by their various associated factors (Table 1)42,44,45. They are 
often recruited to target genes through interactions with sequence-specific transcription 
factors to serve as coactivators or corepressors45. They catalyze a broad range of 
chromatin alterations that includes sliding the histone octamer across the DNA, changing 
the conformation of nucleosomal DNA and/or changing the composition of the histone 
octamer, which can facilitate either activation or repression of gene expression46,47.  
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Table 1: Remodeler composition and orthologous subunits  
 
Table adapted by permission from Annual Reviews: Annual Review of Biochemistry, 
200945 
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1.4.2 Histone modifications 
Chromatin structure can be altered by various post-translational modifications 
(PTMs) of the N-terminal residues of histone proteins48,49. Each histone protein contains 
two common regions, the “histone fold” and the “histone tail”. The histone fold is 
responsible for the formation of stable H2A–H2B and H3–H4 dimers whereas the histone 
tails are unstructured N-terminal regions that flank both ends of the histone fold47. The 
histone tails are highly basic, and contain residues that are targets of PTMs. These 
modifications provide interaction surfaces for protein complexes that contribute to 
transcriptional control. Hence, histone modifications are thought to constitute a “Histone 
Code,” which is “read” by proteins to bring about specific downstream effects50. Most 
common PTMs include methylation on lysine (K) and arginine (R) residues, acetylation 
on K, phosphorylation on serines (S), threonines (T) and tyrosines (Y), ubiquitination on 
K, crotonylation on K, and citrullination on R (reviewed in43,50), with the first three being 
the most common modifications present on histones (Fig 2). Histone 3 (H3) is the most 
commonly modified histone, where K residues on N terminus are targeted for covalent 
attachment of one acetyl or one, two or three methyl groups. 
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Figure 2. Histone modifications regulate gene expression 
(a) The histone tails are targeted for post-translational modification, including phosphorylation, acetylation, and methylation.  Such 
modifications create a distinct pattern, called the ‘histone-code’, that affects gene expression. (b) Acetylation of lysine residues on 
histone tails is usually associated with active genes, whereas reduced or no acetylation is found at inactive genes. Histone acetylation 
is regulated by the opposing activity of Histone acetyltransferases (HATs) and HDACs. Figure adapted by permission from Elsevier: 
Trends in Pharmacological Sciences, 201051.
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1.4.3 Histone code  
Numerous methods such as bisulfite sequencing for DNA methylation and 
chromatin immunoprecipitation (ChIP) for chromatin modifications and DNA-protein 
interactions as well as computational methods for epigenetic analysis have been 
developed, which have rapidly advanced our understanding of epigenetic cues in 
modulation of gene expression. The histone code was first proposed by Strahl and Allis 
in 200052, defined as an epigenetic marking system that use different combinations of 
histone modification patterns to regulate specific and distinct functional outputs of 
eukaryotic genomes52. The histone code is established by a series of “reading”, “writing” 
and “erasing” events performed by histone-modifying enzymes. Writers are enzymes that 
add a covalent modification, while erasers remove them, making it a reversible process. 
Additionally, readers are specific factors that recognize either a particular post-
translational marks on histones or a combination of marks. In general, these histone-
modifying enzymes function as individual components within a diverse set of 
multiprotein complexes that target promoters and enhancers to regulate transcriptional 
responses48,50,53. The following paragraphs provide a brief overview of few of the histone 
modifying enzymes that are relevant to our study.  
1.4.4 Histone acetyltransferases 
In 1964, Vincent Allfrey and colleagues discovered acetylation of histones, 
proposing a regulatory role in transcriptional control54. HATs, HDACs and acetyl-Lys-
binding proteins were subsequently characterized as transcription regulators, thus 
providing evidence for his hypothesis.  Over the past 50 years, extensive research has 
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been conducted to show that acetylation has a significant impact on many cellular 
functions beyond transcriptional regulation55.   
Acetylation of lysine residues at the N-terminus regions of histones is generally 
correlated with increased chromatin accessibility and transcriptional activity56. 
Acetylation of a lysine residue neutralizes the positive charge and weakens the binding 
between the histone and the negatively charged DNA, permitting regulatory proteins to 
bind to DNA55. HATs are enzymes which catalyze the transfer of an acetyl group from 
acetyl-CoA to the lysine -amino groups on the N-terminal tails of histones, transcription 
factors and other chromatin-associated proteins 57. Among the different families of 
histone-modifying enzymes, HATs are the best characterized to date. Five well-studied 
HAT subfamilies include histone acetyltransferase 1, general control nonderepressed 5 
(GCN5)/ P300/CBP-associated factor (PCAF), MOZ Ybf2 Sas2 Tip60, p300/CBP, and 
Rtt10956. X-ray crystallography analysis of each of the five subfamilies revealed a 
conserved core region containing a three-stranded β-sheet and a long helix in parallel, 
important for cofactor binding, but divergent N- and C-termini regions for histone-
specific binding56. For example, GCN5/ PCAF preferentially bind histone H3 over the 
histone H4 and p53 substrates58. Also, most HATs exist as components of multisubunit 
complexes and the different components in the complex determine substrate specificity 
and gene specific targeting50. For instance, recombinant GCN5/PCAF proteins acetylate 
free histones or histone peptides but are much less active on nucleosomes, which suggest 
other components in the complex influence the action of GCN5/PCAF56. Recent studies 
derived quantitative models for correlating various chromatin marks with gene 
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expression. The histone acetylation on H3K9, H4K12, H3K14, H3K27, and H3K122 are 
signatures of active enhancers59. 
Bromodomains recognize the acetylation marks on lysine residues. They are a 
family of evolutionarily conserved motifs identified in 1992 in the brahma gene 
of Drosophila melanogaster60. The human genome encodes 46 bromodomain-containing 
proteins, classified into eight subfamilies on the basis of their structure61. The 
bromodomain and extra terminal family is thoroughly investigated and it is made up of 
bromodomain-containing protein 2, bromodomain-containing protein 3, bromodomain-
containing protein 4, and bromodomain testis associated61. The bromodomain is also 
conserved within many chromatin-associated proteins including HATs, ATP-dependent 
chromatin-remodelling proteins, helicases, methyltransferases, and nuclear scaffolding 
proteins62. Acetylation of histones is a dynamic process that involves the dual action of 
HATs and HDACs and accompanying readers to alter chromatin and influence gene 
expression. 
1.4.5 Histone deacetylases  
HDACs are a family of enzymes that catalyze the removal of acetyl functional 
groups from the lysine residues of both histone and non-histone proteins63. In mammals, 
18 HDACs have been identified, which are divided into four classes based on their 
structure, enzymatic function, subcellular localization, and expression patterns64,65.  
The class I HDAC family consists of HDAC1, HDAC2, HDAC3 and HDAC8, 
which share homology with yeast Reduced Potassium Dependency 366. These HDACs 
are mainly nuclear proteins expressed ubiquitously. Class II HDACs are related to yeast 
HDA1, which include subclass IIa (HDAC4, HDAC5, HDAC7 and HDAC9) and 
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subclass IIb (HDAC6 and HDAC10). Class IIa HDACs shuttle from nucleus to 
cytoplasm and are restricted to brain, muscle, and heart66. HDAC6 is exclusively 
cytoplasmic and is the only enzyme with two deacetylase domains. Class III HDACs are 
better known as Sirtuins (SIRT) and they consist of seven members that occupy different 
subcellular compartments such as the nucleus (SIRT1-7), cytoplasm (SIRT1 and SIRT2) 
and the mitochondria (SIRT3-5)67,68. HDAC11 is the only member of Class IV HDACs. 
It is expressed in the brain, heart, muscle, kidney and testis, but little is known about its 
function. Class I, II and IV HDACs require a zinc ion for deacetylase activity whereas 
Class III HDACs are dependent on nicotinamide adenine dinucleotide cofactor for their 
enzymatic activity66,68. 
Class I HDACs interact with major corepressor complexes, which are then 
targeted to specific genomic regions by interactions with DNA binding factors that 
include transcription factors, nuclear receptors, and epigenetic regulators. HDAC1 and 
HDAC2 are in complex with the SIN3 complex, CoREST complex, NuRD complex 
while HDAC3 is only found with NCoR/SMRT complexes22.  
1.4.5.1  HDAC substrate specificity  
Despite extensive research surrounding HDACs, no definitive histone substrate is 
characterized for each HDAC. This is in part due to most purified recombinant HDACs 
being enzymatically inactive68,69. Functional redundancy is another factor limiting such 
studies, as some HDACs can compensate in the absence of the other. Furthermore, some 
HDACs are part of several different complexes; for example, HDAC1 and HDAC2 form 
a heterodimer in at least 4 different multi-complexes that could possibly have different 
substrate specificity70.  
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1.4.5.2  Regulation of HDAC activity   
The most well defined mechanisms of HDAC regulation are protein–protein 
interactions and posttranslational modifications68. HDACs can undergo a variety of 
posttranslational modifications including acetylation, glycosylation, S-nitrosylation, 
sumoylation, ubiquitination, and phosphorylation71.  
HDAC1 can be phosphorylated by by cAMP-dependent protein kinase A (PKA) 
and casein kinase II (CK2) while HDAC2 is phosphorylated uniquely by protein kinase 
CK272. Phosphorylation of HDAC1 and HDAC2 are essential for enzymatic activity as 
mutations in phosphorylation sites result in a significant reduction in enzymatic activity68. 
Such mutations also disrupt protein complex formation of HDAC1 and 2 with RbAp48, 
MTA2, SIN3, and CoREST68. Recently, D-myo-inositol-1,4,5,6-tetrakisphosphate 
[Ins(1,4,5,6)P4] molecule has been demonstrated to stabilize interaction between HDAC3 
and NCoR repressive complex as well as interactions between HDAC 1 and 2 with 
MTA1 from the NuRD complex73,74.  
1.4.6 DNA methylation  
DNA methylation is an epigenetic mark that involves a transfer of a methyl group 
to the 5th carbon of the cytosine residue (5mCs), mainly in a CpG dinucleotide context to 
silence gene expression75–77. CpG islands are regions of DNA that contain a large number 
of CpG dinucleotide repeats in the genome and are often associated with promoter 
regions, with around 60% of gene promoters reside within CpG islands76.  The 
methylation status in CpG islands are often correlated with the activity of a gene, that is 
actively expressed genes are unmethylated while inactive genes are highly methylated75.  
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Next-generation sequencing aided in characterizing genome wide DNA 
methylation patterns at a single base-pair resolution from plants to humans78–80. These 
methylome maps provided comprehensive details of the frequency and genomic 
distribution of 5mCs, as well as the interplay between DNA methylation and other 
epigenetic mechanisms. 
Three DNA methyltransferases (DNMTs), DNMT1, DNMT3a and DNMT3b, 
catalyze the transfer of a methyl group from S-adenosyl-L-methionine (SAM) to the C5 
position of cytosine76,78. DNMT1 preferentially methylates hemimethylated DNA, 
whereas DNMT3a and DNMT3b are involved in de novo DNA methylation. DNMTs are 
recruited to specific genomic regions directly as they contain specific domains that 
directly recognize certain modifications of the histone H3 tail in chromatin.  For example, 
the ATRX-DNMT3-DNMT3L domain of DNMT3a recognizes unmethylated H3K4 and 
therefore can bind to DNA77,78. In contrast, when H3K4 is trimethylated, an active sign of 
gene expression, DNMT3a cannot be recruited to specific genomic regions. Several 
genome-wide studies showed a strong inverse correlation of DNA methylation and 
H3K4me3 modification to support this hypothesis76,77.  
DNA methylation is essential for regulating tissue-specific gene expression, 
genomic imprinting and X chromosome inactivation77,78. DNA methylation was 
considered a stable tag for long-term repression of gene expression because of the strong 
covalent carbon-to-carbon bond that connects cytosine to a methyl group. Recently, the 
discovery of ten–eleven translocation enzymes showed that DNA demethylation can 
occur through the stepwise oxidation of 5mC to 5-hydroxymethylcytosine, 5-
formylcytosine and finally to 5-carboxylcytosine followed by the removal of the higher 
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oxidized bases by thymine DNA glycosylase and the base excision repair mechanism78. 
Similarly, activation-induced cytidine deaminase/apolipoprotein B mRNA-editing 
enzyme complex is shown to effectively convert 5mC into thymine, thus creating a 
guanine/ thymine  mismatch and inducing the base excision repair pathway to correct the 
base78. Little is known how DNA demethylases are recruited on target genomic regions. 
Crosstalk between DNA methylation with histone modifications is shown to be important 
in regulating transcription.  
1.4.7 Histone methylation  
Histone methylation occurs on arginine and lysine residues and they can be 
monomethylated (me1), dimethylated (me2) or trimethylated (me3) on their ɛ-amine 
group while arginines can only be me181. A variety of histone methyltransferases 
(writers), histone demethylases (erasers), and methylated histone binding proteins 
(readers) have been identified82. Unlike histone acetylation, which neutralizes the positive 
charge on the lysine, no such change in charge is evident with methylation. Instead, the 
methylation site and number of methyl group transferred (whether me1, me2 or me3) can 
determine the status of gene expression59. For example, H3K4me3 on promoters is 
generally associated with active transcription or with genes that are poised for activation, 
whereas H3K9me3, H3K27me3, and H4K20me3 are associated with repressed 
chromatin82. H3K79me2 is important for cell-cycle regulation, whereas H3K36me3 
modification is associated with transcription elongation81,82.  
1.4.7.1  Histone methyltransferases 
To date, numerous histone methyl lysine transferases (HMKTs) have been 
identified. All HMKTs with the exception of disruptor of telomeric silencing-1-like 
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methyltransferase, have an evolutionary conserved Suppressor of Variegation 3-9 
[SU(VAR)3–9], Enhancer-of-Zeste, Trihorax (SET) domain, which contains the catalytic 
site5,50,83. All HMKTs catalyze the addition of methyl groups donated from S-
adenosylmethionine to histones84. Unlike HATs that show no substrate specificity, 
HKMTs tend to be relatively specific enzymes. For example, SET7/9 only mono-
methylates while PR/SET domain 9 (PRDM9) trimethylates H3K443,85.  In general, the 
lysine-binding pocket controls the degree of methylation in the SET domain-containing 
HKMT's86. Methylated histones are recognized by proteins with methyl-binding 
domains48, which include PHD fingers87, Proline-Tryptophan-Tryptophan-Proline 
(PWWP) domains88, ankyrin repeats 89and chromo domains90. 
1.4.7.2  Protein arginine methyltransferases 
There are nine protein arginine methyltransferases (PRMTs) encoded in 
mammalian genomes. These enzymes catalyse three types of arginine methylation — 
monomethylation and two types of dimethylation. Protein arginine methylation is a 
common modification that has been implicated in signal transduction, gene transcription, 
DNA repair and mRNA splicing, among others91. The PRMTs can methylate both 
nuclear and cytoplasmic proteins as well as histone tails. Like other methyl transferases, 
PRMTs also use SAM as a methyl donor and transfer it to the guanidinium side chain of 
arginine (reviewed in 91,92).  
1.4.7.3  Histone demethylases 
Until recently, methylation was considered an irreversible process despite early 
biochemical studies suggesting enzymatic activities that can remove these modifications 
may exist in the cells. However, this dogma of methylation was dismissed with the 
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discovery of LSD1 in 200493. Soon thereafter, several jumonji C (JmjC)-domain-
containing demethylases were identified, and subsequent studies showed that histone 
methylation is in fact reversible94. Since these initial discoveries, an extended family of 
related demethylase enzymes has been identified and their substrate specificities have 
been characterized in detail (reviewed in95–97). Similar to lysine methyltransferases, 
demethylases possess a high level of substrate specificity with regard to their target 
lysine. They are also sensitive to the degree of lysine methylation; for instance, some of 
the enzymes are only capable of demethylating mono- and di-methyl substrates, whereas 
others can demethylate all three states of the methylated lysine95,97.  
1.5 Recruitment of histone regulators on chromatin 
Regulation of how and when histone modifiers are employed to specific histone 
targets is an important area of current research. Numerous ‘reader proteins’ contain 
specific domains that specifically recognize modified histones and employ other 
regulators to the target loci. Acetylated lysines in histones are bound by bromodomains, 
which are often found in chromatin-remodelling complexes62. For example, SWI2/SNF2 
contains a bromodomain that targets it to acetylated histones, which in turn recruits the 
SWI/SNF remodelling complex to rearrange the chromatin in a more active 
conformation62. Methylated lysines are recognized by several domains, including the 
PHD fingers and the so-called Tudor 'royal' family of domains, comprising 
chromodomains, Tudor, PWWP and malignant brain tumor domains53. For instance, 
H3K4me3 – a mark associated with active transcription – is recognized by a PHD finger 
within the inhibitor of growth (ING) family of proteins (reviewed in 98). The ING 
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proteins in turn recruit additional chromatin modifiers such as HATs and HDACs to 
regulate chromatin acetylation. 
Additionally, specific DNA sequences have been identified that are responsible 
for the recruitment of several histone-modifying enzymes. These enzymes directly 
interact with DNA, for example the Drosophila melanogaster Trithorax group (TrxG) 
response elements and the Polycomb group (PcG) response elements, which recruit TRX, 
a H3K4 methyltransferase and  enhancer of zeste homologue 2 (EZH2), a H3K27 
methyltransferase, respectively. TrxG is a heterogeneous collection of proteins that 
function antagonistically against the PcG to activate target gene expression (reviewed 
in79,99). Non-coding RNAs have also been shown to be important for recruitment of 
chromatin modifying complexes100. Furthermore, sequence‐specific DNA‐binding 
transcription factors have been demonstrated to directly target histone modifiers to 
chromatin82.  
1.5.1 Non-coding RNAs recruit complexes onto chromatin 
Over the last few years, numerous studies have revealed examples of long non-
coding RNAs (lncRNAs) involved in targeting several chromatin modification complexes 
to specific genomic locations. lncRNAs are defined as transcripts longer than 200 
nucleotides that do not encode a protein.  lncRNAs have been shown to interact with 
members of the PRC2 complex and LSD1/CoREST/REST complex where they act as a 
modular scaffold and link a histone methylase and a demethylase on target genes100. 
Furthermore, CCAAT/enhancer-binding protein-alpha ncRNA have been demonstrated to 
interact with DNMT1 by forming a stem-loop structure to inhibit DNA methylation101. In 
contrast, lncRNA DNMT1-associated colon cancer repressed lncRNA 1 is found to 
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interact with DNMT1 and enhance DNA methylation at multiple loci without affecting 
DNMT1 protein levels102. 
Recently, loss-of-function studies showed that knockdown of lncRNAs to have 
major consequences on gene expression patterns, comparable to knockdown of some 
known chromatin regulators103. These results strongly suggest that lncRNAs serve to 
modulate the targeting of chromatin modifying complex to specific genomic loci. 
However, future studies will need to investigate the directness of these interactions, and 
determine how lncRNAs confer specificity to highly dynamic chromatin modifying 
complexes.  
Histone marks are associated with distinct transcriptional states, which are 
established through dynamic interplay between histone readers, writers, and 
erasers. Chromo domain protein, Y-like (CDYL) is a highly studied epigenetic reader 
discussed briefly in the subsequent section.  
1.6 The CDY-related gene family 
The chromo domain Y-related (CDY) protein family represents a set of related 
genes discovered in 1999 by Lean et al.104 In humans, the CDY protein family contains 
six proteins (CDY1, CDY1B, CDY2A, CDY2B, CDYL1, and CDYL2). CDY1, CDY1B, 
CDY2A, and CDY2B are four nearly identical genes located on chromosome Y and the 
encoded proteins share more than 96% sequence identity105. The other two members, 
CDYL1 and CDYL2 are autosomal genes, which are located on chromosome 6 and 16 
respectively85. CDYL1 and CDYL2 proteins only share 43% sequence identity. Sequence 
analysis between autosomal proteins and the four “Y” chromosomal proteins showed 
even less conservation105. In humans, the autosomal CDYL genes are ubiquitously 
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expressed, while the CDY genes are only expressed in testis, thus suggesting the CDY 
family of proteins functions in both somatic development and spermatogenesis106.  
1.6.1  Structure, Isoform, and Expression of CDYL 
The CDY family proteins share a N-terminal chromo domain, a central hinge 
region, and a C-terminal enoyl-coenzyme A hydratase/isomerase catalytic domain (also 
known as CoA pocket or CoAP) shown in Fig 3. Crystallization studies of the CDY 
family proteins revealed that CDYL contains three protein molecules per crystallographic 
unit. Also, it is reported that CDYL multimerizes through the CoA pocket, a key step for 
binding methylated histones107. There are three splice variants of CDYL1 namely 
CDYL1a, -b, and –c (Fig 3), which differ in the N-terminal domain107. The CDYL gene 
locus contains 10 exons. CDYL1a isoform is the longest variant generated by splicing of 
the first three to the last six exons. The second splice variant CDYL1b emerges from 
exons 4–10 and a third variant, CDYL1c originates from splicing of exon 4 to exons 6–10 
of the CDYL gene locus.  CDYL1a protein contains extra 62 amino acids in the N-
terminus while CDYL1c lacks the chromo domain region and a 175-aa long part of the 
linker region altogether. Both CDYL1a and CDYL1b isoforms contain a chromo domain 
but only CDYL1b is able to recognize methylated histone lysine residues 
(H3K9me3)85,107. 
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Figure 3. Schematic illustrating the human CDYL isoforms.  
Schematic representation of the protein domain structure of CDYL1 splicing variants a, 
b, and c. All three CDYL isoforms contains a CoA pocket in the C-terminus but only 
CDYL1a and CDYL1b contain a chromo domain in the N-terminus.  
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1.6.2  Binding partners of CDYL1 
CDYL1 is a nuclear protein characterized as a transcriptional corepressor and a 
histone code reader. CDYL1b is the only variant shown to bind methylated histones 
(H3K9me3, H3k27me3). Biochemical studies have identified CDYL1 as a component of 
repressor complexes CtBP and REST/CDYL1/ G9a. CDYL1’s role in CtBP complex is 
still unclear but in the CoREST complex it bridges the interaction between REST and 
G9a and functions as a REST corepressor that facilitates G9a recruitment to REST target 
genes108. Mass spectrometry analysis of Flag-HA-tagged CDYL1 from HeLa nuclear 
extracts revealed MIER1 and MIER2 to be present among 22 other CDYL1 associated 
proteins; the majority of which are involved in transcriptional repression108.  
CDYL has also been shown to bind CoA and HDAC1 and HDAC2 through the C-
terminus CoA pocket 109. Conflicting results have suggested that the CoA pocket of 
CDYL1 possesses HAT activity in the elongation of spermatids during hyper acetylation 
and replacement of histones105. However, the results were not repeated109 and CDYL1 
role as a HAT remains elusive. 
Histone peptide binding assays were performed to characterize the histone-
binding preference of CDYL1. CDYL1 associated strongly with the repressive H3 lysine 
methylation marks, including H3K9me3, H3K27me2, and H3K27me3. In addition, 
CDYL1 is reported to directly interact with EZH2, the catalytic subunit of PRC2, where 
it dramatically enhances the methyltransferase activity of PRC2. Also, genome-wide 
analysis of CDYL targets by ChIP sequencing revealed that CDYL1 and PRC2 share a 
number of genomic targets110,111. 
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Recently, CDYL1 is reported to act as a crotonyl-CoA hydratase to negatively 
regulate histone lysine crotonylation (Kcr), a newly identified histone modification 
enriched at active promoters and potential enhancers in mammalian cells112. The negative 
regulation of histone Kcr by CDYL1 is intrinsically linked to its transcription repression 
activity. Additionally, the authors showed that both the chromodomain and CoAP pocket 
of CDYL1 are required for its negative regulation of Kcr112.  
1.7 Key transcription factors regulating gene expression   
Transcription factors (TFs) are proteins involved in the initiation and regulation of 
gene transcription. Regulation of transcription is the most common form of gene control8. 
The action of transcription factors allows for unique expression of each gene in different 
cell types and during development8. Winged helix/forkhead-box (FOX), Positive 
regulatory domain ( PRDMs) and Restriction element 1 silencing transcription factor 
(REST) are just a few major TFs that will be discussed in brief next as they are important 
to our study.  
1.7.1  Forkhead-box family of proteins 
The winged helix/forkhead-box (FOX) proteins are member of large family of 
transcriptional factors involved in regulating cell growth and differentiation as well as 
embryogenesis and longevity113. The FOX protein contains a FOX domain, a 110-amino 
acid long motif that is conserved from yeast to human and functions as a DNA-binding 
domain114. FOX proteins also contain an extra-FOX protein–protein interaction 
domain115, important for interactions with transcriptional activators, transcriptional 
repressors, or DNA repair complexes114. There are 50 FOX genes in the human genome 
divided into 19 subfamilies116.  
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The subfamily FOXA includes 3 members named FOXA1, FOXA2, and FOXA3, 
which are vertebrate FOX proteins most closely related to Drosophila FOX protein. All 3 
members are shown to regulate the development of a number of endoderm-derived 
organs including liver, lung, pancreas, kidney, and prostate. FOXA control directly or 
indirectly through moderating the expression of a variety of signalling and metabolic 
proteins expressed in the liver117. FOXA can directly bind to the target DNA regions in 
condensed chromatin and remodel its structure, which makes the regulated genes 
available for activation. This activity allows binding of other chromatin modifiers to the 
target gene, which otherwise in the absence of FOXA cannot access their cognate sites 
within DNA118.   
1.7.2 PRDM 
Positive regulatory domains (PRDMs) belong to a structurally related family of 
transcriptional regulators and chromatin modifiers important for driving differentiation of 
a variety of cellular types119. PRDMs are characterised by the presence of at least two 
distinct domains, the zinc fingers and the PR/SET domains (named after the Drosophila 
transcription factors Suppressor of variegation 3–9, Enhancer of Zeste and Trithorax 
(SET) and Positive regulatory domain I-binding factor 1/Retinoblastoma protein-
interacting zinc finger gene 1 (PR) motifs)119–121. There are 17 orthologs of PRDMs in 
primates, which have emerged as key regulators of differentiation modes. Many PRDMs 
are expressed in specific precursor cell populations and are necessary for their 
progression to a fully differentiated phenotype (reviewed in119,122,123). They achieve this 
either by enzymatic activity towards histones or recruitment of interaction partners to 
modify the expression of target genes119,122,124. For example, PRDM1 is involved in the 
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specification of primordial germ cells, forelimb patterning, and reprogramming of 
intestinal enterocytes125. PRDM14 is an important factor in the maintenance of human 
embryonic stem (ES) cells by regulating genes involved in ES cell self-renewal and 
differentiation126. PRDM16 is considered the master regulator of brown fat identity 127and 
recently, PRDM4 has been demonstrated to promote differentiation of brown fat120.  
So far only three PRDMs have demonstrated to possess intrinsic HMTase activity 
despite all possessing SET domains. Recombinant PRDM2 and PRDM8 were both 
shown to act as repressive HMTases by catalyzing H3K9me2 from native H3 124,128, 
whereas PRDM9 catalyzes the activating histone mark H3K4me3 83. Although most 
PRDMs lack intrinsic HMTase activity, they are involved in epigenetic regulation of 
gene expression through the formation of chromatin remodeling complexes containing 
G9a and HDAC1-3119. Additionally, PRDMs act as a scaffold via their C2H2 zinc-fingers 
tethering transcription factors to target gene promoters by recognizing a specific DNA 
consensus sequence to alter expression119,122.  
PRDM4 is also known as Schwann cell factor 1 (SC-1) and associates with 
HDACs1-3 and p75129. Recently, PRDM4 was shown to recruit PRMT5, an arginine 
methyltransferase that catalyzes dimethylation of histone H4 arginine 3 (H4R3me2). This 
modification is often associated with undifferentiated cortical neural stem cells 
(NSCs). Moreover, researchers found that high levels of SC1-PRMT5 complex are 
required in NSCs to maintain the proliferative capacity and “stem-like” cellular state. 
Knockdown of PRDM4 in NSCs lead to precocious neuronal differentiation suggesting 
PRDM4s role in repression of neuronal genes122.  
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1.7.3 REST 
Restriction element 1 silencing transcription factor (REST), also known as 
neuron-restrictive silencer factor (NRSF) is a zinc finger protein that represses neuronal 
genes in non-neuronal tissues. REST was discovered in 1995 by two independent groups 
who showed REST to function as a transcriptional repressor by binding to a conserved 
23bp motif known as repressor element 1 (RE1) in a large number of neuronal genes 
within their regulatory regions130,131. REST has been shown to be an important regulator 
for the establishment of neuronal specificity. It regulates many target genes in stem cells, 
non-neural cells, and neurons, which are involved in neuronal differentiation, axonal 
growth, vesicular transport and release. REST is required to repress more than 2000 
neuron-specific genes that have been examined to date in non-neural tissues and 
undifferentiated neural precursors.  
REST is highly expressed in nonneural cells and decreases with neurogenesis but 
is not fully turned off in mature neurons as expression of REST is detected in the adult 
brain. REST is highly regulated by ncRNAs, including miR-124a, miR-9, and miR-132, 
which is exclusively expressed in the post mitotic neurons. REST expression is also 
controlled by ubiquitin mediated proteolysis via a Skp1-Cul1-F-box protein complex 
containing an E3 ubiquitin ligase. Additionally, REST activity can be regulated by 
translocation of REST in or out of the nucleus132. The authors found that the wild-type 
Huntington protein functions in the cytoplasm of neurons to regulate the availability of 
REST to its nuclear RE1 binding site and that this control is lost in the pathology of 
Huntington’s disease. Furthermore, it has been reported that the canonical Wnt pathway 
directly controls REST expression133.  
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 The mechanisms underlying how REST regulates stem cell differentiation are not 
entirely understood. It inhibits target genes expression by engagement of corepressors, 
SIN3 and CoREST, which in turn recruit HDACs and other chromatin modifying 
enzymes to the promoters of REST-regulated genes to facilitate repression134. Gupta et 
al.135 demonstrated that down regulation of REST in mouse ES cells induced neuronal 
differentiation. The results showed that although control ES cells required induction by 
retinoic acid (RA) to differentiate efficiently into neurons, suppression of REST was 
sufficient to drive the ES cells down the neuronal lineage even in the absence of RA. 
Furthermore, Gao et al.136 reported that in cultured NSCs, knockdown of REST is shown 
to induce the expression of the pro-neuronal genes neuronal differentiation 1 and Tubulin 
3, suggesting that REST knockdown is sufficient to derepress target genes, even in the 
absence of neuronal induction. REST null mice are embryonic lethal at E9.5, exhibiting 
delayed development and a malformed telencephalon137. However, silencing REST does 
not show widespread precocious expression of REST target genes suggesting there are 
other factors that play a role in regulating transcription of neurogenesis genes. REST 
conditional knockout mice revealed a vital role of REST in adult NSCs is to maintain 
them in a quiescent state by inhibiting the neurogenic program136.  
Recent findings reveal that REST also play a role in fine-tuning of genes 
important to synaptic plasticity138. N-methyl-D-aspartate receptors (NMDARs) are 
critical to synaptogenesis, neural circuitry and higher cognitive functions such as learning 
and memory. A hallmark feature of NMDARs is an early postnatal developmental switch 
from those containing primarily GluN2B to primarily GluN2A subunits. The authors 
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reported that REST repressed GRIN2B expression via chromatin remodelling, as the 
switch from GluN2B to GluN2A is important to synaptic function. 
REST has also been shown to function not only as a transcriptional repressor but 
also act as an activator to induce neuronal differentiation139. Kuwabara et al. reported that 
the RE1 dsRNA activates expression of neuron-specific genes through interaction with 
REST transcriptional machinery140. The detailed mechanisms underlying how REST 
regulates its target genes remains elusive, in part due to its functional complexity and 
thousands of target genes. It is also unclear how REST selectively represses distinct 
target genes in different cellular contexts, and why changes in REST expression or 
activity result in changes in expression of only a subset of target genes. Thus, future 
studies investigating its dual roles as repressor/activator and interacting partners will be 
very important for revealing its various functions under different conditions.  
There are four isoforms of REST produced by alternative splicing. The canonical 
isoform of REST protein contains three functional domains: a DNA binding domain 
consist of eight zinc-finger motifs that binds to the RE1 motif, and two independent 
repressor domains, one located at the N- and one at the C- terminus of the protein. The N 
terminus of REST recruits the SIN3A/B HDACs complex and the C-terminal repression 
has been shown to recruit a distinct HDAC complex via its interaction with CoREST141. 
Isoform 2 is missing amino acids 330-1097 and differs in amino acid 301-313; 
ERPYKCELCPYSS → KRSFLVHKFSSLF. Isoform 3 is made up of 1-329 amino acid 
residues while isoform 4 is different from the canonical isoform by missing amino acid 
residues 304-326. Splice variant REST4 expression is seen in mice during seizures as 
well as in small cell lung cancers. It is a poor repressor of transcription because of 
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reduced DNA binding ability and loss of at least one repression domain, resulting in the 
overexpression of REST target genes and imparting a neuroendocrine phenotype on the 
cells142. 
 Several studies have shown that REST is important for normal brain function and 
that its overexpression or mutation is potentially involved in several brain disorders 
including global ischemia, stroke, epilepsy, Alzheimer's and Huntington's disease 
reviewed in 133,143. In addition to regulating neuronal development, REST is also shown 
to function as a tumour suppressor in epithelial tissues. Consequently, inactivating 
mutations, gene deletions, epigenetic gene silencing, and alternative splicing 
of REST have been associated with epithelial cell transformation and malignancies such 
as breast cancer142,144. 
 
1.8 Mesoderm Induction Early Response  (MIER) 
The MIER family consists of three genes encoding related proteins with 
conserved primary sequence, particularly in the ELM2 and SANT domains145. MIER1 is 
the prototypical member, discovered in our lab. MIER2 and 3 were sequenced by the 
NIH Mammalian Gene Collection Program146, and then named based on homology in 
their ELM2 and SANT domains to MIER1.  
1.8.1  MIER1 
MIER1 is a nuclear protein, first identified in Xenopus lavis in our lab as a 
fibroblast growth factor-activated transcriptional regulator147. Human MIER1 is a single 
copy gene on chromosome 1 that spans 63 Kb and consist of 17 exons148. It gives rise to 
multiple isoforms as a result of alternative promoter usage and splicing. The resulting 
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MIER1 protein isoforms vary in their N- and C-terminal sequences but share a common 
internal region that contains the functional domains (Fig 4). MIER1 is highly conserved 
in evolution. Human MIER1 shares 95% identity at a sequence level with the mouse 
MIER1149.  
There are two MIER1 isoforms that have distinct N-termini, which is the 
consequence of using two alternate promoters, P1 and P2. MIER1-3A is transcribed from 
P1, includes a cassette exon 3A resulting in an extended N-terminus, which contains a 
bona fide nuclear export signal (NES)149. The C-termini variants, MIER1α and MIER1β 
result from alternate inclusion of a facultative intron and therefore differ in both size and 
sequence. PCR analysis using multiple breast cell lines has shown that the β variant is 
more abundant than the α isoform150. The α variant C-terminus is made of 23 amino acids 
(aa) including a classic LXXLL motif for interaction with nuclear hormone receptors, 
including ERα151. Previously, our lab has shown that MIER1α interacts with ERα in 
MCF7 cells and MIER1α overexpression inhibits estrogen-stimulated anchorage-
independent growth. The β variant, which results from inclusion of the facultative intron, 
contains 102 aa including a functional nuclear localization signal (NLS) illustrated as 
schematic in Fig 4C148,152. 
Figure 4. Schematic illustrating the human MIER1 gene and isoforms.  
(A) MIER1 structure: Exons are shown as red vertical lines and introns as horizontal 
lines; exon numbers are indicated below each schematic. The pink bar indicates the 
facultative intron 16 and the position of the alpha and beta carboxy-terminal coding 
regions are indicated. The three alternate starts of translation, ML-, MF- and MAE- are 
indicated as are the three polyadenylation signals (PAS): i, ii and iii. (B) Schematic 
illustrating the isoforms of human MIER1. Alternate 5' ends are generated from 
differential promoter usage (P1 or P2) or alternate inclusion of exon 3A. This leads to 
three alternate starts of translation, indicated as ML-, MF- and MAE-, and produces three 
distinct amino termini. The four variant 3' ends, a, bi, bii and biii, produced by alternative 
splicing or alternate PAS usage, result in different size transcripts. (C) Schematic 
illustrating the common functional domains of the MIER1 isoforms and the variant 
amino- (N-) and carboxy- (C-) termini. Transcription from the P1 promoter produces 
proteins that either begin with M-L- or with the sequence encoded by exon 3A 
(MFMFNWFTDCLWTLFLSNYQ). Transcription from the P2 promoter produces a 
protein that begins with M-A-E-. MIER1 isoforms have common domains such as acidic 
stretches, ELM2 and SANT. The two alternate C-termini, alpha and beta, result from 
removal or inclusion and read-through of intron 16, respectively. The alpha C-terminus 
contains a classic LXXLL motif for interaction with nuclear receptors; the beta C-
terminus contains a nuclear localization signal (NLS). 
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1.8.2  MIER2 
Human MIER2 is a single copy gene on chromosome 19 that spans 43 Kb and 
consist of 14 exons. A single transcript of 545 aa long is transcribed. MIER2 contains a 
nuclear localization signal between 244aa-253aa according to NLS prediction 
software153. Recently, we have demonstrated MIER2 to localize mostly in the nucleus but 
also significant cytoplasmic expression was detected145.    
1.8.3  MIER3 
Human MIER3 is also a single copy gene that spans 56 Kb and consist of 13 
exons. It gives rise to 5 isoforms as a result of alternative splicing. Isoform 1 has been 
designated the canonical sequence; isoform 3 differs from this sequence by a single 
amino acid deletion (aa277) in the ELM2 domain. Isoform 2 contains a 5aa insertion near 
the N-terminus, while isoform 4 is missing the first 63aa. Lastly, Isoform 5 is a truncated 
variant containing only the N-terminal 119aa, missing both the ELM2 and SANT 
domains. According to NLS prediction software153, MIER3 encodes a nuclear 
localization signal between 477aa-485aa and we confirmed that indeed MIER3 localizes 
exclusively in the nucleus145.  
1.8.4    MIER structure, function, and expression 
The three MIER family members and their isoforms share a number of features 
with other transcriptional corepressors including the ELM2 domain, and a SANT 
domain149,154,155.  
1.8.4.1  The ELM2 domain  
The ELM2 (EGL27 and MTA1 homology) domain was first discovered in EGL-27, a 
Caenorhabditis elegans protein characterized to play an important role in pattern 
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modulation during embryonic development156. The ELM2 domain is highly conserved 
through evolution and our lab was the first to show a functional role through binding to 
HDAC 1 and HDAC 2157. In MIER1, the ELM2 domain was shown to recruit histone 
HDAC1 and 2 and repress transcription. In addition, MIER1 was discovered to bind 
CBP, inhibiting its HAT activity158. The N-terminal region aa 1-283 of MIER1, which 
includes the ELM2 domains, is responsible for this interaction. Similarly, other 
corepressors such as MTA1-3159 and RCOR1-324 also recruit HDACs through their 
ELM2 domain. Interestingly, most ELM2 domain-containing proteins also possess a 
SANT domain immediately downstream, implying a structural and/or functional 
relationship between these two motifs. 
1.8.4.2  The SANT domain 
The SANT domain is a small highly conserved module made up of ~ 50 amino 
acid residues immediately downstream of the ELM2 domain160. The SANT domain was 
initially defined in the transcriptional factors SWI3, ADA2, N-CoR, and TFIIIB; hence 
the acronym “SANT”160. Subsequently, the SANT domain was found in the subunits of 
many chromatin-remodelling complexes. High-resolution X-ray structure of a SANT 
domain revealed tandem repeats of three α-helices that are arranged in a helix–turn–helix 
motif 160. The SANT domain was first identified based on its homology to the DNA 
binding domain (DBD) of c-Myb, which also consisted of tandem repeats of three α-
helices161. Unlike the DBD of c-Myb, the SANT domain does not bind DNA. Crystal 
analysis of the structure of the c-myb-DNA complex identifies several key residues 
within the third α helix to be involved in DNA interactions, which are not conserved 
within the SANT domain161. In contrast, the SANT domain of ADA2P was demonstrated 
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to interact with histone tails. Also, biochemical analysis of MTA1/CHD4 interactions 
suggests that the SANT containing protein MTA1 acts as a scaffold for NuRD complex 
assembly27. MTA1 is crucial in recruitment of multiple proteins to the target gene loci to 
modulate histone tails to repress transcription. In MIER1, the SANT domain is important 
for interactions with transcription factor specificity protein 1 (SP1)162. SP1 is a sequence-
specific transcription factor that binds GC and GT boxes to activate a wide range of viral 
and cellular genes (reviewed in 163).  Our lab demonstrated that MIER1 via the SANT 
domain formed a complex with SP1 and this interaction interfered with SP1 recognition 
and binding to GC boxes and thus resulted in repression of its own promoter in an 
HDAC-independent manner162. Additionally, MIER1 was unable to bind DNA directly, 
which is consistent with known literature that SANT domain of yeast SWI3P, ADA2P, 
AND RSC8P does not involve DNA binding160.  
1.8.4.3  MIER1 expression 
PCR analysis of the MIER1 in human tissues revealed that the β isoform is more 
widely expressed and much more abundant than the α isoform152. The expression was 
tested in 23 tissues including the heart, placenta, liver, testis, ovary, colon, peripheral 
blood, leukocyte, stomach, thyroid, spinal cord, lymph node and adrenal gland and 
testis152.  The results showed MIER to be present in all 23 tissues but more abundantly in 
the testes.   
An immunohistochemical study of the MIER1α protein expression pattern in 
human tissues revealed an expression pattern predominantly in reproductive and 
endocrine tissues164. The most intensely stained tissues/organs included ovary, testis, 
pancreas, adrenal gland and pituitary. A few non-endocrine tissues/cells consistently 
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displayed intense immunoreactivity; these included neuronal cell bodies in several 
regions of the brain and cardiac muscle fibers. Additional moderate staining was 
observed in the liver and endothelial lining of blood vessels, weak staining in the lungs 
and kidneys while the remaining tissues/organs were negative164. The subcellular 
localization of MIER1α was cytoplasmic in all tissues examined, except in a oocytes, 
mammary ductal epithelia and germinal epithelia, where MIER1α was localized in the 
nucleus164. Immunohistochemical analysis of MIERα expression pattern in normal human 
breast and breast carcinoma samples revealed no difference in expression level but a 
dramatic shift in subcellular localization, from nuclear to cytoplasmic, during progression 
to invasive carcinoma151. MIER1α has been shown to interact with ERα in vitro and 
regulated overexpression in breast carcinoma cells resulted in inhibition of anchorage-
independent growth, which suggested MIER1’s role in breast cancer151. At present, 
there are no published data of MIER2 or 3 expression profiles. 
1.8.5  MIER binding partners 
MIER1 functions as a transcriptional corepressor by recruiting HDAC1 and 2 
through the conserved ELM2 domain157. Also, MIER1α association with HDAC1 and 2 
is key for its nuclear localization, as stated earlier MIER1α does not contain a NLS and 
depends on “piggyback” mechanism to get shuttled between cytoplasm and nucleus154. 
Also, MIER1 was shown to physically associate with SP1 through the SANT domain and 
repress its own expression by interfering SP1 binding to the promoter162. Blackmore et 
al.158 showed MIER1 to interact with CBP via the N-terminal half (amino acids 1–283) of 
MIER1, which includes the N-terminus and ELM2 domain. CBP is a coactivator that is 
shown to possess histone HAT activity.  
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Furthermore, our lab has shown MIER1α to interact with ERα and inhibit 
estrogen-stimulated growth of breast carcinoma cells. As previously discussed, MIER1α 
contains an LXXLL motif, important for interactions with nuclear receptors. McCarthy et 
al.164 showed MIER1α to interact with ERα in the presence or absence of estrogen in 
HEK293 and MCF7 cell lines. Also, overexpression of MIER1a in T47D breast 
carcinoma cells resulted in inhibition of estrogen-stimulated anchorage-independent 
growth, suggesting MIER1α’s role in regulating breast carcinoma cell proliferation. 
Furthermore, immunohistochemical analysis of normal breast tissue and breast carcinoma 
revealed a dramatic shift from nuclear to cytoplasmic localization of MIER1α during 
breast cancer progression. However, the molecular mechanisms of MIER1α localisation 
in breast cancer cells and its role in tumour progression to an invasive phenotype is still 
unclear.  
Additionally, MIER1 has been shown to interact with several chromatin 
regulators including HDAC1 and 2157, CBP162, G9a165, CDYL108, and more recently 
BAHD1155. However, the role of MIER1 binding to these regulators is not yet defined. 
Very little is known about MIER2 or MIER3 proteins and function. Both are predicted to 
be nuclear proteins based on sequence homology with MIER1. Two large-scale 
proteomic/interactome studies have identified MIER1, 2, and 3 proteins in association 
with HDAC1 and/or 263,166 but the functional role of MIER family members in these 
transcriptional repressive complexes is still unclear. As mentioned earlier, it is shown that 
other proteins with ELM2-SANT domains function as scaffolds linking TFs with 
chromatin-modifying enzymes to control gene expression by altering chromatin 
structure22,31.  
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1.9 Implication of chromatin regulators in disease  
Modifications to DNA and histones are dynamic processes that are maintained by 
chromatin-modifying enzymes in a highly regulated manner as briefly outlined 
previously. Consequently, abnormal expression profiles or mutations in chromatin 
regulators can have adverse health effects including cancer45,48. For instance, chimeric 
fusion proteins such as promyelocytic leukemia-retinoic acid receptor, promyelocytic 
leukemia zinc finger-retinoic acid receptor α, and acute myeloid leukemia 1-ETO are 
common in leukemia50. HDACs have been shown to recruit to these genes and mediate 
aberrant gene silencing, which contributes to leukemogenesis167. Importantly, a wide 
range of natural and synthetic compounds have been identified that are able to inhibit the 
activity of HDACs primarily through chelation of the zinc in the catalytic pocket168.  
Similarly, translocations, coding mutations, and/or overexpression in a large 
number of HKMT, including multiple myeloma SET domain, EZH2, and mixed lineage 
leukemia family members have been demonstrated in many different cancers99. 
Overexpression of EZH2 is evident in many cancers including prostate, breast, bladder, 
and melanomas and is associated with worst prognosis82,169. Moreover, EZH2 is critical 
for cancer cell proliferation and survival.  Therefore, EZH2 is currently considered a 
promising drug target, and multiple inhibitors of EZH2 have been developed, some of 
which are in clinical trials169. These inhibitors block the activity of EZH2 by binding to 
the SET domain, active site of the enzyme.  
Similarly, human DNMT enzymes are overexpressed in cancers o colon, breast, 
prostate, liver, and in leukemia, which may partially account for the hypermethylation of 
promoter CpG-rich regions of tumor suppressor genes in a variety of malignancies77. 
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Very little is known about MIER2 or MIER3 proteins and function. Both are 
predicted to be nuclear proteins and function as transcriptional corepressors. These 
characteristics are postulated onto these proteins based on the presence of functional 
domains, ELM2 and SANT also present in MIER1.  
1.10 Hypothesis 
In this thesis, I have begun to characterize MIER2 and MIER3 and compare them 
to MIER1α. I hypothesized that since both MIER2 and MIER3 have highly conserved 
ELM2 and SANT domains, then they would have the same subcellular localization, 
interacting partners in common and function as transcriptional corepressors.  
1.11 Objectives 
1. MIER1 has been well characterized and is known to function as a transcriptional 
repressor through its ability to recruit HDAC1 and 2. Little is known about 
MIER2 or MIER3 function and no study characterizing these two proteins has 
been published. The rationale to investigate MIER2 and MIER3 subcellular 
localization, their potential association with each other, their interaction with 
HDAC1 and 2, the activity of associated deacetylases and mapped key residues 
for HDAC recruitment was to determine whether the MIER proteins have 
redundant, overlapping or unique functions.  
2. MIER1 and 2 are among several other transcriptional repressor associated 
proteins identified in a mass spectrometric analysis of CDYL. CDYL is an 
important chromatin regulator shown to interact with HDAC1/2. I investigated the 
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association of CDYL with the MIER family; mapped key residues for CDYL 
interaction, and explored their function in the repressor complex. 
3. MIER1 is a well-characterized member shown to function as a transcriptional 
corepressor. While I demonstrated that MIER2 interacts with HDAC1/2 
suggesting a role as a transcriptional corepressor, the function of MIER3 is 
largely unknown. Moreover, MIER1-3 target genes are largely unknown. ChIP-
Seq is a powerful method combining chromatin immunoprecipitation (ChIP) with 
massively parallel DNA sequencing to identify genome-wide DNA binding sites 
for proteins of interest. To understand how MIER proteins interact with DNA 
along with other transcriptional regulators is essential for fully understanding their 
role in biological processes. As a result, to identify MIER protein enrichment on 
target genes in the entire genome, I analyzed ChIP-Seq datasets of MIER proteins 
from publicly available database of the ENCODE/HAIB project. 
4. MIER1 and MIER2 are enriched on REST target genes and co-
immunoprecipitation assays revealed that both MIER1 and MIER2 bind REST. 
As a result, I utilized mouse pluripotent P19 cells to identify the role of MIER1 
and MIER2 in neurogenesis.  
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Chapter 2: Materials and Methods 
2.1 Cell lines and culture conditions 
The MCF7 human breast adenocarcinoma (HTB22™), Human Embryonic 
Kidney 293 (HEK293) (CRL 1573™) and HeLa cell lines (CCL-2™) were obtained 
from the American Tissue Culture Collection (ATCC). All cell lines were cultured in 
high glucose DMEM (Thermo Fisher Scientific) containing 10% serum (7.5% calf serum 
(Thermo Fisher Scientific) plus 2.5% fetal bovine serum (Thermo Fisher Scientific) and 
1mM sodium pyruvate (Thermo Fisher Scientific). The P19 mouse embryonal carcinoma 
cell line (CRL1825TM) and the HepG2 human hepatocellular carcinoma cell line (HB 
8065 TM) were also obtained from the ATCC. These two cell lines were cultured in 
MEM-α (Thermo Fisher Scientific) containing 10% fetal bovine serum (Thermo Fisher 
Scientific). Cells were grown a humidified 37°C incubator with 5% CO2. 
2.2 Plasmids and constructs 
1. The human MIER1 gene structure, the sequence of its transcripts and the myc-tag 
vector (pCM3+MT) containing full-length MIER1A have been described previously 152. 
Briefly, an N-terminal myc-tagged construct was produced by subcloning the MIER1Α 
(GenBank accession no. AY124187) coding region with start and stop codon into the 
BamH1 and Bgl II sites of the pCS3+MT. A N-terminal myc tag was chosen to clone all 
MIER constructs because there is no known functional domain at this end and N-
terminal tag was what was available at the time and testing did not indicate any 
interference with known functions of MIER1. MIER1A was subcloned with start and 
stop codon into the EcoRI and XhoI sites of the pCMV-FLAG vector (Clontech 
Laboratories) to produce an N-terminal FLAG-tagged MIER1α protein. 
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MIER2 cDNA (GenBank accession no. BC028203) in pCMV-SPORT6 was 
purchased from Dharmacon. An N-terminal myc-tagged construct was produced by 
subcloning the MIER2 coding region with start and stop codon into the EcoRI and XbaI 
sites of the pCS4+MT vector 154 by PCR, using the following 
primers: 5’-GCGAATTCACCATGGCGGAGGCCTCCTCGC-3’(forward);  
5’-GCTCTAGATCAGCAGGTCATCACGTTACAG-3’(reverse). An N-terminal FLAG-
tagged construct was produced by subcloning the MIER2 coding region with start and 
stop codon into the EcoRI and HindIII sites of the pCMV-FLAG vector by PCR using the 
following primers: 5’-GCGAATTCACCATGGCGGAGGCCTCCTCGC-3’(forward);  
5’-GCAAGCTTTCAGCAGGTCATCACGTTACAG-3’(reverse). 
MIER3 cDNA (GenBank accession no. NM_152622.3) in the pReceiver-M51 
plasmid was purchased from GeneCopoeia. An N-terminal myc- or FLAG-
tagged MIER3 construct was produced by subcloning the coding region with start and 
stop codon into the EcoRI and XhoI sites of the pCS4+MT vector or pCMV-FLAG 
vectors by PCR using the following 
primers: 5’-GCGAATTCACCATGGCGGAGGCTTCTTTTGG-3’(forward);  
5’-GCCTCGAGTCACTCAGAGTGTAGGGC-3’(reverse). 
MTA1 cDNA in the pEnter vector was purchased from ViGene Biosciences and 
subcloned by PCR with start and stop codon into the EcoRI and XhoI sites of the 
pCS4+MT and pCMV-FLAG vectors using the following 
primers: 5’-GCGAATTCACCATGGCCGCCAACATGTACAGG-3’(forward);  
5’-GCCTCGAGCTAGTCCTCGATGACGATGGG-3’(reverse). 
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MIER2 deletion constructs were produced by PCR using the following primers: 
(MIER2-∆1) 5’-GCGAATTCACCATGGCGGAGGCCTCCTCGC-3’(forward),  
5’-GCTCTAGATCACACAGAGCCCATCTCGGATC-3’(reverse); 
(MIER2-∆2) 5’-GCGAATTCACCATGTGGAGTGAAGAGGAGTGCAGG-3’(forward)
, 5’-GCT CTA GAT CAG CAG GTC ATC ACG TTA CAG- 3’(reverse); 
(MIER2-∆3) 5’-GCGAATTCACCATGAAGAAGGAGATCATGGTGGGA-3’(forward)
, 5’-GCTCTAGATCACTTCTTCCACAGGTAGTA-3’(reverse); 
(MIER2-∆4) 5’-GCGAATTCACCATGAAGAAGGAGATCATGGTGGGA-3’(forward)
, 5’-GCTCTAGATCAAGCACAGAGCCCATCTCGGAT-3’(reverse). PCR products 
containing a start and stop codon were ligated into the EcoRI and XbaI sites of the 
pCS4+MT vector to produce N-terminal Myc-tagged proteins. 
MIER3 deletion constructs were produced by PCR using the following primers: 
(MIER3-∆1) 5’-GCGAATTCACCATGGCGGAGGCTTCTTTTGG-3’(forward),  
5’-GCCTCGAGTCATGCAGTCATTCCTTG-3’(reverse); 
(MIER3-∆2) 5’-GGGAATTCACCATGTGGACGGAAGAAGAATGC-3’(forward),  
5’-GCCTCGAGTCACTCAGAGTGTAGGGC-3’(reverse); 
(MIER3-∆3) 5’-GGGAATTCACCATGAGGAAGGAAATAATG-3’(forward),  
5’-GCCTCGAGTCATTTCTTCCACATATA-3’(reverse); 
(MIER3-∆4) 5’-GGGAATTCACCATGAGGAAGGAAATAATG-3’(forward),  
5’-GCCTCGAGTCATGCAGTCATTCCTTG-3’(reverse). PCR products containing a 
start and stop codon were ligated into the EcoRI and XhoI sites of the pCS4+MT vector 
to produce N-terminal Myc-tagged proteins. 
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CDYL1B cDNA (GenBank accession no. NM_004824) in pCMV-SPORT6 was 
purchased from Dharmacon.  An N-terminal myc- or FLAG-tagged CDYL1B construct 
was produced by subcloning the coding region with start and stop codon into the EcoRI 
and XhoI sites of the pCS4+MT vector or pCMV-FLAG vectors by PCR using the 
following primers: 5’-GCGAATTCACCATGATGGCTTCCGAGGAG-3’(forward);  
5’-GCCTCGAGCTAGAACTCATCGATCTTCCT-3’(reverse). 
CDYL1C cDNA (GenBank accession no. BC119682.2) was purchased from 
PlasmID. CDYL1C was subcloned from pCR-BluntII- TOPO into the EcoRI site of the 
pCMV-FLAG vector to produce an N-terminal FLAG-tagged MIER1α protein. 
Several myc-tagged mutant MIER1 and MIER2 constructs, each containing a 
single point mutation were produced using the QuikChange site-directed mutagenesis kit 
(Stratagene), using the appropriate primers listed in the table 8.  
All plasmids were prepared using the NucleoBond Endotoxin-free Maxi Plasmid 
kit (Clontech Laboratories), according to the manufacturer’s instructions. The 
sequences/mutations were confirmed by automated dideoxynucleotide sequencing of both 
strands (DNA Sequencing Facility, The Centre for Applied Genomics, The Hospital for 
Sick Children, Toronto, Canada). 
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Table 2: Antibodies used for Western, CoIP and Immunofluorescence (IF) 
Protein Host/Type Manufacturer  Catalogue 
number  
9E10 anti-myc tag Mouse monoclonal In house production  
HDAC1 Polyclonal rabbit  Santa Cruz Biotechnology H-51 
HDAC1 Mouse monoclonal  Santa Cruz Biotechnology 10E2 
HDAC2  Polyclonal rabbit  Santa Cruz Biotechnology H-54 
Flag M2 Mouse monoclonal Sigma F1801 
CDYL Rabbit polyclonal Abcam Ab5188 
G9a Rabbit polyclonal Millipore 07-551 
REST Rabbit polyclonal Millipore 09-019 
Alexa Flour-488  Jackson ImmunoResearch 
Laboratories 
715-546-151 
HRP-labeled sheep 
anti-mouse 
 GE Healthcare 
 
45000679 
 
HRP-labeled donkey 
anti-rabbit 
 GE Healthcare 
 
45000682 
 
HRP-label goat-anti 
mouse light chain 
specific 
 Jackson ImmunoResearch 
Laboratories 
115-035-174 
 
HRP-label mouse-
anti rabbit light chain 
specific 
 Jackson ImmunoResearch 
Laboratories 
211-032-171 
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2.3 Transient transfection 
MCF7 cells were transfected by electroporation using the Neon® electroporation 
device (Thermo Fisher Scientific) and the following settings: 1000V, 30ms, 2 pulses. 
3x105 MCF7 cells were mixed with 0.5μg myc-tagged plasmid and loaded into a 10μl tip 
for electroporation. HEK293 cells, Hep G2 cells, P19 cells, and HeLa cells (5x105 cells) 
were transfected with 0.5μg plasmid using transfection reagent Mirus TransIT-LT1 
(Medicorp) in a 3:1 ratio of reagent:DNA (v/w), according to the manufacturers’ 
protocol. Transient transfection was utilized to carryout experiments in MCF7 and 
HEK293 cells, as transfection efficiency is high. After transfection, cells were plated at a 
density of 4x104/well in Falcon 8-well culture slides (BD BioSciences) for confocal 
analysis or at 5x105 /well in a 6-well dish for co-immunoprecipitation (co-IP) and 
Western analysis. Transfected cells were cultured for a total of 48hr before processing for 
analysis. 
2.4 Immunofluorescence, confocal microscopy and analysis 
Transfected cells were fixed for 10 min with 4% paraformaldehyde/phosphate-
buffered saline (PBS) and permeabilized with 0.1% Triton X-100/PBS for 15 min. Non-
specific sites were blocked with 5% serum (the animal in which the secondary antibody 
was raised in) in PBS for 1hr before overnight incubation with specific primary antibody 
(1:200 dilution) at 4°C. Subsequently, the cells were incubated with appropriate 
secondary antibody (1:400) for 1hr at RT. Nuclei were counterstained with 2.5μg/ml 4′, 
6-diamidino-2-phenylindole (DAPI; Sigma-Aldrich) for 1hr. All slides were mounted in 
10% glycerol/PBS. Cells were examined under an Olympus FluoView FV1000 confocal 
microscope.  
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Fluorescence images for localization study were obtained by sequential z-stage 
scanning in two channels (DAPI and Alexa Fluor-488); z-stacks were compiled into 
individual images. Quantitative analysis of confocal z-stacks was performed using Image 
J software v1.50g, as described in149. Briefly, cell outlines from compiled z-stacks were 
traced and the sum of the pixel values within the outlines in the 488 channel was 
determined. After subtracting the background, this value was used as the corrected whole 
cell MIER fluorescence. The sum of the pixel values for nuclei was determined in the 
same way and used as corrected nuclear MIER fluorescence. The nuclear value was 
subtracted from the whole cell value to obtain cytoplasmic MIER fluorescence. For each 
construct, the average nuclear and cytoplasmic values from 30–40 cells was calculated. 
Statistical analysis was performed with GraphPad software, using a two-sided Fisher’s 
exact test. 
2.5 Co-immunoprecipitation (co-IP) and western blot analysis 
Transfected cells were washed once with 1xPBS and lysed on ice for 30 min in 
1xIP buffer (1% Triton X-100, 150 mM NaCl, 20 mM Tris-Cl pH7.5, 1 mM EDTA, 
0.02% Sodium Azide, 1 mM phenylmethylsulfonyl fluoride (PMSF), 1% protease 
inhibitor cocktail). Cell lysates were passed 10 times through a 26-gauge needle then 
centrifuged at 12,000xg for 10 min at 4°C. The supernatants were incubated overnight at 
4°C with appropriate antibody (1:100 dilution). 50μl of 50% slurry of either Protein A-
agarose beads (Pierce Biotechnology) or Protein G-agarose beads (EMD Millipore) was 
added to each sample and incubated for 1hr at 4°C. After incubation, the beads were 
washed 3 times with ice-cold 1xIP buffer and once with 150mM NaCl; bound proteins 
were solubilized in 30μl of 1.5x sodium dodecyl sulphate (SDS) sample buffer (50mM 
 
 
52 
Tris-Cl pH6.8, 2% SDS, 5% β-mercaptoethanol, 10% glycerol, 0.1% bromophenol blue) 
and analyzed by SDS-PAGE-Western. Expression levels were determined by Western 
blot analysis using extracts of cells solubilized in SDS sample buffer. 
Protein samples were separated by 7.5% or 4-20% polyacrylamide gels and 
transferred onto 0.2μm PVDF membranes (Trans-Blot TurboTM Transfer Pack; Bio-Rad 
Laboratories) using the Trans-Blot TurboTM system (Bio-Rad Laboratories) set at 2.5A, 
25V for 10 min. The membranes were incubated in a blocking solution (tris-buffered 
saline (TBS) containing 5% non-fat skim milk and 0.5% Tween-20) for 1 h at room 
temperature to reduce nonspecific adsorption of antibodies. After washing with Tris 
buffered saline with Tween® 20 (TBST) (TBS buffer containing 0.5 % Tween-20), the 
membranes were incubated with diluted primary antibodies in TBST for 1 h at room 
temperature or overnight at 4 C. After the membranes were washed with TBST, they 
were treated with diluted secondary antibodies in TBST for 1 h at room temperature. The 
treated membranes were visualized by using the Clarity western ECL substrate (Bio-Rad 
Laboratories). 
Densitometric quantitation of the interaction bands co-immunoprecipitating with 
MIER1, 2 and 3 was performed using Image J v1.50g. The band intensity in each 
immunoprecipitate was measured and the background subtracted. To account for 
variability in the expression level of the transfected protein used for immunoprecipitation 
I normalized the values of the immunoprecipitated (IPed) band to the level of expressed 
protein as follows: the expressed protein band was measured and the background 
subtracted and the ratio of IPed band/ expressed band was determined. The ratio of 
HDAC:MIER, CDYL:MIER and MIER:REST was determined for the 
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immunoprecipitate in each replicate experiment and the average ratio + S.D. was 
calculated. For experiments analyzing the effect of MIER1/2 point mutations on CDYL 
interaction, the value for each band was corrected for the variability in expression levels 
as described in the paragraph above and then the ratios were normalized to the value 
obtained with wild type MIER1/2 and plotted as bar graphs.   
2.6 [3H]-acetate labeling of histones 
HeLa cells were grown to a density of 1x106 cells in a 100mm dish. The culture 
medium was removed and 3 mls of fresh DMEM containing 10mM sodium butyrate and 
0.5mCi/ml 3H-sodium acetate was added. Cells were incubated in humidified 37°C 
incubator with 5% CO2 for 1hr after which the medium was removed and the cells were 
washed twice with PBS. Cells were homogenized in 1ml of ice-cold lysis buffer (50 mM 
Tris-HCl pH 8, 150 mM NaCl, 1% Triton X-100, 10 mM MgCl2, 10% glycerol, 1X 
protease inhibitors); the nuclei were collected by centrifugation at 1,000xg for 10 min and 
washed three times with lysis buffer and once with 10mM Tris-HCl pH 7.4, 13mM 
EDTA, pH 8.0. The pellet was resuspended in 0.1 ml ice cold deionized H2O (dH2O) and 
concentrated H2SO4 was added to a final concentration of 0.2M. The suspension was 
incubated on ice for 1hr and centrifuged at 15,000 g for 5 min. 1 ml of acetone added to 
the supernatant and the sample incubated overnight at -20°C. The pellet containing the 
histones was collected by centrifugation at 15,000xg for 5 min and air-dried. The histones 
were resuspended in 50μl dH2O, the protein quantified using a Qubit protein assay kit 
(Thermo Fisher Scientific) and the 3H incorporated determined by liquid scintillation 
counting. 
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2.7 Histone deacetylase assays 
For each sample, 1x106 cells were transfected with the appropriate construct and 
48hr later, subjected to immunoprecipitation using the relevant antibody. For experiments 
measuring the effect of inositol 1,3,4,5-tetrakisphosphate [Ins(1,4,5,6)P4], Ins(1,4,5,6)P4 
(Cayman Chemical) was added to a final concentration of 12.5μM; immunoprecipitates 
were collected on either Protein A or Protein G beads. HDAC assays consisted of 
immunoprecipitates, HDAC buffer (10 mM Tris-HCl pH 8.0, 150 mM NaCl, 1mM 
MgCl2), 5,000 cpm labeled histones, with or without 5μM trichostatin A (TSA; Sigma-
Aldrich), in a final volume of 200μl. Samples were incubated at 37°C for 2hr on a half 
rotation, after which the reaction was terminated by the addition of 50μl Stop buffer (1M 
HCl/160mM acetic acid for labeled histones). Released 3H-acetate was extracted into 
600μl ethyl acetate (Sigma-Aldrich) and the radioactivity determined using a liquid 
scintillation spectrometer (Beckman LS6500). Statistical analysis was performed using 
one-way ANOVA with post-hoc Tukey HSD. 
2.8 RNA extraction and cDNA generation 
Total RNA from HEK293 cells, MEFs, or HepG2 cells was extracted using the 
RNeasy kit (Qiagen). Genomic DNA was removed by treatment with DNase kit (Qiagen) 
and cDNA were generated from 1μg of total RNA using MultiScribe™ (Applied 
Biosystems) as per the manufacturers' protocols. Relative quantitation of cDNA was 
determined using the ABI PRISM 7500 sequence detection system (Applied Biosystems) 
that measures real-time SYBR green fluorescence and then calculated by means of the 
comparative Ct method (2−ΔΔCt) with the expression of glyceraldehyde 3-phosphate 
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dehydrogenase (GAPDH) or Actin β as an internal control. The primers used for RT-PCR 
were purchased from Qiagen.  
2.9 RT-qPCR  
For RT-qPCR analysis, reaction used was RT2 SYBR Green master mix 
(Qiagen). Each reaction was performed in triplicate. 20 l of cDNA was diluted in 80 l 
of dH20. 2l of diluted cDNA samples were mixed with 10 l of SYBR Green PCR 
master mix and 1l primers in a final volume of 20l. Relative values were calculated 
using the 2−ΔΔCt method normalized to β-actin and/or GAPDH expression.   
2.10 MIER1 and MIER2 knockdown P19 cells 
A HuSH 29mer shRNA construct against MIER1 and control shRNA plasmids 
were purchased from Origene (TR303258) 
5’-CAGTTGGTGAATGTGTAGCATTCTATTAC-3’. A Mission shRNA construct 
against mouse MIER2 was purchased from Sigma (TRCN0000306347) 
5’-TGAGCTCGTGAAGTGTAATTT-3’. shRNA plasmids were target-specific retroviral 
vectors encoding 19-25 nt shRNAs designed to knock down gene expression, and 
contained a puromycin resistance gene for selection of stably transfected cells. The 
control shRNA plasmid encoded a scrambled shRNA sequence that did not degrade any 
known cellular mRNA. Selected shRNA were tested to make sure no off target effects 
were observed. P19 cells were transfected with each plasmid using transfection reagent 
MIRUS-LT1 according to the manufacturer’s protocol. Transfected cells were selected 
with puromycin at a final concentration of 2 μg/mL; a single clone was selected and 
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tested for gene expression using RT-PCR. Single clones were used to carryout 
experiments to ensure cells induced to differentiate have low levels of MIER1/2.   
2.11 Preparation of mouse embryonic fibroblasts (MEFs) 
Mier1 knockout mice (mouse genome informatics:4431567) were originally 
obtained from the European Conditional Mouse Mutagenesis (EUCOMM) and housed in 
bio-bubble in animal care facility in Memorial University. Female Mier1+/- C57BL/6N 
was mated to male Mier1+/- C57BL/6N to generate Mier1+/+ C57BL/6N wild type (WT) 
and Mier1-/- C57BL/6N MIER1 null (KO) progenies. MEFs were isolated from embryos 
on day 13.5 after the vaginal plug was detected. In brief, intact embryos were collected in 
a 150 cm dish, washed with 1xPBS. The head of the embryos, which contain the brain 
and the eyes, was removed in 1.7 ml tube, later used for genotyping. The remaining part 
of the embryos were washed with 1xPBS and transferred into a new dish. The embryo 
was chopped into small pieces using sterile blade and transferred into a 50 ml tube. 2 ml 
of 0.25% trypsin-EDTA solutions was added to each tube and incubated at 37°C for 45 
mins. The suspension was further homogenized by pipetting and the cells plated in 10 cm 
dish in culture media.   
2.12 Genotyping of MEFs 
In order to determine the genotype of the MEFs, embryo heads were solubilized 
to extract DNA using Sigma Xnat kit. Genotyping was carried out using 3 sets of 
primers: 
Mier1_F 5’-TTTCAAGCTGTGGCTTCTGG-3’ 
Mier1_R 5’-CCACACCACACAAATGTCCC-3’ 
CAS_R1_Term 5’-TCGTGGTATCGTTATGCGCC-3’ 
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LacZ_2_small_F 5’-ATCACGACGCGCTGTATC-3’ 
LacZ_2_small_R 5’-ACATCGGGCAAATAATATCG-3’ 
3 PCR assays were set up as cycling parameters are different. The products are as 
follows; WT assay with Mier1_F, Mier1_R primers makes a product of ~600bp, Mutant 
assay with Mier1_F, CAS_R1_Term primers makes a product of ~250 bp, and LacZ 
assay with LacZ_2_small_F, LacZ_2_small_R primers makes a product of ~108 bp. 
Table 3: WT assay cycling parameters  
Cycle No. Settings: Eppendorf Mastercycler Gradient  
1 94°C   5 minutes 
35 94°C   30 seconds 
56°C   30 seconds 
72°C   30 seconds 
1 72°C   5 minutes 
 
 
 
 
 
Table 4: Mutant assay cycling parameters 
Cycle No. Settings: Eppendorf Mastercycler Gradient  
1 94°C   5 minutes 
35 94°C   30 seconds 
58°C   30 seconds 
72°C   30 seconds 
1 72°C   5 minutes 
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Table 5: LacZ assay cycling parameters 
Cycle No. Settings: Eppendorf Mastercycler Gradient  
1 94°C   5 minutes 
35 94°C   30 seconds 
60°C   30 seconds 
72°C   30 seconds 
1 72°C   5 minutes 
 
2.13 PCR analysis to determine the sex of MEFs 
PCR analysis of the SmcX and SmcY loci was carried out as described in170 to 
identify mice with X- and Y-specific alleles, revealing bands of 330 and 301 bp, 
respectively using the following primers;  
Smc forward 5’-TGAAGCTTTTGGCTTTGAC-3’  
Smc reverse 5’-CCGCTGCCAAATTCTTTGG-3’.  
The PCR products were visualized on 2% agarose gel using RedSafe™ Nucleic Acid 
Staining Solution (FroggaBio).  
Table 6: Smc cycling parameters 
Cycle No. Settings: Eppendorf Mastercycler Gradient  
1 97°C   30 seconds 
39 94°C   15 seconds 
55°C   30 seconds 
72°C   30 seconds 
1 72°C   10 minutes 
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2.14 Transcriptome analysis of MEFs 
RNA-Seq libraries were prepared by Neogenomics Laboratories Inc. from 10g 
of total RNA from WT or MIER1 KO MEFs, which I prepared using the RNAeasy kit 
(Qiagen). 100-base-pair pair-end reads generated using Illumina’s HighSeq 2500 
platform were mapped to the mouse genome (UCSC mm10 database) on the Galaxy 
platform. The quality of the sequencing reads was assessed with FASTQC v0.72 
software. Sequences were aligned to the UCSC mm10 using TopHat2 v2.1.1, with default 
parameters. TopHat2171 is aligner software that can align reads of various lengths. 
Visualisation and quantitation of the RNAseq libraries was performed with Seqmonk 
v1.38.3171. SeqMonk is a program to enable the visualisation and analysis of mapped 
sequence data. The RNA-Seq quantitation pipeline (within SeqMonk) was employed with 
uniquely mapped reads to generate a set of probes covering every mRNA in the genome. 
Differential expression analysis between samples was performed on raw counts with 
annotated mRNAs via the Intensity Difference Filter (within SeqMonk), a statistical 
based fold change filter that works by constructing a local distribution of differences for 
mRNAs with similar average intensity to the mRNA being examined. Genes were 
considered significantly differentially expressed when the adjusted P value was <0.5. 
Differentially expressed genes were subjected to enriched gene ontology (GO) 
categorization using the Database for Annotation, Visualization and 
Integrated Discovery (DAVID) GO Analysis v6.8 with default settings172. DAVID is an 
online platform that provides a comprehensive set of functional annotation tools to 
discover biological meaning behind large list of genes172. 
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2.15  Neurogenesis of MIER1 and MIER2 knockdown P19 cells 
MIER1- and MIER2-knockdown P19 cells were seeded at a density of 
106 cells/mL in 90 mm petri dishes under non-adherent culture conditions and allowed to 
aggregate for 72 h. Aggregated embryonic bodies were dissociated into single cells by 
treatment with 0.25% trypsin-EDTA solutions. The cells were then seeded in a 10 cm 
tissue culture dish at a density of approximately 104 cells/mL culture media. After 24 h 
incubation, culture media were replaced with low serum-containing media (MEM-alpha 
with 4% fetal bovine serum (FBS)). The media were replenished every 2 days until cells 
were harvested on the indicative time. 
2.16 ChIP-Seq datasets of MIER1, 2, 3 and REST target genes 
To identify a comprehensive set of MIER1 (ENCBS465MWC) and REST 
(ENCBS048GNZ) target genes in human K562 and MIER2 (ENCGM383QOM), MIER3 
(ENCBS126SWO), and REST (ENCBS114ENC) in HepG2 cell lines, we investigated 
FASTQ-formatted files of ChIP-Seq datasets prepared for the Encyclopaedia of DNA 
Elements (ENCODE) project by Dr. Michael Snyder, Stanford University and Dr. 
Richard Myers, HudsonAlpha Institute for Biotechnology (HAIB); 
www.encodeproject.org    
In their experiments, human K562 were processed for ChIP with the rabbit 
polyclonal rabbit anti-MIER1 antibody (HPA019589, Sigma) to immunoprecipitate 
MIER1 and the anti-REST antibody (HPA006079, Sigma) to immunoprecipitate REST. 
Human HepG2 cells were processed for ChIP with mouse monoclonal anti-REST 
antibody (Protein Expression Center, Caltech) to immunoprecipitate REST and anti-flag 
antibody (F1804, Sigma) to immunoprecipitate MIER2/MIER3. Due to lack of suitable 
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antibodies for MIER2 and 3 for ChIP-Seq analyses Savic et al. (2015) adapted the 
CRISPR genome to edit the genome of a pool of HepG2 cells, inserting a 3xFLAG 
epitope at the 3' end of the target gene. They made a HepG2 immortalized cell line stably 
expressing C-terminal FLAG-MIER2/3 fusion protein. 
Next generation sequencing (NGS) libraries constructed from size-selected ChIP 
DNA fragments were processed for deep sequencing at a read length composed of 100 bp 
for MIER1 and REST in K562 cells or 76 bp for MIER2, and 3 or 36 bp for REST in 
HepG2 cells on a Genome Analyzer (Illumina, San Diego, CA, USA). In both cell types, 
the corresponding libraries made from sonicated chromatin, whose formaldehyde cross-
links are reversed without immunoenrichment, were utilized for input control. 
The sequencing data were uploaded to the Galaxy web platform (usegalaxy.org), 
which is an open source, web-based platform for genome data analysis to analyze the 
data173,174. First, the quality of short reads was evaluated by the FastQC program v0.72. 
Next, FastQ Groomer v1.1.1 was used to convert FASTQ files to Sanger format to carry 
out the alignment with the Bowtie v1.1.2 for Illumina mapping tool under default setting. 
The reads were mapped on the human genome reference sequence version hg19 and data 
was filtered for mapped data only. After clean up of the mapped data, significant peaks 
were identified by using the Model-based Analysis of ChIP-Seq (MACS) program 
v2.1.1.20160309.0 with the stringent condition that satisfies p-value or the false 
discovery rate (FDR) ≤ 0.01 and fold enrichment (FE) ≥ 15 in order to reduce the 
detection of false-positive binding sites. The genomic location of binding peaks were 
characterized using CEAS tool v1.0.2 of MACS that classifies the locations into the 
upstream region, 5′ untranslated region (5′UTR), exon, intron, and 3′UTR. The consensus 
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sequence motifs were identified by importing a 200 bp-length sequence surrounding the 
summit of MACS peaks derived from top genes based on FE≥ 15 into the MEME-ChIP 
program v5.0.1. The utility of QC tools, Bowtie, MACS, and MEME-ChIP is described 
in 48,175,176 and used with default settings. Values were statistical significant  for each test 
when p-values were as follows: ANOVA p<0.05, post-hoc Tukey p<0.05, Benjamani 
p<0.5.  
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Table 7: Primers used for cloning using PCR 
Name Primers 
Myc-MIER2 F 5’-GCGAATTCACCATGGCGGAGGCCTCCTCGC-3’ 
R 5’-GCTCTAGATCAGCAGGTCATCACGTTACAG-3’ 
Myc-MIER3 F 5’-GCGAATTCACCATGGCGGAGGCTTCTTTTGG-3’ 
R 5’-GCCTCGAGTCACTCAGAGTGTAGGGC-3’ 
Flag-MIER1 F 5’-GCGAATTCACCATGGCGGAGCCATCTGTTG-3’ 
R 5’-CCCTCGAGTTATTTTAAAAAGGCATTGGCTC-3’ 
Flag-MIER2 F 5’-GCGAATTCACCATGGCGGAGGCCTCCTCGC-3’ 
R 5’-GCAAGCTTTCAGCAGGTCATCACGTTACAG-3’ 
Flag-MIER3 F 5’-GCGAATTCACCATGGCGGAGGCTTCTTTTGG-3’ 
R 5’-GCCTCGAGTCACTCAGAGTGTAGGGC-3’ 
Myc-MIER2 D1 F 5’-GCGAATTCACCATGGCGGAGGCCTCCTCGC-3’ 
R 5’-GCTCTAGATCACACAGAGCCCATCTCGGATC-3’ 
Myc-MIER2 D2 F 5’-GCGAATTCACCATGCTTGGAGTGAAGAGGAGTGC-3’ 
R 5’-GCTCTAGATCAGCAGGTCATCACGTTACAG-3’ 
Myc-MIER2 D3 F 5’-GCGAATTCACCATGGTAAGAAGGAGATCATGG-3’ 
R 5’-GCTCTAGATCATCTTCCACAGGTAGTAGTAC-3’ 
Myc-MIER2 D4 F 5’-GCGAATTCACCATGGTAAGAAGGAGATCATGG-3’ 
R 5’-GCTCTAGATCACACAGAGCCCATCTCGGATC-3’ 
Myc-MIER3 D1 F 5’-GCGAATTCACCATGGCGGAGGCTTCTTTTGG-3’ 
R 5’-GCCTCGAGTCATGCAGTCATTCCTTG-3’ 
Myc-MIER3 D2 F 5’-GGGAATTCACCATGTGGACGGAAGAAGAATGC-3’ 
R 5’-GCCTCGAGTCACTCAGAGTGTAGGGC-3’ 
Myc-MIER3 D3 F 5’-GGGAATTCACCATGAGGAAGGAAATAATG-3’ 
R 5’-GCCTCGAGTCATTTCTTCCACATATA-3’ 
Myc-MIER3 D4 F 5’-GGGAATTCACCATGAGGAAGGAAATAATG-3’ 
R 5’-GCCTCGAGTCATGCAGTCATTCCTTG-3’ 
Myc-MTA1 F 5’-GCGAATTCACCATGGCCGCCAACATGTACAGG-3’ 
R 5’-GCCTCGAGCTAGTCCTCGATGACGATGGG-3’ 
Flag-MTA1 F 5’-GCGAATTCACCATGGCCGCCAACATGTACAGG-3’ 
R 5’-GCCTCGAGCTAGTCCTCGATGACGATGGG-3’ 
Myc-CDYL1b F 5’-GCGAATTCACCATGATGGCTTCCGAGGAG-3’ 
R 5’-GCCTCGAGCTAGAACTCATCGATCTTCCT-3’ 
Flag-CDYL1b F 5’-GCGAATTCACCATGATGGCTTCCGAGGAG-3’ 
R 5’-GCCTCGAGCTAGAACTCATCGATCTTCCT-3’ 
Flag-CDYL1c F 5’-TAGAATTCTCAGAACTCATCGATCTTC-3’ 
R 5’-TAGAATTCACCATGGATGCATTAACAG-3’ 
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Table 8: Primers used for site directed mutagenesis using PCR 
Name Primers 
Myc-MIER2 
aa228 W → A 
F 5’-GACGCTGGGGTCCGCGAGCAGCTGGTCTTCGTTCTCGT-3’ 
R 5’-CTCTGCCTGATATTGTAAACCAACCATTATTTCCTTCCTCAAATCTT-3’ 
Myc-MIER1 
aa260 L → A 
F 5’-CTTCCTCTGTCCAAACAGATGCTTCCTCTCTAGCTGCTTTTAC-3’ 
R 5’-GTAAAAGCAGCTAGAGAGGAAGCATCTGTTTGGACAGAGGAAG-3’ 
Myc-MIER1 
aa271 L → A 
 
F 5’- GCTGCTTTTACATTAAATCTTAATCTTCTCGCTGCTTCTTCTGTATCAAAATTGCATTTAAC -3’ 
R 5’-GTTAAATGCAATTTTGATACAGAAGAAGCAGCGAGAAGATTAAGATTTAATGTAAAAGCAGC-3’ 
Myc-MIER1 
aa274 L → A 
F 5’-CTCTAGCTGCTTTTACATTAAATCTTGCTCTTCTCAATGCTTCTTCTGTATCAA-3’ 
R 5’-TTGATACAGAAGAAGCATTGAGAAGAGCAAGATTTAATGTAAAAGCAGCTAGAG-3’ 
Myc-MIER1 
aa285 L → A 
F 5’-GTAAAAGCAGCTAGAGAGGAAGCATCTGTTTGGACAGAGGAAG-3’ 
R 5’-CTTCCTCTGTCCAAACAGATGCTTCCTCTCTAGCTGCTTTTAC-3’ 
Myc-MIER2 
aa274 L → A 
F 5’- TTGAAGTTGCATTTCACCGCCTCGTACAGCGCCTGCTC-3’ 
R 5’- GAGCAGGCGCTGTACGAGGCGGTGAAATGCAACTTCAA-3’ 
Myc-MIER2 
aa288 L → A 
F 5’-TGTGGAGGAGGCCGCGCGAAGGCTGCGG-3’ 
R 5’- CCGCAGCCTTCGCGCGGCCTCCTCCACA-3’ 
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3.1 MIER proteins display distinct regions of high homology 
The MSAProbs program 177 was used to perform sequence alignment of the MIER 
family using the α isoform of MIER1, the only isoform for MIER2 and the canonical 
isoform of MIER3, isoform 1. Alignment results revealed that both MIER2 and 3 display 
higher homology in the ELM2-SANT region to MIER1 (63% & 60% identity, 
respectively) than they do to each other (52% identity) (Table 9). The SANT domains of 
the three MIER proteins show a greater degree of conservation than do the ELM2 
domains (70–82% identity vs 46–59%) (Table 9). Moreover, the 18aa residues 
immediately downstream of the SANT domain (SANT extension) are also highly 
conserved in all 3 proteins (72% identity, Table 9, Fig 5). This SANT extension was 
previously identified as a region that is 100% conserved in MIER1 from several different 
species, including mouse, rat, cow, chicken and Xenopus 148, suggesting that this region 
has an important functional role. 
Apart from the ELM2 and SANT domains, very few functional domains have 
been characterized in the MIER2 and MIER3 proteins. Thus, comparison of the protein 
sequences for additional highly conserved regions might aid in the identification of 
putative functional motifs to investigate, while also enabling recognition of domains 
unique to individual family members. Sequence analysis revealed several regions of high 
homology between pairs of family members (blue outlines in Fig 5; bold in Table 9). 
MIER3 has two regions of high homology to MIER1; the first, located at the N-terminus 
(aa 9–65; numbers refer to positions in the MIER1 aa sequence) and containing the first 
two acid-rich regions147, is 74% identical to MIER1 (Table 9; Fig 4), while MIER2 shows 
only 19% and 26% identity in this sequence to MIER1 and MIER3, respectively (Table 
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9). The second consists of a short region (aa 351–368) located immediately downstream 
of the SANT extension that is 84% identical to MIER1; this region in MIER2 shows only 
37% and 11% identity to MIER1 and MIER3, respectively (Fig 5; Table 9). MIER2, on 
the other hand, contains one region of high homology (78%) to MIER1, located at the 
end of the ELM2 domain (aa268-285) (Fig 5; Table 9). This sequence contains one of 
two previously identified ALXXL motifs that are highly conserved in a number of ELM2 
containing proteins 157. MIER3 shows only 39% and 33% identity to MIER1 and MIER2, 
respectively and it lacks the second ALXXL motif. MIER2 and MIER3 share a specific 
region of high homology, located upstream of the ELM2 domain (aa98-149; Fig 5). This 
sequence is 87% identical in MIER2 and 3, but only 35% and 33%, respectively, to 
MIER1 (Table 9). 
Interestingly, the C-termini of these 3 proteins are highly divergent, with only 
sporadic identities amongst them (Fig 5). The two major MIER1 isoforms, MIER1α and 
MIER1β, have distinct C-terminal ends, therefore we compared the β isoform C-terminus 
to determine if MIER2 and 3 are closer in homology to the β isoform. Alignment analysis 
revealed that the β C-terminus also shows only sporadic identities (Fig 6), suggesting that 
member-specific functions might be accomplished through their unique C-termini. 
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Figure 5. Alignment MIER1α, MIER2 and MIER3 protein sequences. 
The MIER1α, MIER2 and MIER3 isoform 1 protein sequences were aligned using 
MSAProbs; gaps introduced by the alignment program are indicated by dashes and aa 
numbers are listed on the right. Identities in all 3 proteins are indicated by an ‘*’ and in 
the ELM2 and SANT domains, are also colored red. The beginning of the ELM2 and the 
SANT domain are indicated by a blue arrow and blue arrowhead, respectively. Identities 
in the region of high homology immediately downstream of the SANT domain (SANT 
extension) are colored pink. Identities in 2 of the 3 proteins are indicated by a ‘+’ sign. 
Regions of high homology (>70% identity) between 2 of the protein sequences are 
indicated by a blue outline. The beginning of the highly divergent C-terminal sequence is 
indicated by a black arrow. 
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Figure 6. Alignment MIER1β, MIER2 and MIER3 C-terminal sequences. 
The MIER1β, MIER2 and MIER3 protein sequences, beginning immediately after the 
SANT domain, were aligned using MSAProbs. Gaps introduced by the alignment 
program are indicated by dashes and aa numbers are listed on the right. Identities in all 3 
proteins are indicated by an ‘*’ and in the SANT extension, are also colored pink. 
Identities in 2 of the 3 proteins is indicated by a ‘+’ sign. Regions of high homology 
(>70% identity) between 2 of the protein sequences is indicated by a blue outline. The 
beginning of the highly divergent C-terminal sequence is indicated by a black arrow. 
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Table 9: Amino acid similarity in various regions between MIER family members.  
The numbers in bold represent regions of high percent identity between only two 
members of the family. 
aa numbers refer to MIER1 sequence.  
 
3.2 MIER2 and MIER3 are localized in the nucleus 
MIER2 and MIER3 are predicted to be nuclear proteins 178,179 and we verified the 
subcellular localization of these proteins. MCF7 cells, transfected with plasmids encoding 
myc-tagged MIER1α, myc-tagged MIER2, myc-tagged MIER3 or myc-tag alone were 
examined by confocal microscopy (Fig 7). Confocal z-stacks were analyzed to determine 
the percentage of cells in which the fluorescence was exclusively nuclear or both nuclear 
& cytoplasmic; for the latter, cells were classified in two categories: 1) showing more 
intense staining in the nucleus than the cytoplasm (N>C) or 2) showing equal intensity (N 
= C). Quantitative measurements of fluorescence in the confocal z-stacks were also 
REGION 
MIER1-
MIER2 
MIER1-
MIER3 
MIER2-MIER3 
 % identity % identity % identity 
Overall 42 50 36 
aa 9-65  19 74 26 
aa 98-149 35 33 87 
ELM2 (180-283) 59 54 46 
ELM2 end (268-285) 78 39 33 
SANT (288-332) 80 82 70 
ELM-SANT (180-332) 63 60 52 
SANT ext. (333-350) 78 89 83 
aa 351-368 37 84 11 
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performed in order to determine the distribution in the nuclear and cytoplasmic 
compartments. As expected, the myc-tag alone was distributed throughout the cell (Fig 
7A, panels a-c) with no cell showing exclusively nuclear staining (Fig 7B) and roughly 
equal amounts in the nuclear and cytoplasmic compartments (Fig 7C). Previously, our 
lab149,154 showed that MIER1α was localized in the nucleus of MCF7 cells and similar 
results were obtained here: 94% of cells displayed exclusively nuclear staining (Fig 7A, 
panels d-f; Fig 7B) and quantitative analysis showed that 92% of the protein is in the 
nuclear compartment (Fig 7C). MIER3 showed a similar pattern to MIER1α, with 91% of 
cells displaying exclusively nuclear staining (Fig 7A, panels j-l; Fig 6B) and 87% of the 
protein in the nuclear compartment (Fig 7C). MIER2, on the other hand, had a slightly 
different pattern. While the majority of cells (59%) displayed exclusively nuclear staining 
(Fig 7A, panels g-i; Fig 6B) and the majority of the protein (69%) is in the nuclear 
compartment (Fig 7C), there was a significant proportion of cells with staining in the 
cytoplasm as well (Fig 7A, panel m; 7B) and 31% of the protein was localized in this 
compartment (Fig 7C). 
MIER2 and 3 subcellular localization patterns were also explored in the HEK293 
cell line to ensure the results seen in MCF7 is not a cell specific phenomenon. As 
presented in Fig 7D–7E, the percentage of HEK293 cells displaying nuclear MIER2 or 
MIER3 (52% and 89%, respectively) was similar to that observed in MCF7, as was the 
proportion of MIER3 in the nuclear compartment (90%). MIER2 (34%) was found in the 
cytoplasmic compartment, which was similar to our findings in the MCF cell line. 
However, the significance of MIER2 in the cytoplasm is unknown at the moment. 
 
 
Figure 7. Confocal analysis of MIER2 and MIER3 subcellular localization. 
(A-C) MCF7 cells were transfected with a plasmid encoding myc tag alone or myc-
tagged -MIER1α, -MIER2 or -MIER3 and localization was analyzed by confocal 
microscopy using DAPI (panels b, e, h, k) and the 9E10 myc tag antibody (AlexaFluor 
488) (panels a, d, g, j, m, n). The merged DAPI and Alexafluor 488 channels are shown 
in panels c, f, i &l. (A) Illustrative examples of cells showing whole cell localization of 
the myc-tag (panels a-c), nuclear localization of MIER1α (panels d-f) and MIER3 (panels 
j-l) and mainly nuclear localization MIER2 (panels g-i). Panels m & n show and 
enlargement of the cells indicated by arrows in panels g & j; the brightness was increased 
in these panels to better illustrate the cyotplasmic localization of MIER2 (m), compared 
to exclusively nuclear localization of MIER3 (n). For all panels, white arrows indicate 
cells that display whole cell staining, with nuclear staining more intense than cytoplasmic 
(N>C); white arrowheads indicate cells showing whole cell staining with nuclear staining 
equal in intensity to cytoplasmic staining (N = C); red arrows with white outlines indicate 
cells with exclusively nuclear staining. (B) Histogram showing the percentage of cells, ± 
S.D., displaying each staining pattern: N, exclusively nuclear; N>C, nucleus more 
intensely stained than cytoplasm; N = C, nucleus and cytoplasm display equal staining 
intensity. Fields were selected at random and the staining pattern of all expressing cells in 
the field were scored visually from the compiled z-stacks. Only cells expressing myc-
tagged proteins were included in the total counts and used to calculate percentages; 50–
80 cells were scored for each construct. (C) Bar graph showing the intracellular 
distribution of each protein. Fields were selected at random and all cells expressing myc-
tagged proteins in the field were analyzed, as described in the Materials and Methods. 
Pixel values for the nuclear and cytoplasmic compartments were measured in compiled 
confocal z-stacks using Image J v1.50 g. Plotted is the average value ± S.D. in each 
compartment, using measurements from 30–40 cells for each construct. (D-E) HEK293 
cells were transfected with a plasmid encoding myc-tag alone or myc-tagged -MIER1α, -
MIER2 or -MIER3 and localization was analyzed by confocal microscopy, as described 
for MCF7. (D) Histogram showing the percentage of cells ± S.D. in each of the 
categories described above. Localization was determined as described above for panel B; 
50–80 cells were scored for each construct. (E) Bar graph showing the intracellular 
distribution of each protein, determined as described above in panel C. Plotted is the 
average value ± S.D. in each compartment, using measurements from 30–40 cells for 
each construct. For panels B-E, asterisks indicate values that are significantly different 
(p<0.05); there was no significant difference between the MIER1α and MIER3 values in 
any of the panels. 
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3.3 MIER1, 2 and 3 exist in distinct complexes 
MIER1α is very similar to MTA1147, both proteins contain contiguous ELM2-
SANT domains, recruit HDACs, interact with ERα to repress its activity and both 
function generally as corepressors 29,147,157,159,164. The MTA family of proteins is encoded 
by three genes, MTA1-3, with MTA1 being the best characterized 31. MTA1, 2 & 3 are 
components of the NuRD corepressor complexes 29 and stoichiometric analyses have 
demonstrated that the 3 proteins generally exist in distinct NuRD complexes180, however 
all three have been detected in the MBD3/NuRD complex181,182. Moreover, MTA1 has 
been shown to exist as a homodimer through interaction mediated by its ELM2 domain 
31.  
The crystal structure of HDAC1 and MTA1 complex showed that the ELM2 
domain is divided into two structural regions31,73. The amino-terminal part of the ELM2 
domain formed an extended conformation (a groove) that wrapped around the HDAC1 
making numerous contacts while the carboxy-terminal region of the ELM2 domain 
contains helices that formed a homodimer upon associating with HDAC1. As a result, 
each MTA1 and HDAC1 complex consists of two molecules of MTA1.  
Sequence alignment of the 10 proteins with the ELM2 and SANT domains that 
included MTA1-3, CoREST1-3, arginine-glutamic acid dipeptide repeats (RERE) and 
MIER1-3 demonstrated that the overall sequence conservation for the ELM2 
dimerization domain was low73. However, the pattern of conservation in these related 
ELM2- containing corepressors was similar and could suffice to adopt a similar fold —
although helix H2 is lacking in the MIER proteins73. Therefore, we investigated whether 
any of the MIER proteins homodimerized or heterodimerized in the complex by 
 
 
74 
performing co-immunoprecipitations of MIER complexes from cells expressing myc- and 
flag-tagged MIER1, 2 or 3 in various combinations. As shown in panel ‘a’ of Fig 8, when 
myc-tagged MIER1α, 2 or 3 is co-expressed with flag-tagged MIER1α, 2 or 3 and 
complexes are immunoprecipitated using a myc-tag antibody, no co-precipitating flag-
tagged MIER protein was detected (lanes 6–14). As a positive control, flag-tagged MTA1 
was shown to co-immunoprecipitate with myc-tagged MTA1 (Fig 8, panel a, lanes 1–2). 
We also confirmed the presence of the myc-tagged MIER protein in each co-IP and that 
each flag-tagged protein was expressed. This was done by restaining the blot in panel ‘a’ 
using the myc-tag antibody and by performing Western analysis on whole cell extracts of 
parallel samples, using an anti-flag antibody. As can be seen in Fig 8, panel b, lanes 6–
14, each myc-tagged MIER protein was present and levels were similar to that of the 
positive control, myc-tagged MTA1 (Fig 8, panel b, lane 2). Likewise, each flag-tagged 
protein was expressed (panel c, lanes 6–14) at a level at least as high as that of the 
positive control, flag-tagged MTA1 (panel c, lane 2). These results demonstrate that 
MIER proteins do not form homodimers or heterodimers to co-exist in the same complex. 
In addition, each complex contains only one molecule of MIER protein as no myc-tagged 
MIER proteins were pulled down with any of the flag-tagged MIER proteins.   
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Figure 8. Co-immunoprecipitation analysis of flag-tagged with myc-tagged MIER 
proteins. 
HEK293 cells were transfected with a plasmid encoding myc-tagged MTA1 (lanes 1–2), 
myc tag alone (lanes 3–5), myc-tagged MIER1α (lanes 6–8), myc-tagged MIER2 (lanes 
9–11) or myc-tagged MIER3 (lanes 12–14) along with either flag-tag alone (lane 1), flag-
tagged MTA1 (lane 2), flag-tagged MIER1 (lanes 3, 6, 9 & 12), flag-tagged MIER2 
(lanes 4, 7, 10 & 13) or flag-tagged MIER3 (lanes 5, 8, 11 & 14). Extracts were either 
subjected to immunoprecipitation with the 9E10 anti-myc tag antibody or loaded directly 
onto the gel. The immunoprecipitates (panel a) were analyzed by Western using a flag-
tag antibody. The experiment was repeated three times and representative Western blot 
results are shown. The arrows to the right of panel a indicate the positions where flag-
tagged -MIER2, -MIER3 and -MIER1α are expected to run (upper to lower arrow, 
respectively). The blot was stripped and restained with the 9E10 antibody (panel b) to 
verify the presence of myc-tagged MIER or MTA1 protein in each immunoprecipitate. 
Expression of the flag-tagged MIER proteins was verified using whole cell lysates from 
parallel samples and Western analysis with an anti-flag-tag antibody (panel c).  
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3.4 HDAC1 and 2 are differentially recruited by MIER proteins   
Our lab has previously demonstrated that MIER1 interacts with HDAC1&2 154,157. 
More recently, Joshi et al.63 employed a mass spectrometry-proteomic approach to 
characterize protein interactions for all 11 HDACs and in addition to MIER1 they 
detected MIER2 and 3 in HDAC1 and HDAC2 containing complexes. By contrast, 
proteomic target profiling of HDAC inhibitors by Bantscheff et al.168 identified MIER2 
and 3 in a complex with HDAC2, but not with HDAC1. To investigate and validate these 
MIER-HDAC interactions, we performed co-immunoprecipitation analysis using extracts 
from HEK293 cells expressing myc-tagged MIER1α, MIER2 or MIER3. Myc-tagged-
MTA1 was also included as a positive control. As has been demonstrated previously73,154, 
both HDAC1 and 2 are present in MIER1α and MTA1 immunoprecipitates (Fig 9A, 
panels a-b, lanes 2 & 5). Likewise, both HDACs co-precipitated with MIER2 (Fig 9A, 
panels a-b, lane 3), albeit at lower levels than that seen with MIER1α. HDAC1 and 2 
were also present in MIER3 immunoprecipitates (Fig 9A, panels a-b, lane 4), however 
levels varied between experiments and ranged from being barely detectable above the 
control (Fig 9A, panels a-b, lane 1) to the levels shown in Fig 11A. Therefore, to provide 
a more accurate representation of the level of interaction, we quantified the bands by 
densitometry using blots from all experiments for Fig 9 and Fig 11 and plotted the 
average ratio of HDAC:MIER in the immunoprecipitate Fig 9B. This analysis revealed 
that the level of HDAC 1 and 2 associated with the MIER2 complex was 20% of that in 
the MIER1α complex (Fig 9B). The MIER3 complex contained even lower levels of 
HDAC1 and 2, approximately 9% of that in MIER1α complex. The lower level of 
HDAC1/2 recovered with MIER2 & 3 was not due to a difference in MIER2 or 3 
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expression since re-staining of the blots in Fig 9A, panels a & b with an anti-myc tag 
antibody (Fig 9A, panels c-d) revealed expression levels similar to that of MIER1α 
(compare lanes 3 & 4 to lane 2 in Fig 9A, panels c-d). In addition, HDAC1 & 2 levels 
were comparable among the samples (Fig 9A, panels e-f). 
Isoform 3 of MIER3 differs from isoform 1, used in the above experiments, by a 
single amino acid deletion (277E) in the ELM2 domain, which is conserved among the 
three family members and other ELM2 containing corepressors. X-ray crystallography of 
MTA1 demonstrated that the equivalent amino acid was in contact with HDAC1. Given 
that the ELM2 domain has been shown to be responsible for MIER1 interaction with 
HDACs, we investigated whether this deletion affects HDAC recruitment by MIER3. Co-
immunoprecipitation analysis using extracts from HEK293 cells expressing myc-tagged 
isoform 1 or isoform 3 of MIER3 did not reveal any substantial difference in HDAC 1 or 
2 levels (Fig 9C, panels a-b, compare lanes 1&2). Restaining of panels a-b for MIER3 
showed equivalent expression levels (panels c-d); likewise, analysis of whole cell extracts 
revealed equivalent levels of HDAC1 and 2 expression in the samples (panels e-f). These 
results demonstrate that the 277E in the MIER3 ELM2 domain is not important for HDAC 
recruitment. 
Our data show that MIER2 and 3 are much less effective than MIER1α at 
recruiting HDAC1/2. To verify that is not a HEK293-specific result, we repeated this 
analysis using MCF7 cells. Interestingly, only HDAC1 co-immunoprecipitated with 
MIER2 in this cell line (Fig 9D, panels a-b, lane 3; Fig 9E) and no detectable interaction 
of HDAC1 or 2 was detected with MIER3 (Fig 9D, panels a-b, lane 4; Fig 9E). Given the 
variation in HDAC recruitment between these two cell lines, a third cell line, HeLa, was 
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tested. The results obtained with HeLa cells were similar to that obtained with MCF7: 
only HDAC1 was associated with MIER2 (Fig 10, panel a, lane 3) and neither HDAC1/2 
were detected with MIER3 (Fig 10, panels a-b, lane 4). 
Next, we assessed the deacetylase activity of MIER-associated HDAC, using 3H-
labelled core histones in combination with complexes immunoprecipitated from HEK293 
cells expressing myc-tag alone or myc-tagged MIER1α, 2 or 3 proteins and then 
measuring the 3H-acetate released. Like previously demonstrated in our lab157, MIER1α 
complexes contain HDAC activity that is inhibited by TSA (Fig 9F) and therefore 
MIER1α serves as a positive control, while the myc-tag alone provides the background 
control level. MIER2 immunoprecipitates contained significant levels of TSA-sensitive 
HDAC activity above background (Fig 9F), demonstrating that MIER2 complexes 
contain functional HDACs. Unlike MIER2, no significant HDAC activity above control 
levels was detected in MIER3 immunoprecipitates using one-way ANOVA with post–
hoc Tukey (p = 0.276; Fig 9F).  
 
 
 
Figure 9. Co-immunoprecipitation of HDAC1 and 2 with MIER proteins. 
(A) HEK293 cells were transfected with a plasmid encoding myc tag alone (lane 1) or 
myc-tagged -MIER1α (lane 2), -MIER2 (lane 3), -MIER3 (lane 4) or -MTA1 (lane 5). 
Extracts were either loaded directly on the gel (panels e-f) or subjected to 
immunoprecipitation with the 9E10 anti-myc tag antibody (panels a-d). The 
immunoprecipitates were analyzed by Western using either anti-HDAC1 (panel a) or 
anti-HDAC2 (panel b). The blots in panels a & b were stripped and restained using the 
9E10 anti-myc tag antibody (panels c-d) to verify levels of MIER protein in each 
immunoprecipitate. Whole cell extracts were analyzed by Western using anti-HDAC1 
(panel e) or anti-HDAC2 (panel f) to verify equivalent HDAC levels in each sample. This 
experiment was performed 4 times. (B) Quantitation of the HDAC and MIER band 
intensities in the HEK293 immunoprecipitates was performed by densitometry using 
Image J 1.50g, as described in the Materials and Methods. Plotted is the average 
HDAC:MIER ratio ± S.D. for the 4 experiments from (A) and 3 experiments from Fig 
11A(minus IP4 values only). (C) HEK293 cells were transfected with a plasmid encoding 
myc-tagged -isoform 1 (lane 1) or -isoform 3 (lane 2) of MIER3. The experiment was 
performed twice and Western analysis was completed as in (A). Note that a longer 
exposure than in (A) is shown here, in order to enhance visualization of the MIER3 
associated HDAC bands. (D) MCF7 cells were transfected with a plasmid encoding myc-
tag alone (lane 1) or myc-tagged -MIER1α (lane 2), -MIER2 (lane 3) or -MIER3 (lane 4). 
Western analysis was performed as in (A). (E) Quantitation of the HDAC and MIER 
band intensities in the MCF7 immunoprecipitates was performed as described in (B). 
Plotted is the average HDAC:MIER ratio ± S.D. for 4 experiments. (F) HEK293 cells 
were transfected with a plasmid encoding myc-tag alone or myc-tagged -MIER1α, -
MIER2 or -MIER3. Extracts were subjected to immunoprecipitation with the 9E10 anti-
myc tag antibody. Immunoprecipitates were assayed for histone deacetylase activity 
using [3H]-labeled histones as described in the Methods and Materials. HDAC assays, 
with or without TSA, were performed on duplicate samples and plotted is the average of 
three experiments ± S.D. Statistical analysis, using one-way ANOVA with post-hoc 
Tukey HSD, revealed all -TSA values were significantly different each other (p<<0.05), 
except for MIER3 when compared to Con; # indicates values that are not significantly 
different (p>0.05). 
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Figure 10. Co-immunoprecipitation of HDAC 1 and 2 with MIER proteins in HeLa 
cells. 
Cells were transfected with a plasmid encoding myc tag alone (lane 1) or myc-tagged -
MIER1α (lane 2), -MIER2 (lane 3) or -MIER3 (lane 4). Extracts were either loaded 
directly on the gel (panels e-f) or subjected to immunoprecipitation with the 9E10 anti-
myc tag antibody. The experiment was repeated three times and representative Western 
blot results are shown. Western blot analysis was performed using either anti-HDAC1 
(panel a) or anti-HDAC2 (panel b). The blots in panels a & b were stripped and restained 
using the 9E10 anti-myc tag antibody (panels c-d) to verify the levels of the relevant 
MIER protein in the immunoprecipitate. The blots in panels e & f were stained with anti-
HDAC1 or anti-HDAC2, respectively, to verify equivalent HDAC levels in the cell 
extracts. 
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3.5 Ins(1,4,5,6)P4 does not enhance HDAC activity or recruitment by MIER2 or 
MIER3 
Watson et al.74 investigating the structure of HDAC3 and the SANT domain of 
SMRT has shown that an inositol-(1,4,5,6)-tetrakisphosphate (IP4) molecule bound into a 
basic pocket at the interface between the two proteins. The authors also found that IP4 
had a key role in activating HDAC3, since high salt treatment caused the enzyme to 
become inactive and addition of exogenous IP4 lead to enhanced activation. Similarly, 
Millard et al.73 investigated the role of IP4 with the MTA1 and HDAC1 complex. The 
amino acid residues coordinating IP4 binding in HDAC3 and SMRT are conserved in the 
HDAC1 and in the SANT domain of MTA1, and a similar basic pocket is formed at the 
interface between MTA1 and HDAC1. The authors showed that as with HDAC3: SMRT, 
addition of IP4 to the HDAC1: MTA1 complex enhanced HDAC activity, and mutations 
of amino acid residues (mutations in HDAC1, R270A and R306P; mutations in MTA1, 
Y327A, Y328A, and K331A) inhibited HDAC activity73. Interestingly, the IP4 
interacting residues are not only conserved in SMRT-SANT and MTA-SANT domains 
but also in all related corepressor proteins such as CoREST1-3, MIER1-3 and RERE and 
all could possibly form an inositol-binding pocket. The authors proposed that the binding 
of inositol phosphates would be a common activating mechanism for all class I HDAC 
corepressor complexes. 
Consequently, I explored the possibility that Ins(1,4,5,6)P4 might increase HDAC 
activity and/or HDAC recruitment by MIERs. Extracts from HEK293 cells expressing 
myc-tagged MIER1, 2 or 3 were subjected to immunoprecipitation in the presence or 
absence of Ins(1,4,5,6)P4. Immunoprecipitates were analyzed by Western blot for the 
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presence of HDAC1 and 2 proteins; parallel samples were tested for HDAC activity. No 
substantial difference in HDAC recruitment by any of the MIER proteins was detected 
when Ins(1,4,5,6)P4 was present (Fig 11A, panels a-b). A small, but statistically 
significant, increase in HDAC activity of MIER1 complexes was observed in the 
presence of Ins(1,4,5,6)P4 (Fig 11B), however no difference was detected in the 
deacetylase activity of either MIER2 or MIER3 complexes. Inositol phosphates may not 
be a common activating mechanism for all class I HDAC corepressors as proposed by 
Millard et al73.    
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Figure 11. HDAC activity in the presence of Ins(1,4,5,6)P4.  
HEK293 cells were transfected with a plasmid encoding myc tag alone or myc-tagged -
MIER1, -MIER2 or -MIER3. Extracts were subjected to immunoprecipitation with the 
9E10 anti-myc tag antibody, either in the absence (A, panels a-c, lanes 1,3,5,7; B) or 
presence (A, panels a-c, lanes 2,4,6,8; B) of Ins(1,4,5,6)P4. Immunoprecipitates were 
either analyzed by Western for associated HDAC1 and 2 (A) or assayed for histone 
deacetylase activity using [3H]-labeled histones (B). (A) Western blot analysis of 
immunoprecipitates using anti-HDAC1 (panels a); the blot in panel a was stripped and 
restained using anti-HDAC2 (panel b) and finally using the 9E10 anti-myc tag antibody 
(panel c). Whole cell extracts were analyzed by Western, using anti-HDAC1 (panel e) or 
anti HDAC2 (panel f) to verify equivalent HDAC levels in each sample. (B) 
Immunoprecipitates, incubated with or without Ins(1,4,5,6)P4, were assayed for histone 
deacetylase activity, as described in the Methods and Materials. Assays were performed 
on duplicate samples and plotted is the average of three experiments + S.D. Asterisks 
indicate values that are significantly different when Ins(1,4,5,6)P4 is added (p< 0.05). 
 
 
 
84 
3.6 An intact ELM2 domain is required for recruitment of HDAC1 and HDAC2 
by MIER2 
Previously, our lab has shown that the ELM2 of MIER1 is responsible for 
interaction with HDACs. Using deletion analysis with myc-tagged constructs, we 
investigated which region of the MIER2 sequence is required for recruitment of HDAC1 
and 2. Deletion constructs consisted of: 1) an N-terminal half that included the ELM2 
domain, aa1-301 (Δ1); 2) a C-terminal half that included the SANT domain, aa302-545 
(Δ2); 3) ELM2 + SANT domains only, aa194-346 (Δ3); 4) the ELM2 domain alone, 
aa194-301 (Δ4). Expression of each construct was confirmed by Western blotting (Fig 
12B, panel c), as was the expression level of HDAC1 and 2 in the cell extracts (Fig 12B, 
panels d-e). 
Immunoprecipitates from extracts of HEK293 cells expressing full-length or one 
of the deletion constructs of MIER2 (Fig 12) were analyzed by Western blot for the 
presence of HDAC1 and HDAC2 (Fig 12B, panels a-b). Analysis of MIER2 revealed that 
HDAC1 & 2 only co-precipitated with constructs containing an ELM2 domain (Fig 12B, 
panels a-b, lanes 3–6) and that the ELM2 domain in isolation is sufficient for interaction 
(Fig 12B panels a-b, lane 6). 
To further investigate the role of the ELM2 domain, we performed a mutational 
analysis. Our lab had previously demonstrated that 214W in the ELM2 domain of MIER1 
is a highly conserved residue across all ELM2 containing proteins.  Additionally, our lab 
showed 214W in the ELM2 domain of MIER1 to be critical for recruitment of HDAC1/2 
since mutation of this tryptophan to alanine resulted in loss of HDAC1/2 from the MIER1 
complexes. MIER2 contain a W in the equivalent position in its ELM2 domains (aa 228 
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in Fig 4), therefore we investigated the effect of mutating this residue on HDAC 
recruitment. Extracts from HEK293 cells expressing full-length wild-type or mutant 
MIER2 (Fig 12C) were subjected to immunoprecipitation and analyzed for the presence 
of HDAC1 and 2 by Western blot. Mutation of 228W to A compromised the recruitment 
of HDAC1 and HDAC2 by MIER2 (Fig 12C, lane 3). These data demonstrate that 
MIER2 behaves similarly to MIER1 in recruitment of HDACs, with 228W in MIER2 
being a critical residue.
Figure 12. Interaction of HDAC1 and 2 with MIER2 deletion constructs. 
(A) Schematic showing a scaled representation of the MIER2 protein sequence, 
indicating the location of the ELM2 (dark pink) and SANT (dark blue) domains; the 
remaining sequence is colored light blue. The amino acid numbers for the beginning and 
end of the protein as well as beginning and end of ELM2 & SANT domains are indicated 
above the schematic. (B) Immunoprecipitation of HDAC1 and 2 with MIER2 deletion 
constructs. Extracts from HEK293 cells transfected with a plasmid encoding myc tag 
alone (lane 1), myc-tagged full-length MIER2 (lane 2) or one of the following myc-
tagged deletion constructs: Δ1 (aa1-301; lane 3), Δ2 (aa302-545; lane 4), Δ3 (aa194-346; 
lane 5), Δ4 (aa194-301; lane 6) were either loaded directly on the gel (panels d-e) or 
subjected to immunoprecipitation with the 9E10 anti-myc tag antibody. Western blot 
analysis was performed using either anti-HDAC1 (panel a) or anti-HDAC2 (panel b). The 
blots in panels a & b were stripped and restained using the 9E10 anti-myc tag antibody to 
verify the presence of the relevant MIER2 deletion construct in the immunoprecipitates; 
the restained blot from panel a is shown in panel c. The blots in panels d & e were stained 
with anti-HDAC1 or anti-HDAC2, respectively, to verify equivalent HDAC levels in the 
cell extracts. A schematic illustrating the MIER2 sequence included in the deletion 
construct used is shown above each lane. The experiment was repeated three times and 
representative Western blot results are shown.  (C) HEK293 cells were transfected with a 
plasmid encoding myc tag alone (lane 1) or myc-tagged -wild-type MIER2 (lane 2) or -
MIER2 containing a point mutation, 228W→A, in the ELM2. The experiment was 
repeated three times and representative Western blot results are shown.   
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Chapter 4: Characterization of MIER family with CDYL  
4.1 MIER1 and MIER2 but not MIER3 interact with CDYL 
Human CDYL belongs to a family of chromodomain Y-related proteins, which 
has been implicated in epigenetic regulation and transcription repression108,110,183. CDYL 
was shown to be part of multi protein chromatin repressive complexes, functioning as a 
corepressor by recognizing and binding specific chromatin marks (H3K9me3, 
H3K27me2, H3K27me3) and recruiting other modifiers to repress gene expression. 
Mulligan et al. 108 employed a mass spectrometry-proteomic approach to characterize 
protein interactions for CDYL and reported the presence of MIER1 and 2 in the CDYL 
complexes. Similarly, MIER1 and MIER2 were also detected using a mass spectrometry-
proteomic approach in the Escamilla et al. study of undifferentiated and differentiated 
mouse embryonic stem cells to identify proteins interacting with CDYL184.  To 
investigate and validate these MIER-CDYL interactions, we performed co-
immunoprecipitation analysis using extracts from HEK293 cells expressing myc-tagged 
MIER1α, MIER2 or MIER3 with flag-tagged CDYL1b or CDYL1c. Both CDYL1b and 
CDYL1c are present in MIER1 immunoprecipitates (Fig 13B, panel a, lanes 5, 6). 
Likewise, both CDYL isoforms co-immunoprecipitated with MIER2 (Fig 13B, panel a, 
lanes 8, 9).  Levels of interaction between MIER1 and MIER2 with CDYL1b and 
CDYL1c varied between experiments and ranged from low levels shown in Fig 13B and 
to more robust interaction of MIER1 and MIER2 with CDYL1c. Therefore, to provide a 
more accurate representation of the level of interactions, we quantified the bands by 
densitometry using blots from two experiments and plotted the average ratio of 
CDYL:MIER in the immunoprecipitate (Fig 13C). This analysis revealed that the level of 
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MIER1 associated with CDYL1b was 60% of that in the MIER1-CDYL1c complex. 
MIER2 contained a similar level of interaction with CDYL1b (57%) to that in MIER2-
CDYL1c associations. Statistical analysis using one-way ANOVA revealed that the 
difference observed with MIER1 (p=0.889; Fig 13B, panel a, lanes 5, 6) and MIER2 
(p=0.922; Fig 13B, panel a, lanes 5, 6) interactions with both CDYL isoforms are not 
significant. Unlike MIER1 and MIER2, no CDYL interactions were detected in MIER3 
immunoprecipitates above that of the control (p = >0.9999; Fig 13B, panel a, lanes 11, 
12). The differences in the level of interaction was not due to different levels of MIER1, 
MIER2, MIER3 expression as similar expression of each construct was confirmed by 
Western blotting (Fig 13B, panel b), as was the expression level of CDYL1b and 
CDYL1c in the cell extracts (Fig 13B, panel c)
Figure 13. Co-immunoprecipitation of CDYL1b and -1c with MIER proteins.  
(A) Schematic showing a scaled representation of the isoforms of CDYL protein 
sequence, indicating the location of the chromo (green) and CDYL1a N-termini (blue); 
CDYL1b N-terminus (pink) and the remaining sequence is colored yellow. (B) Co-
immunoprecipitation of CDYL1b and -1c with MIER proteins. HEK293 cells were 
transfected with plasmid encoding myc tag alone (lanes 1-3) or myc-tagged -MIER1 
(lanes 4-6),  -MIER2 (lanes 7-9), -MIER3 (lane 10-12) along with either FLAG tag alone 
(lanes 1, 4, 7 &10), FLAG-tagged CDYL1b (lanes 2, 5, 8 & 11), FLAG-tagged CDYL1c 
(lanes 3, 6, 9 & 12). Extracts were either loaded directly on the gel (panels c) or subjected 
to immunoprecipitation with the 9E10 anti-myc tag antibody (panels a-b). Western blot 
analysis was performed using either anti-flag (panel a). The blots in panels a were 
stripped and restained using the 9E10 anti-myc tag antibody (panels b) to verify levels of 
MIER protein in each immunoprecipitate. Whole cell extracts were analyzed by Western 
using anti-flag (panel c) to verify equivalent CDYL levels in each sample. The 
experiment was repeated three times and representative Western blot is shown. (C) 
Quantitation by densitometry of the results from the experiment illustrated in (B). The 
values for each band was corrected for the variability in expression levels as described in 
the Materials and Methods and plotted is the average CDYL:MIER ratio ± S.D. 
Statistical analysis, using one-way ANOVA with post-hoc Tukey HSD, revealed MIER1 
and MIER2 significantly different from myc tag alone Con (p<<0.05) but no difference 
in binding with CDYL1b or CDYL1c , designated as n.s., except for MIER3 when 
compared to Con; # indicates values that are not significantly different. 
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4.2 The ELM2-SANT domain is important for recruitment of CDYL by MIER1 
and MIER2 
Using deletion analysis with myc-tagged constructs, we mapped the region of 
MIER1 and MIER2 required for recruitment of CDYL. MIER1 deletion constructs 
consisted of: 1) an N-terminal half that included the ELM2 domain, aa1-288 (Δ1); 2) a C-
terminal half that included the SANT domain, aa289-433 (Δ2); 3) ELM2 + SANT 
domains only, aa180-332 (Δ3); 4) the ELM2 domain alone, aa180-288 (Δ4). Likewise, 
MIER2 deletion constructs consisted of: 1) an N-terminal half that included the ELM2 
domain, aa1-301 (Δ1); 2) a C-terminal half that included the SANT domain, aa302-545 
(Δ2); 3) ELM2 + SANT domains only, aa194-346 (Δ3); 4) the ELM2 domain alone, 
aa194-301 (Δ4). Expression of each MIER1 and MIER2 construct was confirmed by 
Western blotting (Fig 14B, panel b) and (Fig 15B, panel b) respectively, as was the 
expression level of CDYL in the cell extracts (Fig 14B and Fig15B, panels c).  
Immunoprecipitates from extracts of HEK293 cells expressing one of the deletion 
constructs of MIER1 were analyzed by Western blot for the presence of CDYL1b or c 
(Fig 14B, panel a). Analysis of MIER1 revealed that both CDYL1b and CDYL1c co-
precipitated with constructs only when they contained an ELM2 + SANT domain (Fig 
14B, panel a, lanes 8-9). Similarly, deletion constructs of MIER2 were 
immunoprecipitated with 9E10 antibody from HEK293 cell lysates and were analyzed by 
Western blot for the presence of CDYL1b or c (Fig 15B, panel a). Analysis of MIER2 
also revealed that both CDYL1b and CDYL1c co-precipitated only with constructs 
containing an ELM2 + SANT domain (Fig 15B, panel a, lanes 8-9).
 Figure 14. MIER1 interact with CDYL1b and -1c via ELM+SANT domain.  
Interaction of CDYL1b and -1c with MIER1 deletion constructs. (A) Schematic showing 
a scaled representation of the MIER1 protein sequence, indicating the location of the 
ELM2 (dark pink) and SANT (purple) domains; the remaining sequence is colored light 
blue. The amino acid numbers for the beginning and end of the protein as well as 
beginning and end of ELM2 & SANT domains are indicated above the schematic. (B) 
HEK293 cells were transfected with a plasmid encoding one of the following myc-tagged 
deletion constructs: Δ1 (aa1-288; lanes 1-3), Δ2 (aa289-433; lanes 4-6), Δ3 (aa180-332; 
lanes 7-9), Δ4 (aa180-288; lanes 10-12) along with either flag tag alone (lanes 1, 4, 7,10) 
or flag-tagged –CDYL1b (lanes 2, 5, 8, 11), –CDYL1c (lanes 3, 6, 9, 12). Extracts were 
either loaded directly on the gel (panel c) or subjected to immunoprecipitation with the 
9E10 anti-myc tag antibody. The immunoprecipitates were analyzed by Western using 
anti-flag (panel a). The blots in panel (a) were stripped and restained using the 9E10 anti-
myc tag antibody to verify the presence of the relevant MIER1 deletion construct in the 
immunoprecipitates; the restained blot from panel (a) is shown in panel (c). The blots in 
panel (c) were stained with anti-flag to verify equivalent CDYL levels in the cell extracts. 
A schematic illustrating the MIER1 sequence included in the deletion construct used is 
shown above each lane. The experiment was repeated three times and representative 
Western blot image is shown.
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Figure 15. MIER2 interact with CDYL1b and -1c via ELM+SANT domain.  
Interaction of CDYL1b and -1c with MIER2 deletion constructs. (A) Schematic showing 
a scaled representation of the MIER2 protein sequence, indicating the location of the 
ELM2 (dark pink) and SANT (purple) domains; the remaining sequence is colored light 
blue. The amino acid numbers for the beginning and end of the protein as well as 
beginning and end of ELM2 & SANT domains are indicated above the schematic. (B) 
HEK293 cells were transfected with a plasmid encoding one of the following myc-tagged 
deletion constructs: Δ1 (aa1-301; lanes 1-3), Δ2 (aa302-545; lanes 4-6), Δ3 (aa194-346; 
lanes 7-9), Δ4 (aa194-301; lanes 10-12). Extracts were either loaded directly on the gel 
(panel c) or subjected to immunoprecipitation with the 9E10 anti-myc tag antibody. The 
immunoprecipitates were analyzed by Western using anti-flag (panel a). The blots in 
panel (a) were stripped and restained using the 9E10 anti-myc tag antibody to verify the 
presence of the relevant MIER2 deletion construct in the immunoprecipitates; the 
restained blot from panel (a) is shown in panel (c). The blots in panel (c) were stained 
with anti-flag to verify equivalent CDYL levels in the cell extracts. A schematic 
illustrating the MIER2 sequence included in the deletion construct used is shown above 
each lane. The experiment was repeated three times and representative Western blot 
results are shown. 
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4.3 MIER1 aa274 L→A in the ELM2 domain reduces MIER1-CDYL 
interactions  
The physical interaction between proteins is sometimes mediated by 
corresponding coiled coil regions185,186. The coiled coil is a motif characterized by the 
presence of two or three alpha helices twisted around one another, in either a parallel or 
anti-parallel configuration186. Coiled coils are extremely prevalent structures and they can 
adopt a wide range of structural arrangements with variations in helix orientation and 
oligomerization state186,187. The structures are encoded by a seven-residue heptad pattern 
and the positions in the repeat are denoted by the letters a-g.  The ‘a’ and ‘d’ positions are 
occupied by hydrophobic residues and oppositely charged residues in ‘e’ and ‘g’ 
positions. Consequently, alpha helices from such repeating sequences exhibit distinct 
amphipathic character, with both hydrophobic and polar faces. The association of two 
helices via their hydrophobic faces drives coiled-coil formation.  
 Several algorithms have been developed to detect the presence of coiled coil 
motif in protein sequence based on the heptad repeat186. We used the COILS program of 
Lupas and PAIR2COIL programs available online https://embnet.vital-
it.ch/software/COILS_form.html, http://cb.csail.mit.edu/cb/paircoil2/paircoil2.html to 
check whether any of the MIER family members encompasses a coiled coil motif185,188. 
MIER1 and MIER2 are predicted to contain a coiled coil motif from aa255-286 and 
aa260-297 respectively (Fig 16, panel A; Fig 17, panel A); these amino acids are in the 
C-terminal region of the ELM2 domain in both proteins. In contrast, MIER3 does not 
contain a coiled coil motif in the ELM2 domain (Figure 18 panel B). The ELM2 domains 
of MIER proteins are predicted to form 3 alpha helices according to secondary structure 
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prediction software189 as well as based on the structural studies of proteins with an ELM2 
domain (Fig 18, panel A)73. Also, analysis of the MIER1- and MIER2- ELM2 domains 
using a helical wheel prediction revealed that both MIER1 and MIER2 make amphipathic 
helices, characteristics of those containing coiled-coil motifs (Fig 16, panel B; Fig 17, 
panel B). Examination of the MIER3 helical wheel also predicted an amphipathic helix 
(Fig 18, panel C) but the hydrophobic surface is different from MIER1 and MIER2 in 
that it is missing the leucine residues highlighted with asterisks in the Fig 18, panel C.  
To investigate whether MIER1 and MIER2 interact with CDYL1b through their 
predicted coiled coil motif, we performed mutational analysis of myc-tagged MIER1 and 
MIER2. We explored the effect of mutating the “a” and “d” positions in heptad repeat 
(leucine residues in the predicted motif of MIER1 and MIER2) on CDYL1b recruitment. 
The CDYL1b isoform was selected in all the subsequent experiments because it is the 
isoform that is shown to interact with chromatin regulators and can bind methylated 
histones. Extracts from HEK293 cells expressing full-length wild-type or mutant MIER1 
(Fig 16) or mutant MIER2 (Fig 17) were subjected to immunoprecipitation and analyzed 
for the presence of CDYL1b by Western blot. Mutation of 274L→A significantly reduced 
recruitment of CDYL1b by MIER1 (p=0.04, Fig 16 C, panel a, lane 6), while mutation of 
260L→A, 271L→A and 288L→A did not. Restaining of panels a with 9E10 antibody 
against the myc tag showed equivalent expression levels of MIER1 constructs (panel b). 
Panel (a) was also restained for HDAC1 (panel c) and HDAC2 (panel d) to explore 
whether any of these mutations had an effect on MIER1-HDAC interactions. Even 
though the HDAC band appeared less intense in 260L→A, the difference was not 
statistically significant (p= 0.44; Fig 16D, panel c, lane 4). Likewise, other leucine 
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mutations (271L→A, 274L→A and 288L→A) did not affect the interaction between MIER1 
and HDAC1.  Also, analysis of whole cell extracts revealed equivalent levels CDYL1b, 
MIER1, HDAC1 and 2 expressions in the samples (panels e-h). These results 
demonstrated that the 274L in the MIER1 ELM2 domain is critical for CDYL recruitment. 
Mutation of the MIER2 288L →A motif reduced the interaction between CDYL1b 
and MIER2 (Fig 17 D, panel a, lane 5) but did not eliminate the interaction. Panel (a) was 
restained for HDAC1 (Fig 17D, panel c) and HDAC2 (Fig 17D, panel d) as well as for 
MIER2 (Fig 17D, panel b) to verify equivalent protein pull down.  Similarly, whole cell 
extracts were analyzed with Western showing equivalent levels CDYL1b, MIER2, 
HDAC1 and 2 expressions in the samples (panels e-h).  These data demonstrated that 
MIER2 behaves similarly to MIER1 in recruitment of CDYL, with aa 288L in MIER2 
being a critical residue. Also, presence of CDYL1b had no effect on the association of 
MIER1 or MIER2 with HDAC1/2. Additionally, mutation of leucine residues in MIER1 
and MIER2 C-terminal region of ELM2 domain did not influence the level of interaction 
between MIER1 and HDAC1/2 or MIER2 and HDAC1/2
 Figure 16. Interaction of MIER1 with CDYL is reduced by a point mutation aa274 
L→A in the ELM2 domain of MIER1. 
(A) Schematic showing a scaled representation of the MIER1 protein sequence, 
indicating the location of the ELM2 (dark pink) and SANT (purple) domains; the 
remaining sequence is coloured light blue. The amino acid numbers for the beginning and 
end of the protein as well as beginning and end of ELM2 & SANT domains are indicated 
above the schematic. The amino acid sequence below the schematic shows the location of 
different mutations designated by asterisks. (B) Probability of coiled coil formation in 
MIER1 protein scored with the algorithm by McDonnell. (C) Helical wheel prediction of 
MIER1 alpha helical coiled coil motif (aa256-aa286). Yellow: positions occupied by 
nonpolar hydrophobic amino acids and red, blue and green are polar residues. (D) Effect 
of MIER1 point mutations on interaction with CDYL. Extracts of HEK293 cells 
transfected with a plasmid encoding myc-tag alone (lane 1) or myc-tagged –wild type 
MIER1 (lane 2, 3) or –MIER1 containing a point mutation, 260L→A  (lane 4), 271L→A 
(lane 5), 274L→A (lane 6), 285L→A (lane 7), in the ELM2 domain along with either flag-
tag alone (lane 2) or flag-tagged CDYL1b (lanes 1, 3-7) were either subjected to 
immunoprecipitation with the 9E10 anti-myc tag antibody or directly loaded onto the gel. 
Western blot analysis was performed using a flag-tag antibody (panel a) or HDAC1 
antibody (panel c). The blot was stripped and restained with HDAC2 antibody (panel d) 
or the 9E10 antibody (panel b) to verify the presence of myc-tagged -wildtype or -mutant 
MIER1 proteins in each immunoprecipitate. Expression of the myc-tagged MIER1 
proteins and flag-tagged CDYL1b proteins were verified using whole cell lysates from 
parallel samples and Western analysis with the 9E10 antibody (panel f), anti-flag-tag 
antibody (panel e), anti-HDAC1 (panel g), or anti-HDAC2 (panel h). The experiment was 
repeated three times and a representative image is shown. (E) Quantitation by 
densitometry of the results from experiments illustrated in (D). The values for each band 
were corrected for the variability in expression levels as described in the Materials and 
Methods page 53 and plotted relative to that obtained with wild type MIER1± S.D. 
Statistical analysis, using one-way ANOVA with post-hoc Tukey HSD, revealed MIER1 
274L→A interaction with CDYL is significantly different from wild type MIER1 
(p<<0.05). 
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Figure 17. Interaction of MIER2 with CDYL is reduced by a point mutation aa288 
L→A in the ELM2 domain of MIER2. 
(A) Schematic showing a scaled representation of the MIER2 protein sequence, 
indicating the location of the ELM2 (dark pink) and SANT (purple) domains; the 
remaining sequence is coloured light blue. The amino acid numbers for the beginning and 
end of the protein as well as beginning and end of ELM2 & SANT domains are indicated 
above the schematic. The amino acid sequence below the schematic shows the location of 
different mutations designated by asterisks. (B) Probability of coiled coil formation in 
MIER2 protein scored with the Paircoil2 algorithm. (C) Helical wheel prediction of 
MIER2 alpha helical coiled coil motif (aa270-aa299). Yellow: positions occupied by 
nonpolar hydrophobic amino acids and red, blue and green are polar residues.  (D) Effect 
of MIER2 point mutations on interaction with CDYL. Extracts of HEK293 cells 
transfected with a plasmid encoding myc-tag alone (lane 2) or myc-tagged –wild type 
MIER2 (lane 1, 3) or –MIER2 containing a point mutation, 274L→A (lane 4) and 288L→A 
(lane 5) in the ELM2 domain along with either flag-tag alone (lane 1) or flag-tagged 
CDYL1b (lanes 2-4). Extracts were either subjected to immunoprecipitation with the 
9E10 anti-myc tag antibody or directly loaded onto the gel. Western blot analysis was 
performed using a flag-tag antibody (panel a) or HDAC1 antibody (panel c). The blot 
was stripped and restained with HDAC2 antibody (panel d) or the 9E10 antibody (panel 
b) to verify the presence of myc-tagged -wildtype or -mutant MIER2 proteins in each 
immunoprecipitate. Expression of the myc-tagged MIER2 proteins and flag-tagged 
CDYL1b proteins were verified using whole cell lysates from parallel samples and 
Western analysis with the 9E10 antibody (panel f), anti-flag-tag antibody (panel e), anti-
HDAC1 (panel g), or anti-HDAC2 (panel h). The experiment was repeated three times 
and a representative image is shown. (E) Quantitation by densitometry of the results from 
experiments illustrated in (D). The values for each band were corrected for the variability 
in expression levels as described in the Materials and Methods page 53 and plotted 
relative to that obtained with wild type MIER2± S.D. Statistical analysis, using one-way 
ANOVA with post-hoc Tukey HSD, revealed no significantly difference between WT 
MIER2 and mutants. 
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 Figure 18. The ELM2 domain of MIER3 does not make a coiled coil structure.   
(A) Alignment of MIER1 aa 215-269, MIER2 aa 221-275 and MIER3 aa 235-289 protein 
sequence, the location of the helices are highlighted in yellow. (B) Probability of coiled 
coil formation in MIER3 protein scored with the Paircoil2 algorithm. (C) Helical wheel 
prediction of MIER3 alpha helical coiled coil motif (aa247-aa277). Yellow: positions 
occupied by nonpolar hydrophobic amino acids and red, blue and green are polar 
residues. The amino acid designated by asterisks are different in MIER3 as compared to 
MIER1 and MIER2   
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4.4 The interaction between CDYL and HDAC1 and 2 is enhanced by MIER1 
and MIER2 
CDYL was previously demonstrated to be part of at least two multi-protein 
subcomplexes108. The first complex consisted of MIER1/2, HDAC1 and 2108 and the 
second complex contained REST, widely interspaced zinc finger motifs (WIZ), and three 
histone lysine-specific methyltransferases (HKMTs) (euchromatic histone lysine 
methyltransferase 2 (EHMT2) also known as G9a, G9a-like protein (GLP), and SET 
domain bifurcated 1 (SETDB1)108. Also, CDYL was shown to interact with HDAC1 and 
2109. I showed that MIER1 and MIER2 interact with CDYL (Fig 13B, panel a) and 
HDAC1 & 2 (Fig 9A, panels a-b) and that exogenous expression of CDYL does not 
affect HDAC1/2 binding to MIER1/2 (Fig 16D, Fig17D; panels c-d), suggesting that the 
interaction between them is not influenced by CDYL. To determine whether MIER1 or 
MIER2 may mediate the interaction between CDYL and HDAC 1/2, I carried out co-
immunoprecipitation assays using extracts from HEK293 cells expressing myc-tagged 
MIER1α or MIER2 and flag-tagged CDYL1b. The immunoprecipitates were analyzed by 
Western using either 9E10 anti-myc (panel a) or anti-HDAC1 (panel b). The blot in 
panels a & b were stripped and restained using anti-HDAC2 (panel c) and anti-flag tag 
antibody (panel d) to verify levels of CDYL1b protein in each immunoprecipitate. 
Similarly, whole cell extracts were also analyzed for Western showing equivalent 
expression of MIER1, CDYL1b, HDAC1 and HDAC2 in all the samples (panel e-h).  
As we demonstrated in the previous experiments, both MIER1 and MIER2 were 
present in CDYL1b immunoprecipitates (Fig 19B, panel a, lane 3 & Fig 20B, panel a, 
lane 3 respectively). As has been previously reported109, both HDAC1 and 2 were 
 
 
100 
detected with CDYL1b in the absence of transfected MIER1 (Fig 19B, panel b-c, lane 2)  
and MIER2 (Fig 20B, panel b-c, lane 2), albeit at much lower levels than that seen with 
MIER1 and MIER2 overexpression. Actually, our data showed that the interaction 
between CDYL1b and HDAC1 & 2 were augmented 4.5X by MIER1 (p = 0.004; Fig 
19B, panel b-c, lane 3) and 5X by MIER2 (p = 0.001; Fig 20B, panel b-c, lane 3) 
respectively. To provide a more accurate representation of the level of interaction, the 
bands were quantified by densitometry using blots from three representative experiments 
and plotted the average ratio of CDYL: MIER and CDYL: HDAC1/2 in the 
immunoprecipitate. This analysis revealed that the level of MIER1 274L →A associated 
with CDYL1b was 20% of that of MIER1 (Fig 19B, panel a, lane 4).  In addition, MIER1 
274L →A returned the level of interaction between CDYL1b and HDAC1 and 2 to levels 
seen in CDYL1b alone precipitate (p = 0.01; Fig 19B, panel b-c, lane 4). However, 
mutating MIER2 288L →A motif did not alter the interaction between MIER2 and 
CDYL1b (Fig 20B, panel a, Lane 4) and MIER2 288L →A reduced the binding by 30% 
but the levels varied between experiments and ranged from barely detectable above 
control to the levels shown in Fig 20B. Statistical analysis of the band intensities obtained 
from densitometry analysis showed no significant difference between MIER2 and MIER2 
288L →A in average level of associations with CDYL1b (p >0.05). The recruitment of 
HDAC1 and 2 by CDYL1b in the presence of MIER2 274L →A or MIER2 288L →A were 
also unaffected (Fig 20B, panel b-c, Lanes 4-5) as compared to MIER2 (Fig 20B, panel 
b-c, Lanes 3). These co-immunoprecipitation assays demonstrated that the level of 
HDAC1 and 2 associated with CDYL complexes were improved when MIER1 or MIER2 
was present. 
Figure 19. The level of HDAC1 and 2 associated with CDYL complex is increased 
when MIER1 is present.  
(A) Schematic showing a scaled representation of the MIER1 protein sequence, with a 
vertical line indicating the location and amino acid change of the mutant. (B) Effect of 
MIER1 on interaction of CDYL with HDAC1 & 2. Extract from HEK293 cells 
transfected with a plasmid encoding myc tag alone (lane 2) or myc-tagged –wildtype 
MIER1 (lanes 1, 3) or –MIER1 containing a point mutation, 274L→A, in the ELM2 
domain along with either flag tag alone (lane 1) or flag-tagged CDYL1b (lanes 2-4) were 
either loaded directly on the gel (panel h) or subjected to immunoprecipitation with the 
anti-flag antibody. Western blot analysis was performed using anti-myc antibody (panel 
a) and anti-HDAC1 antibody (panel b). The blots in panels a & b were stripped and 
restained with anti-HDAC2 antibody (panel c) and the flag antibody to verify the 
equivalent presence of CDYL1b (panel d) protein in the immunoprecipitates. The blots in 
panel c were stained with anti-flag to verify equivalent CDYL levels in the cell extracts.  
Expression of the myc-tagged MIER1, flag-tagged CDYL1b, endogenous HDAC1 and 2 
proteins were verified using whole cell lysates from parallel samples and Western 
analysis with the 9E10 antibody (panel e), anti-HDAC1 (panel f), anti-HDAC2 (panel g), 
or anti-flag-tag antibody (panel h). The experiment was repeated 3 times and a 
representative image is shown. (C) Quantitation by densitometry of the results from the 
experiments illustrated in (B). The values for MIER1, HDAC1, HDAC2 bands was 
corrected for the variability in expression levels as described in the Materials and 
Methods and plotted is the average ratios ± S.D. Statistical analysis, using one-way 
ANOVA with post-hoc Tukey HSD, revealed significant difference between MIER1 and 
274L→A in CDYL immunoprecipitate (p<<0.05) and HDAC1 & HDAC2 also 
significantly different between MIER1 and 274L→A (p<<0.05). 
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Figure 20. The level of HDAC1 and 2 associated with CDYL complex is increased 
when MIER2 is present.  
(A) Schematic showing a scaled representation of the MIER2 protein sequence, with a 
vertical line indicating the location and amino acid change of the mutant. (B) Effect of 
MIER2 on interaction of CDYL with HDAC1 & 2. Extract of HEK293 cells transfected 
with a plasmid encoding myc tag alone (lane 2) or myc-tagged –wildtype MIER2 (lanes 
1, 3) or –MIER2 containing a point mutation, 274L→A (lane 4) and 288L→A (lane 5), in 
the ELM2 domain along with either flag tag alone (lane 1) or flag-tagged CDYL1b (lanes 
2-5) were either loaded directly on the gel (panel h) or subjected to immunoprecipitation 
with the anti-flag antibody. Western blot analysis was performed using anti-myc antibody 
(panel a) and anti-HDAC1 antibody (panel b). The blots in panels a & b were stripped 
and restained with anti-HDAC2 antibody (panel c) and the flag antibody to verify the 
equivalent presence of CDYL1b (panel d) protein in the immunoprecipitates. The blots in 
panel c were stained with anti-flag to verify equivalent CDYL levels in the cell extracts.  
Expression of the myc-tagged MIER2, flag-tagged CDYL1b, endogenous HDAC1 and 2 
proteins were verified using whole cell lysates from parallel samples and Western 
analysis with the 9E10 antibody (panel e), anti-HDAC1 (panel f), anti-HDAC2 (panel g), 
or anti-flag-tag antibody (panel h). The experiment was repeated three times and a 
representative image is illustrated. (C) Quantitation by densitometry of the results from 
the experiments illustrated in (B). The values for MIER2, HDAC1, HDAC2 bands was 
corrected for the variability in expression levels as described in the Materials and 
Methods and plotted is the average ratios ± S.D. Statistical analysis, using one-way 
ANOVA with post-hoc Tukey HSD, revealed significant difference between HDAC1 & 
HDAC2 levels in CDYL immunoprecipitate (p<<0.05) in the presence of MIER2 as 
compared to myc-tagged control depicted with an asterick. 
 
 
102 
 
 
 
103 
4.5 Genome-wide identification of chromatin targets of MIER  
Genome-wide mapping of protein–DNA interactions and epigenetic marks is 
important for a complete understanding of transcriptional regulation. A detailed map of 
binding sites for transcription factors, core transcriptional machinery and other DNA-
binding proteins is key for understanding the regulatory networks that underlie various 
biological processes. Recently, the next-generation sequencing (NGS) technology has 
had a great impact on the field of genome research. Chromatin immunoprecipitation 
followed by deep sequencing (ChIP-Seq) serves as a highly efficient NGS method for 
genome-wide profiling of DNA-binding proteins, histone modifications, and 
nucleosomes190. Increasing amounts of NGS data have been deposited in public 
databases, such as the Sequence Read Archive (SRA) (http://www.ncbi.nlm.nih.gov/sra) 
and the Encyclopaedia of DNA Elements (ENCODE) Consortium.   
To identify the genome-wide enrichment sites for the MIER proteins, I analyzed 
ChIP-Seq datasets available from the public database. ChIP-Seq data sets for MIER1, 
MIER2 and MIER3 were prepared by the ENCODE Consortium. Short sequencing reads 
were aligned to the human assembly GRCh37 (also known as hg19) and enrichment of 
binding sites were identified by peak caller model-based analysis of ChIP-Seq using 
MACS program on Galaxy, which is an open source, web-based platform for genome 
data analysis. MACS identified 4577 ChIP-Seq peaks of MIER1 in K562 cells and 
53,480 ChIP-Seq peaks of MIER2 and 65835 peaks of MIER3 target genes in HepG2 
cells. After performing stringent criteria that satisfied both false discovery rate (FDR) ≤ 
1%, which is calculated from the number of control peaks divided by the number of 
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ChIP-seq peaks with the same p-value and fold enrichment (FE) ≥ 15, the results were 
further reduced to 448 genes (MIER1), 1614 genes (MIER2), and 1030 genes (MIER3).  
Among 448 genes detected in the MIER1 sample, the peaks were located in the 
promoter region (15.3%), downstream region (4.0%), 5′UTR (1.9%), exon (2.3%), intron 
(41.4%), 3′UTR (1.5%), and distal intergenic (33.6%) (Fig 21A). Likewise, within 1614 
genes detected in MIER2 in HepG2 cells, the peaks were located in the promoter region 
(18.5%), downstream region (4.4%), 5′UTR (3.2%), exon (2.9%), intron (39.7%), 3′UTR 
(1.7%), and distal intergenic (29.6%)(Fig 22A). Similarly, in 1030 genes detected in 
MIER3 in HepG2 cells, the peaks were located in the promoter region (16.9%), 
downstream region (4.2%), 5′UTR (3.1%), exon (2.8%), intron (41.1%), 3′UTR (1.7%), 
and distal intergenic (30.2%) shown in Fig 23A. Thus, introns serve as a major MIER-
binding site in both K562 and HepG2 cells. As shown in Fig 21C the distribution of 
MIER1 around the transcriptional start site (TSS) presents a peak just before and also 
after TSS. In contrast, the profile of MIER2 and MIER3 in the TTS region shows a strong 
increase just at the TTS (Fig 22C, Fig 23C respectively). 
I next screened for consensus binding motifs for MIER proteins on sequences 
within ±200 base pair relative to each MIER-binding peak summit. I used MEME-
ChIP176 based on FE ≥ 15 to do an unbiased search. The results showed that the MIER1 
consensus binding motif is composed of a well-defined REST RE1 
5′CAG[CG]ACC[AT][TC]GGA[CG]AG3′ (E-value = 7.7 × 10−1156) motif and a PRDM4 
motif composed of 5’GTTTC[AT]AGG3′ ( E-Value = 3.2 × 10−103) (Fig 21B). The E-
value is an estimate of the expected number of motifs with the given log likelihood ratio 
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(or higher) and with the same width and site count that one would find in a similarly 
sized set of random sequences. 
 Likewise, MIER2 consensus motif contains 
5′[TG][TC]CAG[CG]ACC[AT][TC]GGACAG[CA][GT]3′  (E-value = 3.7 × 10−2082), 
which is also REST RE1 binding motif (Fig 22B). Similarly, I performed MIER3 
consensus binding motif search with MEME-ChIP. The results indicated that the MIER3 
consensus sequence contains a REST RE1 motif made up of 
5′[TG][TG]CAG[CG]ACC[AG][TC]GGACAG3′ (E-Value = 9.9 × 10−113) as well as 
FOXA1/2 5′T[GA]TTT[AG][CT]3′ ( E-Value = 7.8 × 10−116) (Fig 23B). Importantly, I 
found significant enrichment of MIER-binding signals within the RE1 sites of known 
REST target genes. 
4.6 Functional analysis of MIER target genes 
Finally, to gain further insights into the MIER protein genome binding targets, we 
performed functional annotation analysis using the GREAT program. Functional analysis 
of MIER1 and MIER2 target genes gives us a clear view of biological pathways and that 
both MIER1 and MIER2 may be involved in neural development (Figs 21D & 22D). 
GREAT analysis suggested that MIER1 target genes were significantly enriched in 
neurological functions including “synaptic transmission”, “multicellular organismal 
signalling”, “transmission of nerve impulse”, “signal release”, and “adenylate cyclase-
inhibiting G-protein coupled glutamate receptor signalling pathway” as the top 5 
significant pathways for MIER1 (Fig 21D). Similarly, MIER2 target genes were analyzed 
and the top 5 pathways were “transmission of nerve impulse”, “multicellular organismal 
signalling”, “synaptic transmission”, “signal release”, and “neurotransmitter transport” 
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(Fig 22D). These data suggests MIER2 target genes are involved in neural processes. 
Additionally, list of MIER3 target genes were uploaded in GREAT to predict the 
pathways that MIER3 is possibly a part of. The result of the top 5 pathways include, 
“acute phase response”, “negative regulation of intrinsic apoptosis signalling pathway”, 
“acute inflammatory response”, “regulation of cytokine biosynthetic process”, and 
“mitochondrion organization”  (Fig 23D).  
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Figure 21. Genome-wide identification of MIER1 target genes in human K562 cell.   
(A) Genomic distribution of MIER1 binding regions determined by ChIP-seq analysis. (B) MEME motif analysis of MIER1 genes 
identified the presence of REST (top panel) and PRDM4 (bottom panel) DNA-binding motif. (C) Average binding profile of MIER1 
at TSS (±3 kb). (D) Functional enrichment analysis of biological processes associated with MIER1 ChIP-seq genes (TSS ±2 kb). 
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Figure 22. Genome-wide identification of MIER2 target genes in human HepG2 cell.   
(A) Genomic distribution of MIER2 binding regions determined by ChIP-seq analysis. (B) MEME motif analysis of MIER2 genes 
identified the presence of REST DNA-binding motif. (C) Average binding profile of MIER2 at TSS (±3 kb). (D) Functional 
enrichment analysis of biological processes associated with MIER2 ChIP-seq genes (TSS ±2 kb). 
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Figure 23. Genome-wide identification of MIER3 target genes in human HepG2 cell.   
(A) Genomic distribution of MIER3 binding regions determined by ChIP-seq analysis. (B) MEME motif analysis of MIER3 genes 
identified the presence of FOXA1 (top panel) and REST (bottom panel) DNA-binding motif. (C) Average binding profile of MIER3 at 
TSS (±3 kb). (D) Functional enrichment analysis of biological processes associated with MIER3 ChIP-seq genes (TSS ±2 kb). 
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REST and MIER1-3 peaks with FE ≥ 15 and FDR <1% computed from MACs 
software was uploaded to GREAT, an online tool to predict functions of cis-regulatory 
regions within 2,000 base pairs around transcriptional start site (TSS). This list was then 
used to identify overlapping target genes between REST and MIER proteins. As 
expected, there was a considerable overlap between MIER1 & REST and MIER2 & 
REST target genes as shown in Fig 24. MIERs were found to bind proximally to many of 
the well-characterized neuronal genes in, previously noted in REST ChIP-Seq studies191. 
REST was found on TSS regions of bdnf, calb1, l1cam, chat, gria2, chrm4, nrcam, grin1, 
stmn2, scg2, syn1, syp, syt4, glra1, and chrnb2 in 14 or more cell types191,192. Among 
these, 6 genes (l1cam, chat, syn1, syp, glra1, and chrnb2) were bound by all three MIER 
proteins. MIER2 bound to all the 15 genes whereas MIER1 was found on TSS of 11 
genes. Our results suggest that MIER2 associates with REST more broadly across 
different cell types as compared to MIER1 and MIER3. 
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Figure 24. Overlap of REST and MIER1, MIER2 and MIER3 target genes.  
(A) Venn diagram shows the overlap of genes targeted by REST and MIER1 in K562 
cells, REST and MIER2 and REST and MIER3 in HepG2 cells, with the number of genes 
indicated in each area.  
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4.7 MIER2 interacts more efficiently with REST than MIER1 and MIER3  
ChIP-Seq data analysis of the MIER proteins revealed that all 3 family members 
were associated with the well-known REST target genes. And motif analyses have 
identified genomic binding sites for MIER proteins to be nearly identical with canonical 
RE1 motif. Previous (unpublished studies) from our lab showed that MIER1 was not a 
DNA binding protein. These findings prompted us to ask whether MIER proteins interact 
with REST. To investigate MIER-REST interactions, I performed co-
immunoprecipitation analysis using extracts from HEK293 cells expressing myc-tagged 
MIER1α, MIER1 MIER2 or MIER3. Myc-tagged-CDYL1b was included as a positive 
control. CDYL has been previously demonstrated to bind REST and bridge the 
interaction between REST and G9a to repress transcription108.  
As has been previously reported108, CDYL1b was present in REST 
immunoprecipitate (Fig 25, panel a, lane 6). Likewise, MIER2 co-precipitated with REST 
(Fig 25, panel a, lane 4), albeit at higher levels than that seen with CDYL1b.  MIER1 & 
MIER3 were also present in REST immunoprecipitates (Fig 25, panel a, lanes 2, 5), 
however levels varied between experiments and ranged from being barely detectable 
above the control (Fig 25, panel a, lane 1) to the levels shown in Fig 25. Therefore, to 
provide a more accurate representation of the level of interaction, I quantified the bands 
by densitometry using blots from 3 experiments and plotted the average ratio of REST: 
MIER in the immunoprecipitate. This analysis revealed that the level of MIER1α with 
REST was 15% of that of MIER2 (Fig 25B). MIER3 level of interaction was even lower, 
approximately 11% of that of MIER2. The lower levels of MIER1 and MIER3 
immunoprecipitated with REST were not due to differences in REST expression since re-
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staining of the blots in Fig 25, panels “a” with anti-REST antibody (Fig 25, panel b) 
revealed that the amount of REST was the same in all the samples. Similarly, whole cell 
extracts were analyzed by Western blotting with antibodies against myc-tag (panel c) and 
REST (panel d) to verify equivalent MIER proteins & CDYL and REST levels 
respectively in each sample.   
To verify the differential recruitment of REST by the MIER proteins was not a 
HEK293-specific result; co-IP was repeated using HepG2 cells. Interestingly, only 
MIER2 co-immunoprecipitated with REST in this cell line (Fig 26, panels a, lane 4) and 
no REST was associated with MIER1 or 3. Again, CDYL1b was used as a positive 
control and interacting band between CDYL1b with REST in HepG2 cells was detected 
(Fig 26, panel a, lane 6). Taken together, my data suggest that MIER2 is associated with 
REST more robustly than MIER1 and MIER3, which is in agreement with the ChIP-Seq 
analysis where I showed MIER2 presence on all the REST target genes.   
Figure 25. Co-immunoprecipitation of REST with MIER proteins.  
HEK293 cells were transfected with plasmid encoding myc tag alone (lanes 1) or myc-
tagged -MIER1 (lanes 2), -MIER1b (lane 3)  -MIER2 (lane 4), -MIER3 (lane 5). 
Extracts were either loaded directly on the gel (panels c, d) or subjected to 
immunoprecipitation with anti-REST antibody (panels a-b). (A) The immunoprecipitates 
analyzed by Western using either the 9E10 anti-myc antibody (panel a) or anti-REST 
antibody (panels b) to verify levels of MIER and REST protein respectively in each 
immunoprecipitate. Whole cell extracts were analyzed by Western using anti-myc (panel 
c) and anti-REST (panel d) to verify equivalent MIER and REST levels in each sample. 
The experiment was repeated three times and representative Western blot is shown. (B) 
Quantitation by densitometry of the results from the experiment illustrated in (A). The 
values for each band was corrected for the variability in expression levels as described in 
the Materials and Methods and plotted is the average MIER:REST ratio ± S.D. Statistical 
analysis, using one-way ANOVA with post-hoc Tukey HSD, revealed MIER2 and 
CDYL1b significantly immunoprecipitated with REST (p<<0.05) compared to control. 
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Figure 26. Co-immunoprecipitation of REST with MIER proteins.  
HepG2 cells were transfected with plasmid encoding myc tag alone (lanes 1) or myc-
tagged -MIER1 (lanes 2), -MIER1b (lane 3)  -MIER2 (lane 4), -MIER3 (lane 5). 
Extracts were either loaded directly on the gel (panels c, d) or subjected to 
immunoprecipitation with anti-REST antibody (panels a-b). The experiment was repeated 
three times and a representative Western blot is shown. The immunoprecipitates analyzed 
by Western using either the 9E10 anti-myc antibody (panel a) or anti-REST antibody 
(panels b) to verify levels of MIER and REST protein respectively in each 
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immunoprecipitate. Whole cell extracts were analyzed by Western using anti-myc (panel 
c) and anti-REST (panel d) to verify equivalent MIER and REST levels in each sample.  
 
4.8 The C-terminal portion of MIER2 is crucial for recruitment of REST  
Using deletion analysis with myc-tagged constructs, we investigated which region 
of the MIER 2 sequence is required for recruitment of REST. MIER2 deletion constructs 
consisted of: 1) an N-terminal half that included the ELM2 domain, aa1-301 (Δ1); 2) a C-
terminal half that included the SANT domain, aa302-545 (Δ2); 3) ELM2 + SANT 
domains only, aa194-346 (Δ3); 4) the ELM2 domain alone, aa194-301 (Δ4). Expression 
of each construct was confirmed by Western blotting (Fig 27B, panel c), as was the 
expression level of REST in the cell extracts (Fig 27B, panels d). 
REST was immunoprecipitated from extracts of HEK293 cells expressing full-
length or one of the deletion constructs of MIER2 (Fig 27). Western blot analysis using 
anti-myc tag antibody of immunoprecipitates revealed that REST only co-precipitated 
with full length MIER2 (Fig 27B, panel a, lanes 2) and Δ2 constructs containing aa 302-
545 a C-terminal half that included the SANT domain (Fig 27B, panel a, lanes 4) and that 
the SANT domain alone is not sufficient for interaction (Fig 27B panels a-b, lane 5).  
To investigate whether HDAC1 &2 and/or CDYL mediate the interaction 
between REST and MIER2 we performed mutational analysis. Previously, I showed that 
the 228W in the ELM2 domain of MIER2 (Fig 12C) was critical for recruitment of 
HDAC1/2 since mutation of this tryptophan to alanine resulted in loss of HDAC1/2 from 
MIER2 complexes. Similarly, I found that 288L in the ELM2 domain of MIER2 (Fig 20B) 
was important for binding to CDYL1b since mutation of this leucine to alanine resulted 
in reduced association of CDYL1b with MIER2. Therefore, I investigated the effect of 
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mutating 228W and 288L residues on REST recruitment. Mutations of 228W→A or 288L 
→A did not change the level of interaction between MIER2 and REST (Fig 27B, panel a, 
lanes 7-8).  
Together, these data suggests that MIER2 binding to REST is mediated through a 
region encompassing aa 301-545. However, the SANT domain does not appear to be 
sufficient for the recruitment of REST by MIER2 since REST is unable to bind to the Δ3 
construct, which includes the SANT domain. It is not surprising that the mutation of 
228W→A or 288L →A does not alter interaction between MIER2 and REST as these 
residues are in the ELM2 domain of MIER2. These data lead to the conclusion that 
neither CDYL nor HDAC1/2 recruit REST to MIER2 and that the interaction between 
REST and MIER2 is independent of HDAC and CDYL.  
Figure 27. MIER2 interact with REST via the C terminus of MIER2.  
Interaction of REST with MIER2 deletion constructs. (A) Schematic showing a scaled 
representation of the MIER2 protein sequence, indicating the location of the ELM2 (dark 
pink) and SANT (purple) domains; the remaining sequence is colored light blue. The 
amino acid numbers for the beginning and end of the protein as well as beginning and 
end of ELM2 & SANT domains are indicated above the schematic. (B) HEK293 cells 
were transfected with a plasmid encoding myc tag alone (lane 1), myc-tagged full-length 
MIER2 (lane 2), one of the following myc-tagged deletion constructs: Δ1 (aa1-301; lane 
3), Δ2 (aa302-545; lane 4), Δ3 (aa194-346; lane 5), Δ4 (aa194-301; lane 6) or myc-
tagged MIER2 containing a point mutation, 228W→A or 288W→A, in the ELM2 domain 
(lanes 7, 8 respectively). Extracts were either loaded directly on the gel (panels c & d) or 
subjected to immunoprecipitation with anti-REST antibody. The experiment was repeated 
three times and representative Western blot results are shown. The immunoprecipitates 
were analyzed by Western using the 9E10 anti-myc tag antibody (panel a). The blots in 
panels a were restained with the anti-REST antibody to verify equivalent REST protein in 
each immunoprecipitates (panel b). The blots in panel c were stained with anti-myc to 
verify equivalent MIER2 constructs levels in the cell extracts. A schematic illustrating 
the MIER2 sequence included in the deletion construct used is shown above each lane.
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4.9 Effect of MIER1/2 knockdown on neuronal differentiation in P19 cells 
Analysis of MIER ChIP-Seq datasets suggested that MIER1 and MIER2 might 
play an important role in regulating genes involved in neural processes. Genome-wide 
binding of MIER1 by ChIP-Seq showed MIER1 was enriched on approximately 90% of 
REST target genes whereas MIER2 bound almost exclusively to REST target genes. 
Also, I found that MIER1 and MIER2 interacted with REST, a transcriptional repressor 
of neuronal differentiation, known to inhibit neuronal genes in non-neuronal cells and to 
regulate neurogenesis.  To investigate the potential role of MIER1 or MIER2 in neural 
differentiation, loss-of-function analyses were conducted in P19 cells, using MIER1 and 
MIER2 selective shRNAs. P19 cells are a line of embryonal carcinoma cells that were 
derived from a teratocarcinoma in mice by McBurney et al. 193. P19 cells can be 
stimulated to differentiate by nontoxic drugs. Treatment of these cells with retinoic acid 
(RA) effectively induces the development of neural lineages including neurons, astroglia 
and microglia cell as shown in schematic (Fig 28A).  
 In this study, I generated stable clones expressing shRNAs against MIER1 and 
MIER2. As a negative control, I stably transfected P19 cells with non-targeting shRNA. 
Using quantitative RT-PCR, I showed MIER1 and MIER2 mRNA levels are 
approximately 30% in knockdown clones compared to that in the control clones (Fig 
28B). The mRNA expression levels are average of three independent experiments and are 
relative to GAPDH.  
Two individual MIER1- and MIER2-knockdown P19 clones were allowed to 
aggregate for 3 days in bacterial grade plates and aggregated embryonic bodies were then 
dissociated into single cells. MIER1- and MIER2-knockdown cells were cultured in 
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monolayers for 10 days. As controls, the non-targeting shRNA P19 clone and 
untransfected P19 cells were incubated for 10 days with or without RA. The expression 
levels of neuron-specific marker and a glia-specific marker, tubulin 3 and glial fibrillary 
acidic protein (GFAP) respectively, were then examined by Western blot and confocal 
analysis.  
As has been previously reported194, P19 parental cells were able to differentiate 
into both neurons and astrocytes in the presence of RA, as evidenced by expression of 
tubulin 3 (Fig 28C, panel a, lane 2) and GFAP (Fig 28C, panel b, lane 2) detected by 
Western blot. As expected, P19 and Con (non-targeting shRNA clone) cells did not 
differentiate into any of the neural lineage without RA treatment (Fig 28C, panels a-b, 
lane 1, 3). Interestingly, the MIER1 knockdown clones in the absence of RA induction 
expressed tubulin 3 (Fig 28C, panel a, lane 4-5), which is a marker of differentiated 
neurons.  Knockdown of MIER1 in P19 cells triggers cells to differentiate into neurons 
suggesting MIER1 involvement in maintaining stem cells in an undifferentiated state,. 
Surprisingly, MIER2 knockdown in P19 cells caused a smaller effect on the expression 
of tubulin 3 (Fig 28C, panel a, lane 6-7) as compared to MIER1 knockdown clones. No 
GFAP expression was present in MIER1 or MIER2 clones (Fig 28C, panel b, lanes 4-7) 
in the absence of RA treatment implying that MIER1/2 may have a specific role in 
lineage differentiation. The results demonstrate that MIER1 and MIER2 play important 
roles in controlling neurogenesis. There are differences in differentiation of MIER1 and 
MIER2 knockdown clones, which may be that the two proteins are important at different 
times during the process of neurogenesis.   
 
Figure 28. Knockdown of MIER1 or MIER2 triggers neuronal differentiation in P19 
cells.   
(A) P19 cells were stably transfected with shRNA plasmids against MIER1 or MIER2. 
MIER1- or MIER2-silenced P19 cells were allowed to aggregate in suspension, minus or 
plus retinoic acid (RA), for 3 days. The resulting embryoid bodies were cultured in a 
monolayer for 10 days. The experiment was repeated three times and representative 
results are shown in B & C. (B) RT-PCR analysis to confirm knockdown of MIER1 or 
MIER2 in P19 cells. (C) Expression levels of the indicated neuronal marker genes were 
examined using Western in P19 parental line in the absence (lane 1) or presence of RA 
(lane 2), scrambled shRNA samples (lane 3), MIER1 knockdown (lanes 4-5) and MIER2 
knockdown samples (lanes 6-7).  
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Next, I confirmed the results of the Western blots using confocal analyses. 
MIER1 and MIER2 knockdown clones along with control non-targeting shRNA clones 
were subjected to differentiation with or without RA to analyze the effect of supressing 
MIER1 or MIER2 on the neural differentiation of P19 cells. Control P19 clone cells 
differentiated into neurons and astrocytes after simple aggregation culture in the presence 
of RA, expressing tubulin 3 as well as GFAP (Fig 29, panel b).  
 In both MIER1 (Fig 29, panels c-d) and MIER2 (Fig 29, panels e-f) knockdown 
clones without RA treatment, tubulin 3 staining is very clear. Again, neither knockdown 
clones showed GFAP staining. These results were consistent with the data obtained from 
Western blot analysis, as shown in Fig 28 and the observations support the results of 
Western blot analysis of neural markers, which showed that MIER1/2 silenced cells 
expressed neuron-specific marker tubulin 3 only (Fig 28C). Taken together, my data 
suggest that MIER1 and MIER2 play a crucial role in neural differentiation.  
 
 
 
 
 
 
 
 
Figure 29. Knockdown of MIER1 or MIER2 triggers neuronal differentiation in P19 
cells.   
P19 cells were stably transfected with shRNA plasmids against MIER1 or MIER2. 
MIER1- or MIER2-silenced P19 cells were allowed to aggregate in suspension, minus or 
plus retinoic acid (RA), for 3 days. The resulting embryoid bodies were cultured in a 
monolayer for 10 days. The experiment was repeated three times and representative 
images are shown. Immunocytochemical staining of MIER1/2 silenced P19 cells that 
were differentiated without retinoic acid (green indicates neuron-specific label tubulin 3; 
red indicates the astrocyte-specific label GFAP; blue indicates the nucleus-specific label 
DAPI). Scale bar = 150 μm.  
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4.10  Neuronal differentiation genes are altered in Mier1-/- MEFs 
Gene targeting is used to engineer any alteration in the genome by homologous 
recombination in mouse ES cells, from point mutations to large chromosomal 
rearrangements195. The European Conditional Mouse Mutagenesis (EUCOMM) program 
is a large-scale knockout consortium aimed to generate null mutations in C57BL/6 mouse 
ES cells. The reason why C57BL/6 strain was chosen is because it is the best-
characterized inbred strain, it is the reference strain for the mouse genome sequence and 
it breeds well in the laboratory195. Consequently, Mier1 null mice were also generated by 
EUCOMM using a “knockout-first” strategy. The method is to insert a cassette into an 
intron of an intact gene to produce a knockout at the RNA processing level196. A splice 
acceptor in the cassette captures the RNA transcript and an efﬁcient polyadenylation 
signal, truncating the transcript so that the gene is not transcribed into mRNA 
downstream of the cassette site. A knockout-ﬁrst strategy also contains an expression 
reporter like the -galactosidase gene to monitor the activity of the promoter. Mier1 
knockout first was engineered by inserting the cassette between exon 9 and exon 10, 
which is the start of ELM2 domain, to generate an MIER1 null mouse. Data collected by 
Wellcome Trust Sanger Institute (WTSI) using MIER1-Knockout (KO) mice 
demonstrated MIER1 null mice exhibited gender specific phenotypes. Male KO mice 
exhibit decreased body weight, trunk curl, increased body fat amount, decreased 
circulating free fatty acids and glucose levels as well as abnormal behavior. Female KO 
mice displayed trunk curl, abnormal vocalization, tremors and decreased circulating 
glucose levels. Details of experimental designs, statistical analysis and data can be found 
on www.mousephenotype.org.  
 
 
125 
Phenotypes such as trunk curl, abnormal vocalization, tremors and abnormal behaviors 
are all traits that may be associated with brain function and development. This is 
consistent with MIER1’s potential role in neurogenesis, evidenced by its enrichment on 
REST target genes and by the fact that silencing MIER1 in P19 cells triggered neuronal 
differentiation in the absence of RA treatment. MIER1 is shown to interact with 
HDAC1/2, CDYL and REST, which play important roles in neurogenesis136,143,197,198. 
Understanding which genes are under direct control of MIER1 can help understand its 
specific role in neural development.   
To address this point, we analyzed transcriptomes of mouse embryonic fibroblasts 
(MEFs) derived from WT and MIER1-KO embryos at stage E13.5 by RNA sequencing. 
The results of this analysis revealed 152 up-regulated and 405 down-regulated genes 
(intensity differences p < 0.5) in MIER1-KO MEFs, when compared to WT MEFs (Fig 
30A, B). The most significant biological processes associated with deregulated genes 
in MIER1-KO MEFs were regulation of neuron differentiation, cell adhesion and growth, 
axon guidance and synapse assembly (Fig 30C). Altogether, these findings show that 
changes in MIER1 levels alter expression of genes controlling neuron differentiation and 
function.  
 
 Figure 30. RNA-seq analysis of gene expression in MIER1-KO MEFs and WT 
MEFs.  
(A) RNA-seq analysis was performed using SeqMonk using default parameters and a 
threshold value of 0.5. SeqMonk scatter plot showing both the up- and downregulated 
genes between the log 2 -transformed reads-per-million mapped reads values for the 
MIER1-KO and WT MEFs mRNA samples. (B) Heat maps of the relative expression of 
the 152 upregulated genes and 405 downregulated resulting from MIER1 depletion. (C) 
Gene ontology enrichment analysis of transcripts differentially expressed in MIER1-KO 
relative to WT MEFs. The top 11 annotation clusters are listed as derived from the 
DAVID bioinformatics tool. Count values represent number of genes and Benjamini 
values are similar to a p-value corrected for multiple hypothesis testing using the false 
discovery rate. 
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Chapter 5: Discussion 
The MIER family consists of three proteins namely MIER1, MIER2 and MIER3, 
grouped together based on sequence identities in their ELM2 and SANT domains145. 
MIER1 is a very well characterized member, shown to function as a transcriptional 
corepressor by recruiting HDAC1 and 2157. Little is known about the structure and 
function of MIER2 and MIER3. Both are predicted to be nuclear proteins and recently, 
MIER3 has been identified as a candidate breast cancer susceptibility gene199. Several 
large-scale proteomic/interactome studies have identified MIER proteins in association 
with HDAC1 and/or HDAC263,168. Furthermore, such studies have demonstrated that 
MIER1, 2 & 3 are not components of the CoREST, NuRD, SIN3 or NCoR corepressor 
complexes, but rather form distinct HDAC-containing complexes. While large-scale 
interactome analyses are very useful for providing information about the potential 
function of uncharacterized genes, it is important to validate any identified activities 
and/or properties. My results showed that transcriptional complexes formed by MIER 
proteins have different protein compositions suggesting that each MIER-containing 
complex has overlapping as well as unique function with other complexes. 
5.1 MIER family members share high sequence similarity in the ELM2-SANT  
Sequence Alignment tools such as ClustalW200 and MSAProbs177 programs are 
often used to identify regions of similarity that may suggest functional and/or structural 
relationships between biological sequences. I began my study of the MIER family 
characterization by comparing sequences of MIER2 and MIER3 to MIER1 and also to 
each other. Alignment results revealed that both MIER2 and 3 display higher similarity in 
the ELM2-SANT region to MIER1 (63% & 60% identity, respectively) than they do to 
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each other (52% identity) (Table 9). In contrast, the C-termini diverge amongst the three 
proteins suggesting specific functional roles. Millard et al.73 highlighted the amino acid in 
the ELM2 and SANT domain important for binding HDAC1. Sequence alignment 
analysis of ELM2-SANT containing proteins such as MTA1-3, RCOR1-3 and MIER1-3 
showed at least two amino acids that are conserved in all of the proteins except in 
MIER3. MIER3 contains 178I instead of V and 268Y instead of L. Previously157 our lab 
showed that MIER1 binds HDAC1 and 2 via the ELM2 domain and found that 213W as a 
critical residue for HDAC recruitment. Alignment analysis revealed that this tryptophan 
is identical in all ELM2-SANT containing proteins including MIER2 and MIER3. The 
identity at the amino acid residues level in the ELM2 and SANT domains between three 
members of the MIER family is high, implying that they may bind to the same partners 
and have similar functions.   
5.2 MIERs are nuclear proteins 
Cellular structure is highly organized with various sub compartments that ensure 
homeostasis operation of the entire cell. These subcellular structures include nuclei, 
mitochondria, endoplasmic reticulum, Golgi apparatus, cell membrane, and extracellular 
matrix4. Newly synthesized proteins on ribosomes must be transported to their designated 
subcellular compartment to exert their biological function. Misplaced proteins are often 
result in various disease states, which includes many cancers. Therefore, the subcellular 
location of proteins is an important feature of a protein, which is useful in determining 
protein function, in revealing the mechanism of molecular interaction, and in 
understanding the complex physiological processes178.  
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MIER1 was shown to be a nuclear protein154. The MIER1 isoform has a nuclear 
localization signal (NLS) while MIER1 does not, but still resides in the nucleus via a 
“piggy back” mechanism with HDAC 1 &2154. MIER2 and MIER3 are predicted to 
localize in the nucleus and contain an NLS between 244aa-253aa and 477aa-485aa 
respectively. I performed an analysis of the confocal z-stacks, using an Image J software 
program to provide a quantitative measure of the fluorescence in the nuclear and 
cytoplasmic compartments of cells overexpressing each protein. My results showed that 
more than 90% of the MIER1α and MIER3 protein was localized in the nucleus (Fig 7). 
While the majority of MIER2 protein (69%) was in the nuclear compartment (Fig 7C), 
there was a significant proportion of cells where it localized to the cytoplasm as well (Fig 
7A, panel m; 7B) and 31% of the protein was localized in this compartment (Fig 7C). I 
verified the MIER2 and 3 subcellular localization patterns in HEK293 to make sure the 
observation is not cell type-specific. Findings in HEK293 cells were similar to what I 
observed in the MCF7 cell line: that all MIER members are nuclear proteins and that 
there is also a significant percent of the MIER2 protein localized in the cytoplasm. The 
significance of MIER2 in the cytoplasm is currently unknown. There are at least 3 
explanations as to why I see MIER2 staining in the cytoplasm. First of all, the newly 
synthesised protein may be expressed at high concentration such that the nuclear import 
complexes cannot keep up to shuttle them efficiently into the nucleus. Secondly, MIER2 
protein may be actively exported from the nucleus to the cytoplasm, where it has unique 
functions. For example, REST is a nuclear protein but it is actively shuttled from nucleus 
to the cytoplasm to affect its repressive function133. I have demonstrated MIER2 to be in 
complex with REST and translocation of MIER2 from nucleus to cytoplasm may be the 
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same control mechanism to mediate its repressive functions along with REST. Lastly, 
other proteins may be trapping MIER2 in the cytoplasm, thus preventing nuclear import. 
Future experiments to either block import or export are required to answer some or all of 
these questions which to understand the functional role, if any, of cytoplasmic MIER2.  
5.3 One molecule of MIER is present in each regulatory complex 
My data show that MIER family members do not dimerize or multimerize. 
Additionally, there is only one molecule of MIER present in a given regulatory complex. 
Several lines of evidence indicate that complexes formed with MIER1 are different from 
those formed with MIER2 or MIER3: (i) coimmunoprecipitation assays show that the 
three MIER proteins do not interact with each other or with itself to form dimers or 
multimers, (ii) MIER2 immunocomplexes display significantly lower HDAC activity 
than those constituted by MIER1 and insignificant HDAC activity is observed in MIER3 
immunocomplexes, (iii) coimmunoprecipitation assays show that the three MIER 
proteins interact with same proteins at different levels; for example the interaction of 
MIER2 with HDAC1/2 is significantly lower than those exhibited by MIER1 and no 
interaction is seen between MIER3 and HDAC1/2. Similarly MIER1 and MIER2 interact 
with CDYL1b/c but no CDYL1b/c is present in MIER3 immunoprecipitate, and (iv) 
ChIP-Seq analysis showed that the three MIER proteins largely tethered to unique 
regions across the human genome.   
My finding that the MIER proteins do not co-exist in the same complex is similar 
to that of the MTA and CoREST proteins. These two families also harbour ELM-SANT 
domains and recruit HDAC1/2 to function as corepressors. Similarly, MTA1-3 and 
COREST1-3, each family of proteins is encoded by three genes and stoichiometric 
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analyses have demonstrated that the 3 proteins generally exist in distinct complexes. On 
the other hand, MTA1-3 proteins are reported to form homodimers through the ELM2 
domain31 and the homodimerization of MTA1 was shown to be crucial for interactions 
with HDAC 1. Therefore, I tested whether the MIER proteins also formed dimers to 
recruit HDAC 1 and 2. I was able to recapitulate previous findings31 and show MTA1 to 
form dimers but none of the MIER proteins were found to form dimers (Fig 8). Sequence 
alignment analysis of MIER proteins with MTA1 revealed that the ELM2 domain in 
MIER proteins lacks helix 2 that is present in MTA1. MIER proteins are predicted to 
form 3 alpha helices whereas crystallography analysis of MTA1 showed it consists of 4 
helices in the ELM2 domain. The authors showed the helices H1 and H4 of the ELM2 
domain of MTA1 formed the primary dimer interface, with a smaller contribution from 
helix H2. Although there is high degree of conservation of residues on other three helices, 
also shown to be important to form homodimers, helix 2 is missing in MIER proteins and 
may be the reason they do not form homodimers.        
Co-immunoprecipitation assays of the MIER proteins revealed that the MIER 
family members bind the same proteins differentially. For example, MIER1 recruits 
HDAC1/2 most efficiently and contains an augmented HDAC activity compared to 
MIER2, while MIER3 does not possess any HDAC activity and does not bind HDAC1 
and HDAC2. Such observations further supports that the MIER proteins are not together 
in a same complex as they have unique interacting partners and HDAC activity, 
suggesting distinct functions.   
Finally, genome wide characterization of MIER proteins binding sites revealed 
distinct distribution patterns for each MIER proteins. Although the three members shared 
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some target genes, there were far more genes that were unique to each member. Taken 
together, these data demonstrate that the MIER family members function as single 
molecules in unique complexes.  
5.4 Differential HDAC1 and 2 recruitment by members of the MIER family 
Previously, our lab has shown MIER1 to recruit HDAC1 and 2 through its ELM2 
domain157. I began characterization of MIER2 and MIER3 by investigating whether they 
also recruit HDACs given that they share the highly conserved ELM2 domain known to 
be important for HDAC interactions. My results demonstrated that only MIER1 and 
MIER2 recruit HDAC activity and that recruitment levels and stoichiometry vary with 
cell type. The results with HEK293 are consistent with those reported by Joshi et al.63 
who used the CEM-T lymphoblast cell line, but are in contrast to those reported by 
Bantscheff et al.168 who used the myelogenous leukemia cell line K562. In the former 
study, all 3 MIERs were identified in the HDAC1 and HDAC2 interactome, whereas in 
the latter study, MIER2 and 3 only interacted with HDAC2. My data showed that MIER2 
and 3 are much less effective than MIER1α at recruiting HDAC1/2. MIER3 is least able 
to recruit HDACs, so I tested whether the 277E in the MIER3 ELM2 domain is critical for 
HDAC recruitment as it is highly conserved. Co-immunoprecipitation assays established 
that neither MIER3 isoforms recruited HDACs efficiently. Interestingly, in MCF7 cells, 
only HDAC1 co-immunoprecipitated with MIER2 (Fig 9D, panels a-b, lane 3; Fig 9E) 
and no significant levels of HDAC1 or 2 were detected with MIER3 (Fig 9D, panels a-b, 
lane 4; Fig 9E). The results obtained with HeLa cells were similar to that obtained with 
MCF7: only HDAC1 was associated with MIER2 and neither was detected with MIER3 
(Fig 10). It is interesting that MIER2 did not bind HDAC2 in these cells as HDAC1 & 2 
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are highly similar proteins (85% identity) and co-exist as heterodimers in multiprotein 
complexes. There are few studies showing HDAC1 and HDAC2 form homodimers and 
have distinct roles72,201, so possibly MIER2-HDAC complexes have a unique role in 
HEK293 cells separate from complexes formed in MCF7 cells. HDAC1 and 2 are 
phosphorylated, a modification that is required for these enzymes to be assembled into 
the multiprotein SIN3, NuRD, and CoREST corepressor complexes72. However, it is 
unlikely that HDAC2 in MCF7 cells are not phosphorylated as both HDAC1 & 2 
enzymes are phosphorylated by casein kinase II on the same sites. On the other hand, 
HDAC1 is also phosphorylated by PKA, which may explain why only MIER2 interacted 
with HDAC1 in MCF7 cells. These data serve to emphasize the cell line-dependent 
variability in the composition of MIER-HDAC complexes. What remains unclear is the 
functional significance of differential HDAC recruitment by MIERs. This will require in 
part the knowledge of the gene targets of MIER1, 2 and 3 complexes and their complex 
composition in order to elucidate their distinct cellular functions.  
Next, I found MIER1α and MIER2 complexes immunoprecipitated from HEK293 
cells to contain deacetylase activity, while no significant HDAC activity above control 
levels was detected in MIER3 immunoprecipitates (p = 0.276; Fig 9F). The low level of 
HDAC1/2 recruitment by MIER3, even though MIER3 levels in the cell were high due to 
exogenous expression, and the fact that no MIER3-associated deacetylase activity could 
be detected, lead to conclude that MIER3 is unlikely to function in HDAC recruitment 
under physiological conditions. An alternate explanation is that MIER3 requires another 
molecule, or co-factor, or specific environmental condition to activate its ability to 
interact with HDACs. Millard et al.73 reported that Ins(1,4,5,6)P4 enhances the 
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deacetylase activity of both HDAC3:SMRT and HDAC1:MTA1 complexes. 
Interestingly, the inositol phosphate interacting residues are conserved in all corepressor 
proteins including MTA1-3, RCOR1-3, MIER1-3 and RERE. However, I did not find 
substantial difference in HDAC recruitment by any of the MIER proteins when 
exogenous Ins(1,4,5,6)P4 was added to the samples (Fig 11A, panels a-b). A small, but 
statistically significant, increase in HDAC activity of MIER1 complexes was observed in 
the presence of Ins(1,4,5,6)P4 (Fig 11B), however no difference was detected in the 
deacetylase activity of either MIER2 or MIER3 complexes. In addition, Millard et al.73 
showed that the SANT domain of SMRT complex had HDAC activity and mutation of 
Ins(1,4,5,6)P4 binding site on SANT domain of SMRT abolished HDAC activity. As a 
result, the authors concluded that Ins(1,4,5,6)P4 was key in regulating HDAC activity. 
However, our lab has previously157 shown that the SANT domain of MIER1 does not 
have any HDAC activity. Also, the concentration of Ins(1,4,5,6)P4 used in my assays 
were not a factor as I used Ins(1,4,5,6)P4 at a final concentration of 12.5 μM, which is 
what the authors used when they were conducting their HDAC activity assays. Together, 
the data presented here do not support the hypothesis that Ins(1,4,5,6)P4 is required for 
class 1 HDAC activation73. However, they do illustrate differences in the three members 
of the MIER family and presumably the complexes that they form. My data further 
demonstrates that MIER family members may form a distinct binding conformation with 
HDAC1 & 2 as compared to MTA1 and SMRT. Future studies investigating the binding 
pocket of MIER proteins with HDACs would be useful to create specific inhibitors of 
HDACs, which are currently being tested in many cancers.   
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Previously in our lab, the ELM2 in MIER1 was shown to be responsible for 
interaction with HDAC1 and 2. I found that MIER2 behaves similarly to MIER1 in 
recruitment of HDACs, with 228W in MIER2 being a critical residue. It was no surprise 
that 228W in MIER2 is key for HDAC interaction as the amino acid tryptophan is 
conserved among all three MIERs. Sequence alignment analysis revealed that the MIER1 
and MIER2 are 59% identical in the ELM2 domain while MIER1 and MIER3 share 54% 
identity. This raises the question as to why MIER3 does not interact with HDACs given 
the sequence identity among proteins are comparable. Thus, analysis of the ELM2 end 
(aa268-285), the sequence identity almost doubles between MIER1 and MIER2 (78% 
identical), which might explain as to why MIER2 only bind HDACs well compared to 
MIER3 (39% identity to MIER1 and 33% identity to MIER2). I also tested whether the 
ELM2 domain of MIER3 alone could interact with HDAC1/2 in HEK293 cells and yet 
again no HDACs were detected in MIER3 immunoprecipitate (data not shown). The 
reason why I tested the ELM2 domain of MIER3 alone was to determine whether steric 
hindrance of folded protein inhibited the HDAC interaction with MIER3, but this was not 
the case.  
These data clearly demonstrate that the three MIER proteins recruit HDAC1 and 
HDAC2 at different capacities but the reason could not be demonstrated experimentally. 
In order to ascertain whether the differences in the ELM2 domain of MIER3 is solely 
responsible for differences in HDAC recruitment, one could produce chimeric constructs 
of MIER3 containing the MIER1’s ELM2 domain and tested whether it could bind 
HDACs. This experiment would have confirmed whether the differences in the ELM2 
domain alone are responsible for differential HDAC recruitment. However, differential 
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recruitment of HDACs by MIER members is not unique as it is also seen in CoREST 
corepressor complexes24 and NuRD corepressor complexes28.  
5.5 Summary of MIER proteins binding to HDAC1/2   
In the first part of this report, the data presented here constitute the first 
characterization of MIER2 and MIER3 proteins. The results show that MIER2 and 3 are 
mainly localized in the nucleus. MIER2 can recruit HDAC1 and 2 activity, but this 
depends on cell type, and it does not do so as effectively as MIER1α. MIER proteins do 
not dimerize and Ins(1,4,5,6)P4 only enhances MIER1α associated HDAC activity. As 
with MIER1, there is a key tryptophan in the ELM2 domain of MIER2, 228W that is also 
required for HDAC recruitment. What remains largely unexplored is the possible effect 
of MIER1 and MIER2 on HDAC activity. It is known that HDAC activity is influenced 
by phosphorylation as well as protein-protein interactions and in the future our lab could 
explore whether MIERs could regulate HDAC activity or interaction.  
5.6 MIER3 does not interact with CDYL  
CDYL consist of a N-terminal chromo domain, a central hinge region, and a C-
terminal enoyl-coenzyme A hydratase/isomerase catalytic domain shown to function as a 
corepressor. In 2008, Mulligan et al.108 executed an affinity purification of Flag-HA-
tagged CDYL from HeLa nuclear extracts to isolate CDYL and its associated proteins, in 
an attempt to determine the function of CDYL. They carried out a mass spectrometry 
analysis and identified more than 22 associated proteins that copurified with CDYL. 
These included: HDAC1, HDAC2, G9a, GLP, WIZ, REST and MIER1/2. Next, they 
performed a glycerol gradient sedimentation analysis to determine whether these proteins 
form single or discrete subcomplexes. Their data demonstrated that there are at least two 
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multiprotein subcomplexes; first subcomplex was made up by MIER1/2, HDAC1, and 
HDAC2, while the second slower sedimenting complex included CDYL, REST, WIZ, 
G9a, and GLP.  
My data revealed that MIER1 and MIER2, but not MIER3, interact with CDYL1b 
and CDYL1c shown in Figure 13. These data shows that MIER1 and MIER2 interact 
with both isoforms, CDYL1b and CDYL1c suggesting aa1-289 CDYL is not responsible 
for this interaction. There was little difference in the interaction level between MIER1/2 
with CDYL1c and CDYL1b (p > 0.05). There is little or no data about specific role of 
CDYL1a or CDYL1c. CDYL1b is known to be the most abundant isoform107 and is 
tethered to chromatin regulators such as G9a183, HDAC1/2109, REST108, CoREST108 and 
EZH2110. Therefore, CDYL1b variant was used for the rest of this study since MIER1 is 
shown to interact with some of the same repressors.   
A more detailed analysis of the ELM2 end in MIER1 (aa255-286) and MIER2 
(aa260-297) revealed high conservation of sequences and high probability to form coiled-
coil. No coiled-coil structure was identified in the same region in the MIER3 and may be 
the reason why no CDYL was recruited by MIER3. Coiled-coils are characterized by an 
heptad repeat, which is a repeating unit of seven amino acid residues, labeled a, b, c, d, e, 
f or g. Interaction specificity is determined by hydrophobic interactions at positions a and 
d, which form a zig-zag pattern that interlock with a similar pattern on another strand to 
form a tight-fitting hydrophobic core186. Sequence analysis of MIER1 and MIER2 
proteins revealed multiple leucine residues that are positioned on “a” and “d” position of 
heptad repeat. I hypothesized that mutating these residues would alter the coiled-coil 
structure and as a result observe a reduced interaction with CDYL. My results showed a 
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statistically significant reduction in recruitment of CDYL by MIER1 when 274L was 
mutated to A. Mutating other leucines did not alter the interactions between 
MIER1/MIER2 and CDYL. I had expected to observe loss of coiled coil structure and 
attenuated MIER-CDYL interactions with either leucine to alanine mutations but detected 
loss of interaction with MIER1 274L. These findings suggest that MIER1 does not interact 
with CDYL through the coiled coil structure, as altering leucines on other heptad 
locations did influence the interaction levels between MIER1/2 and CDYL, as we had 
predicted initially. However, in order to get a more complete picture, one would need to 
mutate the remaining a and d residues in the predicted region to check if it would alter 
the interaction.  
Furthermore, our mutational analysis revealed that an equivalent 288L in MIER2 
as in MIER1, was also important for MIER2 to bind CDYL. There were differences 
between MIER1 and MIER2 when mutating an equivalent amino acid responsible for 
CDYL recruitment. Sequence alignment analysis of the region aa268-295 in MIER1 
showed a high degree of conservation in MIER2. One explanation is that CDYL is 
tethered to MIER2 complex through a three-dimensional structure that includes another 
molecule. MIER2 is shown to bind REST very robustly and CDYL binds REST. Thus, 
mutation of 288L on MIER2 only weakens the interaction as REST can still recruit CDYL 
to the complex. CDYL is shown to interact with CoREST to bridge G9a to REST 
complex but the region responsible for this interaction is not defined108. Sequence 
analysis of MIER1-3 with other ELM2-SANT proteins (MTA1-3, RERE, and CoREST1-
3)73 of the ELM2 domain showed absolute conservation of the leucine residue except in 
 
 
139 
MIER3 (Y instead of L). Therefore, the data suggests that all ELM2-SANT containing 
proteins have the critical conservation of the residue to interact with CDYL.  
 Data showed no interaction between MIER3 and CDYL and this was not as a 
result of low expression of the protein as the co-immunoprecipitation assays were carried 
out with exogenous myc-tagged proteins. These results are in agreement with Mulligan et 
al.108 finding as I was able to detect MIER1 and MIER2 binding to both CDYL and 
HDACs. Furthermore, as mentioned earlier, I did not detect any HDAC activity or 
HDAC1/2 binding with MIER3, which strengthens my observation that MIER3 is very 
different from both MIER1 and MIER2. MIER3 associated with neither HDACs nor 
CDYL, both of which are shown to be a part of the same complex. The question remains 
as to why MIER3, which contains the ELM2-SANT functional domains as in MIER1 and 
MIER2, does not interact with any of known binding partners.    
5.7 MIER1 and MIER2 augments HDACs association with CDYL  
In 2003, Caron et al. reported CDYL as a new co‐repressor of transcription that is 
able to recruit HDAC1 and 2 but not HDAC3 in COS7 cells. They noted that the 
interaction between CDYL and HDACs is direct through its C-terminal CoAP domain by 
an in vitro binding assay. It is interesting that I observed CDYL-MIER1/2 interactions via 
the CoAP domain as well (Fig 13B). I have shown that MIER1 and MIER2 are present in 
distinct complexes; both recruit HDAC1, HDAC2 and CDYL. Results showed exogenous 
expression of both MIER1 and MIER2 increased the level of HDAC1/2 associated with 
CDYL complexes (Fig 18-19). On the other hand, CDYL did not have any effect on the 
level of MIER1/2 and HDAC1/2 binding (Fig 16-17). Additionally, mutating MIER1 274L 
to A not only reduced interaction between MIER1 and CDYL1b but also lowered the 
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level of interaction between CDYL1b and HDAC1/2. There are at least two possibilities 
that could explain these results. First, MIER1 and MIER2 may be recruiting HDAC1 and 
2 to the CDYL complex or alternatively, MIER1/2 upon binding to CDYL alter the 
structure of CDYL that allows more HDAC1/2 to bind to the complex. Future studies are 
required to confirm and one may do so by carrying co-immunoprecipitation assay with 
mutant W214A in MIER1 and W228A in MIER2, in the ELM2 domain that are shown to 
be crucial for HDAC1/2 binding and determine whether level of HDAC1/2 is influenced 
in the CDYL complex.  
The role of CDYL in the MIER1/2 complexes is not known. CDYL is known to 
function as a methyl reader on histone tails and as a corepressor of REST complex by 
bridging methyltransferase G9a to REST to repress target genes by altering the chromatin 
structure 108. We performed co-immunoprecipitation assays and found MIER1 and 
MIER2 to bind to G9a (data not shown) but we did not investigate whether the 
interaction was mediated by CDYL. In the future, one could test whether the interaction 
between G9a and MIER1 and 2 is direct or via CDYL.  
Recently, CDYL was shown to act as a crotonyl-CoA hydratase to negatively 
regulate histone crotonylation112.  Crotonylation is a newly identified post-translational 
modification on lysine resides in all four histones, which has been demonstrated to 
associate with active promoters and to directly stimulate transcription112,202. CDYL does 
not catalyze decrotonylation from histones but rather acts as a crotonyl-CoA hydratase to 
convert crotonyl-CoA to β-hydroxybutyryl-CoA, thereby destroying crotonyl-CoA for 
Kcr reaction112. This is a newly identified role for CDYL, an intrinsic enzymatic activity 
to inhibit transcription distinct from its previously known function of recruiting histone 
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regulators to facilitate the establishment of repressive modifications such as H3K27me3 
at target regions for repression110. CDYL’s newly identified role raises several questions 
that are yet to be explored. Does CDYL enzymatic activity also depends on cellular 
metabolism, as reported by Sabari et al.203 studying the role of p300 as histone 
crotonylator and if so, what causes the change in levels of crotonyl-CoA vs. acetyl-CoA. 
How is the structure of chromatin regulated through lysine crotolynation? Are there 
selective readers for histone Kcr? Do MIER1 and MIER2 influence CDYL hydratase 
activity? What enzymes regulate the addition or removal of Kcr? Further investigation is 
necessary to answer these questions and determine the biological importance of Kcr.  
5.8 Key points discovered from CDYL and MIER1/2 report 
The data presented here showed that both MIER1 and MIER2 interact with 
CDYL1b and CDYL1c. I have also mapped region of both MIER1 and MIER2 and 
CDYL responsible for the interaction between CDYL and MIER. Additionally, I have 
shown MIER1/2 to enhance the interaction between CDYL1b and HDAC1/2. I have 
hypothesized that MIER1/2 facilitate gene suppression through chromatin remodelling as 
shown in other corepressors by facilitating the assembly of specific histone-modifying 
regulators to the complexes. Therefore, a mass spectrometry analysis of each MIER 
proteins will aid to determine complete list of their binding partners.   
5.9 Genome-wide characterization of MIER1, MIER2 & MIER3 target genes  
My data so far suggests that MIER3 is different from the other two MIER 
proteins. I have shown that MIER3, unlike MIER1 and MIER2, does not interact with 
any of the chromatin modifiers such as HDAC1, 2 or CDYL. In an attempt to 
characterize mechanisms and/or biological functions of the MIER proteins I sought 
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publicly available MIER ChIP-Seq data sets for analysis. These analyses demonstrated 
that both MIER1 and MIER2 were enriched on genes that are well known REST targets. 
Similarly, CDYL was shown to bind REST target genes suggesting that CDYL, MIER1/2 
and REST may be in the same complex to control transcription of target genes 183. It is 
interesting to know whether CDYL is present with MIER1/2 when in complex with 
REST. Does CDYL also bring G9a to REST and MIERs? Previous (unpublished data 
from our lab) shows MIER1 and MIER2 to interact with G9a but it is not clear whether 
the interaction is mediated via CDYL. This is a very novel discovery despite extensive 
amount of research surrounding REST, no study detected MIER proteins to be part of 
REST repressor complex.  
This is the first report characterizing MIER proteins’ binding sites in the human 
genome. The molecular pathways of MIER proteins were predicted using GREAT. 
MIER1 and MIER2 were predicted to be involved in pathways important for neuronal 
function. Similarly, a list of MIER3 target genes was uploaded in GREAT, which showed 
that it might play a role in part in cellular stress response. REST gets recruited to target 
genes by binding to a DNA element called repressor element 1 (RE1). It recruits two 
major HDAC-containing complexes namely SIN3 complex and Co-REST complex via 
the N- and C-termini respectively to repress transcription. It is interesting to find that 
MIER proteins are enriched on known REST genes (Fig 24)191. Numerous studies have 
been conducted to identify REST target genes and associated proteins, yet no such study 
reported any of the MIER proteins to be associated with REST. Many of the apparent 
discrepancies in the current literature concerning subunit composition and identity of 
protein complexes might result from differences in the preparation of extracts and 
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purification procedures. In addition, the ever-increasing sensitivity of protein 
identification by mass spectrometry techniques accounts for the identification of novel 
subunits that were missed in previous approaches. 
 Analyses of ChIP-Seq data for MIER proteins have revealed that the MIER 
family is enriched on known REST target genes. Our lab has previously demonstrated 
that MIER1 does not bind DNA directly (unpublished data) so I hypothesized that MIER 
proteins like other corepressor molecules are recruited to target genes by a transcription 
factor like ER or SP1. Such observations lead me to ask whether MIER proteins interact 
with REST or REST binding partners or are they a part of a novel unidentified complex 
recruited to REST target genes.  
5.10 MIER proteins bind to REST 
As predicted by the analysis of the MIER ChIP-Seq datasets, I discovered MIER1 
and MIER2 to be present in the REST immunoprecipitates in HEK293 cells. The 
association of MIER proteins and REST were also verified in HepG2 cells, where very 
robust MIER2 binding to REST was detected but no MIER1 or MIER3 were present with 
REST. The results in HEK293 showed that MIER1 binds REST but at much lower levels 
compared to MIER2. Moreover, I was able to map MIER2-REST association and 
determine that it occurs through aa 301-545 of MIER2, which contains the SANT 
domain. However, constructs containing the SANT domain and lacking the SANT 
extension were not able to recruit REST. In the future, one could construct a 
SANT+SANT extension to determine whether the interaction between MIER2-REST is 
due to this region, as it is highly conserved among MIER proteins. There are several 
possible reasons why MIER1 and MIER2 interact differentially with REST. Firstly, the 
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C-termini region of MIER proteins shown to be important for interaction with REST are 
very different from each other at the amino acid level and may be causing it to fold 
differently, thus influencing the interaction. Secondly, MIER proteins may be post-
translationally modified causing changes in the binding pocket, which may cause one to 
interact better than the other. Thirdly, MIER2 may be binding REST directly whereas 
MIER1 may need another cofactor to interact with REST that is absent or present at low 
levels in the cells. We observed cell line-dependent variability in the composition of 
MIER1/2-REST complexes, which may be explained by REST and its association with 
cofactors to repress target genes.   
My finding that MIER1 and MIER2 are interacting with REST changes the 
current knowledge that SIN3A and Co-REST are the only corepressor complexes 
mediating HDACs and other regulators to the REST complex to repress genes. It is 
known REST exerts its transcriptional regulatory roles by cooperating with other 
proteins. CDYL was identified as REST corepressor by physically bridging REST and 
the histone methylase G9a to repress transcription and through histone modifications108. 
In this thesis, I have shown that MIER1 and MIER2 to interact with CDYL and REST 
and HDAC1/2, which inhibit transcription by altering the chromatin structure. The 
dynamics of REST binding and cofactor recruitment and its recruitment on the target 
genes as well as the significance of so many possible binding partners remain unclear.  
Observations made in this report identify MIER family as novel corepressors of REST 
and open up a number of questions to be explored. What role do MIER proteins play in 
the REST complex? Are MIER proteins involved in the modulation of neural 
developmental gene expression programs along with REST and CDYL? Do MIER 
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proteins mediate gene networks underlying neural stem cell multi-lineage potential and 
fate restriction? 
In the future, to elucidate MIERs’ regulatory networks, it is important that 
genome-wide mapping by ChIP be coupled with assessments of differential gene 
expression of MIER knockdowns and mass spectrometry analysis of the recruitment of 
transcriptional cofactor to the MIER complexes to further expand our understanding of 
the complexes and their roles. 
5.11 Silencing of MIER1/2 in P19 cells promotes neuronal differentiation  
REST is a transcription factor widely expressed during embryogenesis. It plays an 
important in neurogenesis via epigenetic remodeling to actively repress a vast number of 
genes including those encoding ion channels, neurotransmitter receptors, synaptic vesicle 
proteins and adhesion molecules in neural stem cells133. Interactions of two distinct 
corepressors, SIN3 and CoREST, are identified as key element for REST-mediated gene 
repression. It has been shown that knockdown of CoREST and SIN3A/B leads to ablation 
of REST functions and triggers differentiation of non-neuronal cells into neurogenic 
cells22,204. In addition, there are several reports that demonstrate CDYL play a crucial role 
in neurogenesis108,111,197,198,205. Knockdown of CDYL in induced pluripotent stem 
cells spontaneously differentiated into neuronal lineage205.  
The results of the genome-wide MIER-binding site analysis indicated that MIER1 
and MIER2 are distributed on significant number of well-known REST target genes. 
Also, results of the co-IP assays in this report showed that both MIER1 and MIER2 
interact with REST and CDYL. To examine the functional role of MIER1 or MIER2 in 
differentiation, loss-of-function analyses were conducted in pluripotent P19 cells using 
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MIER1 and MIER2 selective shRNAs. P19 cells are pluripotent cells that are derived 
from teratocarcinoma in mouse and can be differentiated into a variety of cell types. P19 
cells can be differentiated into all the neural lineages by retinoic acid (RA) induction194. 
There are several specific markers to identify whether the cells are of neural lineages, in 
this report, I used neuron-specific class tubulin 3 and astrocyte specific GFAP. 
 My data demonstrated that knockdown of MIER1 or MIER2 resulted in 
differentiation of pluripotent P19 cells into neurons without the treatment of RA. It is an 
exciting result revealing MIER1/2 role in stem cells and lineage commitment. 
Observations made in confocal immunofluorescence analysis showed that neuron-like 
cells differentiated from P19 cells by silencing MIER1 and MIER2 without RA 
treatment. However, I did not determine whether MIER1/2 knockdown P19 cells are 
differentiated into functional neurons. This finding is in line with functions of other 
known REST corepressors like SIN3 and CDYL, where attenuating expression levels 
results in increase in neuronal gene expression111,204,205. 
 Also, I detected higher expression of tubulin 3 in the MIER1 KD clones versus 
MIER2 KD clones by Western analysis. Analysis of ChIP-Seq data and CoIP assays 
illustrated MIER2 to be involved with REST more strongly than MIER1 but the 
differentiation assay results were different. Reduction of MIER1 levels mediates neuronal 
differentiation more robustly compared to MIER2. This may in part be explained by the 
results of the MIER1 ChIP-Seq analysis, which revealed that MIER1 was also enriched 
on genes with another transcriptional factor PRDM4, shown to play a role in neural 
differentiation122. PRDM4 has been shown to recruit the histone arginine 
methyltransferase PRMT5 and the complex is required to maintain the proliferative 
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capacity and “stem-like” cellular state of the neural stem cells. Furthermore, knockdown 
of PRDM4 in PC12 cells resulted in increased expression of tubulin 3122. MIER1 ChIP-
Seq data showed that MIER1 is on 57 regions (out of 448 total sites FE>15) with 
PRDM4 and the remaining 391 sites are REST genes. In this report, I showed MIER1 to 
interact with REST but did not test whether MIER1 is associated with PRDM4. It is 
possible that MIER1 is a component of the PRDM4-PRMT5 repressive chromatin-
remodelling complex recruited by PRDM4 and also a component in REST repressive 
complex recruited by REST, where MIER1 in both complexes is in turn mediating 
repression by engaging HDAC1/2 to the complex.   
Another possibility is that MIER proteins have specific roles in controlling the 
precise timing of neurogenesis that are distinct from one another. MIER1 might be 
crucial for maintenance of neural stem cell population while MIER2 may play a role in 
lineage differentiation. Furthermore, analysis of ChIP-Seq data identified MIER2 target 
genes encoding helix–loop–helix (HLH) transcription factors known to be play diverse 
roles in neural development for example neurogenin 2, NEURODD, hairy and enhancer 
of split 1/3/6 (HES1/3/6), AND inhibitor of DNA binding 2/4 (ID2/4)206. ID proteins 
promote the maintenance and self-renewal of neural stem cells (NSC) and progenitor 
cells and also control the precise timing of neurogenesis (ID1/2) and 
oligodendrogliogenesis (ID2/4) by regulating proneural HLH and other neural 
differentiation factors207. Also, ID2 promotes NSC maintenance by sustaining HES1 
expression208, which in turn inhibits the differentiation of neuronal and glial lineage209. 
Likewise, both HES1 and HES3 are essential for the maintenance and proliferation of 
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NSC. The expression levels of these transcriptional factors were not tested but could be 
in future studies, to determine whether MIER2 regulates any one of these proteins. 
RT-PCR showed clear knockdown of MIER1 or MIER2 transcripts in stable 
knockdown clones. I could not measure MIER1/2 protein levels since the antibodies 
against them did not detect endogenous MIER levels in P19 cells. I did not observe 
proliferation differences between control and knockdown clones during differentiation. 
However, I had fewer clones in the knockdown sample as compared to control initially 
when selecting stable clones expressing shRNA against MIER1 or MIER2. It is very 
likely that MIER1 and MIER2 play role in proliferation and maintenance of pluripotent 
cells. REST expression is high in the adult hippocampus, which is required to maintain 
the adult neural stem cell (NSC) pool and orchestrate stage-specific differentiation. In the 
future, one would test these observations and check if MIER1 and MIER2 may also play 
a role in maintenance of NSC. The levels of MIER1/2 and REST were not examined in 
differentiated cells. While REST expression is known to decrease during neural 
differentiation, MIER1/2 levels are unknown and need to be examined in the future.  
P19 embryonal carcinoma cells were used as a differentiation model, which is an 
invaluable tool for approximating the mechanisms that govern neuronal differentiation. 
However, they are often cultured under conditions that promote unrestricted non-
neuronal growth that compromises neuronal viability. One possibility to avoid this is to 
treat the culture with Cytosine β-d-arabinofuranoside and 2′-Deoxycytidine so that the 
cultures were more consistently enriched toward the neuronal differentiation vs non-
neuronal differentiation194.  
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Next, I was interested to investigate the changes in gene expression in mouse 
MIER1 knockout embryonic fibroblast cells. I established MEFs at 13.5 days and 
performed transcriptome analysis of WT versus KO MEFs. The results were in 
agreement with what was shown with ChIP-Seq analysis and P19 neural differentiation 
findings that MIER1 was involved in regulation of neuron differentiation. Several REST 
target genes (BDNF, NGF, ANKRD1, STMN2, CNN1) were upregulated in MIER1 null 
MEFs, which again further demonstrate MIER1’s involvement with REST as a 
corepressor. There were 154 genes that were upregulated in MIER1 KO MEFs compared 
to ~1000 peaks identified by ChIP-Seq in K562 cells. It is not surprising that only a small 
fraction of genes were affected, as other corepressor complexes such as MIER2, SIN3 
and CoREST also regulate REST-mediated repression. Brain development and function 
is complex, relying on many regulatory circuits to carry normally. The MIER proteins are 
enriched on genes that are important in such pathways and understanding their specific 
role in the brain would heighten our present knowledge, which will help find treatments 
for neurodegenerative diseases.  
These are preliminary findings showing MIER1 & MIER2’s role as an important 
player in neurogenesis. I have demonstrated aberration of MIER1/2 levels result in 
neuronal differentiation, but we need to identify the specific roles in vivo and how are 
they involved in neural development in mouse and or human. Deletion of MIER1 in mice 
does not lead to embryonic lethality or anatomical malformations in fetuses. However, 
we observed MIER1 null mice show decreased body weight and the Mouse Phenotyping 
Consortium and The Wellcome Trust Sanger Institute also reported decreased body 
weight and reduced levels of circulating glucose and cholesterol in MIER1 null mice. 
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They also found null mice to display tremors, abnormal vocalization and abnormal 
behaviour, which are pathways controlled by cell signalling in the brain and exerting such 
phenotypes are a strong argument in favour of MIER1 and REST cooperating to control 
the expression of genes involved in neurogenesis in the brain.  
5.12 MIER1/2 are new players in the REST complex 
In this report, I established that the consensus binding motifs of MIER proteins 
and REST are almost identical. MIER1 and MIER2 share extensive common genomic 
targets with the transcription repressor REST. Moreover, I showed MIER1 and MIER2 to 
interact with REST and mapped the region on MIER responsible for binding. Taken 
together, I have identified MIER1/2 as novel corepressors that bring HDACs to REST for 
transcriptional repression.  REST binds two other corepressor complexes, SIN3 and 
CoREST, which contain many of the chromatin regulators such as CDYL, HDACs and 
G9a that we know MIER1/2 bind as well. This raises the plausible hypothesis that the 
MIER1/2-associated chromatin complex could act as a transcriptional co-repressor in 
synergy with SIN3 and CoREST in the context of neural development and function. 
5.13 Overall summary and our working model 
In summary, in this report I have shown that MIER1, MIER2 and MIER3 are 
nuclear proteins functioning as single molecules in distinct complexes. While both 
MIER1 and MIER2 were found to interact with HDAC1, HDAC2, CDYL and REST, 
MIER3 did not, despite containing the ELM2 and SANT domains important for binding 
to these proteins. Previously, our lab has demonstrated that MIER1 functions in 
transcriptional repression by recruiting HDAC1 and 2. Similarly, in this thesis I have 
discovered that MIER2 also interacts with HDAC 1/2 through its ELM2 domain and 
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possesses HDAC activity. I also found that MIER1 and MIER2 bind to CDYL via their 
ELM2 domain and MIER2 interacts with REST through the C terminus containing the 
SANT domain. I characterized genome-wide binding sites for MIER proteins and 
discovered that all three members share a small number of genes between them. Taken 
together, these data suggest that MIER2 is very similar to MIER1 whereas MIER3 is 
undeniably different. I did not investigate the transcription activity of MIER3 or its 
association with FOX1A/B in this report. FOX1A/B is a transcription factor that 
regulates liver and gut specific genes as well as controls glucocorticoid receptor mediated 
genes. So, it is likely that MIER3 may also play a role in mediating such genes but the 
function of MIER3 is still unclear.      
My data suggest that MIER1 and MIER2 are subunits of distinct transcriptional 
factor mediated (REST) corepressor complexes. Corepressor complexes are recruited by 
transcriptional factors to specific loci to inhibit transcription by modulating the chromatin 
structure via alterations of epigenetic marks on histones. Likewise, MIER1 and MIER2 
are shown to interact with REST, a transcriptional factor that binds RE1 sites on target 
genes, which we have shown to in turn recruit HDAC1/2 as well as other chromatin 
modifiers such as CDYL and G9a to repress genes.  
Based on MIER1 and MIER2 reported functions of interacting partners and 
immunoprecipitated MIER1/2 complexes possessing HDAC activity, a working model is 
proposed that explains how MIER1 and MIER2 containing complexes inhibit 
transcription. First, MIER1/2 is directed to target genes by REST, which binds DNA via 
the RE1 site on regulatory region of targeted gene (Fig 31). MIER1/2 then orchestrates 
the modulation of a chromatin by recruitment of at least the HDAC1 & 2, CDYL, G9a to 
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remove acetyl groups from lysines and methylate in return to stimulate establishment of 
heterochromatin and inhibition of transcription.  The sequence assembly of the complex 
as well as the complete composition of the MIER1 and MIER2 complexes is not yet 
identified. It also remains elusive is whether MIER1 and MIER2 are functioning 
redundantly or they are core part of diverse corepressor complexes with distinct roles.   
5.14  Future Directions 
In order to understand the function and mechanism of the MIER proteins we will 
have to perform mass spectrometry analysis to determine the stoichiometry of protein 
assemblies in each complex. Also, knowledge of the expression of each MIER proteins in 
adult brain as well as in developing embryo will aid in understanding the importance of 
each member. In addition, transcriptome analysis of MIER knockdown in neural stem 
cell will further advance the understanding underlying MIER1/2 roles in neurogenesis.   
Taken together, I have demonstrated MIER proteins function as corepressors by getting 
recruited to target genes by transcriptional factor REST and in turn act as a scaffold to 
bring chromatin regulatory enzymes such as readers, writers and erasers to modulate the 
epigenetic marks to repress expression at specific gene targets.  
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Figure 31. A model of MIER1/2-mediated transcriptional repression.  
MIER1/2 is directed to target genes by interacting with REST that binds DNA on the 
regulatory domain of target genes through RE1 site. MIER1/2 act as a scaffold to recruit 
HDAC1/2 to remove the acetyl (Ac) groups off the histones and tether CDYL and G9a to 
methylate (me) in return to silence transcription.   
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